The momentum continues....
Agenus
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. More on Wikipedia
-
Agenus
@Agenus_Bio
-
Agenus
@Agenus_Bio
New at @sitcancer’s #sitc2026: more than half of patients in our Phase 1b MSS mCRC cohort achieved long-term survival on BOT+BAL, and some remain alive and off all cancer therapy. Read more in our press release: investor.agenusbio.com/news/default.aspx
-
Agenus
@Agenus_Bio
Agenus reported third quarter 2026 financial results, highlighting progress toward Phase 3 ROBBIN initiation, new clinical evidence from NEST and UNICORN, and the first BOT+BAL marketing authorizations in Armenia. Read the full press release: investor.agenusbio.com/news/default.aspx
-
Agenus
@Agenus_Bio
Results from UNICORN, the Phase 2 trial for BOT+BAL in preoperative colon cancer, have been published in @NatureMedicine, showing deep responses in MSS colon cancer and supporting continued advancement of ROBBIN, our planned Phase 3 trial. Read more: investor.agenusbio.com/news/default.aspx
-
Agenus
@Agenus_Bio
Preparations for Phase 3 ROBBIN are moving forward. Following ESMO, our medical team joined investigators and site teams in São Paulo, Brazil, to prepare for the study’s planned Q1 2027 opening, part of our ongoing work to ready sites worldwide.
-
Agenus reposted
OncoDaily
@oncodaily
Highlights from Big Questions during ESMO 2026
On October 24 in Madrid, OncoDaily brought together leading voices from across the oncology community for an open discussion on the decisions shaping cancer research, treatment, and patient access.
Chaired by Prof. Jean-Yves Blay, the session featured Dr. Julie Gralow, Martha Raymond, and Dr. Jennifer S. Buell, bringing perspectives from clinical leadership, cancer policy, patient advocacy, and the biopharmaceutical industry.
🤝 With perspectives spanning clinical practice, research, industry, and patient advocacy, the discussion highlighted the importance of collaboration and shared responsibility in advancing cancer care.
@jeanyvesblay @jrgralow @jbuell01This media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
New Phase 2 data at #esmo26: Following treatment with BOT+BAL before surgery, 83% of patients with locally advanced dMMR colon cancer achieved major pathologic response and 72% achieved a pathologic complete response.
Learn more: investor.agenusbio.com/news/default.aspx
@myESMO -
Agenus reposted
Elad Sharon
@EladSharonMD
Here at the @oncodaily event @myesmo with some major leaders from @asco (@jrgralow, CMO), @Agenus_Bio (@jbuell01) and more! Come join us at Cafe Ramon here just outside the conference center #esmo26 (registration is still open!) oncodaily.com/big-questions-during-esmo-2026
-
Agenus
@Agenus_Bio
Agenus announces it will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the U.S. financial markets open.
Read more: investor.agenusbio.com/news/default.aspx
NASDAQ: $AGEN
#agenus #earnings #biotech -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
Yes! It is great to see MiNK CEO Dr. Jennifer S. Buell recognized among @oncodaily 100 Influential Women in Oncology 2026!
Breaking barriers, advancing immunotherapy, and redefining what’s possible for patients.
#womeninoncology #inkt #minktherapeutics
OncoDaily
@oncodaily
Continuing a special OncoDaily tradition - 𝟭𝟬𝟬 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘁𝗶𝗮𝗹 𝗪𝗼𝗺𝗲𝗻 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 - we are proud to present the 8th part of our 2026 list, celebrating the next 10 remarkable women whose leadership and contributions are shaping the future of oncology
🪄Jennifer S. Buell,(@jbuell01) PhD is the President and CEO of MiNK Therapeutics (@MiNK_iNKT) and Chair of the Executive Council and a Director at @Agenus_Bio, bringing more than 27 years of experience in cancer drug development and biotechnology. Previously President and COO of Agenus, she helped transform the company from a single-product biotechnology business into a fully integrated organization with a broad immuno-oncology pipeline and multiple global partnerships. Today, she leads MiNK’s development of allogeneic invariant natural killer T-cell therapies, while continuing to shape Agenus’ strategy for next-generation cancer immunotherapies.
🔗oncodaily.com/100/100-influential-women-610980
#oncology #oncodaily100 #oncodaily #cancer #100influentialwomen #womeninoncology -
Agenus reposted
OncoDaily IO
@OncoDailyIO
Agenus - A Defining Moment for Cancer Immunotherapy During ESMO 2026
@Agenus_Bio
oncodaily.com/voices/agenus-613111 -
Agenus reposted
OncoDaily Biotech
@OncoDailyBio
Jennifer S. Buell Highlights Armenia’s First Marketing Authorizations for Botensilimab and Balstilimab
@jbuell01 @Agenus_Bio
oncodaily.com/industry/jennifer-s-buell-605101 -
Agenus reposted
Jennifer Buell
@jbuell01
News from @MiNK_iNKT :
Three catalysts in three weeks:
#aacr2026 (Apr 20) → Phase II refractory GEJ
#asgct2026 (May 11-15) → mechanism in cancer + lung dx
#ats2026 (May 20) → expanding pulmonary benefit
$INKT #biotech #catalyst #immunotherapy #celltherapy #breathe -
Agenus reposted
Jennifer Buell
@jbuell01
At #aacr26, Dr. Sam Cytryn @MSKCancerCenter reports INKT+BOT/BAL and chemo in r/r GEJ:
- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets
In refractory disease, durability defines impact. @MiNK_iNKT @Agenus_Bio @YJanjigianMD -
Agenus reposted
Jennifer Buell
@jbuell01
A glimpse of what’s ahead #mhsrs2026 👀🫁— Dr. @TereseH43662 will present first look from a randomized Ph2 of agenT-797 in pulmonary dx at an outstanding MHSRS meeting #majgenclintonmurray @HHSGov #ukraine @DeptofWar @MiNK_iNKT
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics will share early findings from the first patients dosed in its randomized Phase 2 study of agenT-797 for hypoxemic pneumonia/ARDS at #mhsrs2026.
📅 Aug. 6 | 11:30–11:45 a.m.
Session: Cellular Therapies for Trauma
#agent797 #ards #celltherapy -
Agenus reposted
Jennifer Buell
@jbuell01
A world first 🇦🇲 Armenia grants the first marketing authorizations for botensilimab + balstilimab in previously treated MSS metastatic colorectal cancer. Gratitude to the patients, families & investigators who made this possible. @Agenus_Bio #crcsm #immunotherapy
Agenus
@Agenus_Bio
Armenia has granted the first marketing authorizations for BOT+BAL in adults with previously treated MSS mCRC without active liver metastases.
Read more: investor.agenusbio.com/news/default.aspx -
Agenus reposted
Jennifer Buell
@jbuell01
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 www.biopharmawatch.com/news/INKT/mink-therapeutics-sitc-2…
-
Agenus
@Agenus_Bio
Our Head of Corporate Development and Investor Relations, Zack Armen, will participate in Chardan’s 10th Annual Healthcare Conference: The Next 10 years of Disruptive Innovation. See details below and in our press release: investor.agenusbio.com/news/default.aspx
-
Agenus
@Agenus_Bio
Armenia has granted the first marketing authorizations for BOT+BAL in adults with previously treated MSS mCRC without active liver metastases.
Read more: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
We presented 3-year follow-up data from our Phase 1b study of BOT+BAL in recurrent ovarian cancer at @IGCSociety’s #igcs2026. Estimated overall survival was 48% at 3 years, unchanged from the 2-year estimate, in a heavily pretreated population. Learn more: investor.agenusbio.com/news/default.aspx
-
Agenus
@Agenus_Bio
We will present new BOT+BAL research in colorectal cancer at #sitc2026, including long-term survivor data in refractory MSS mCRC and translational research evaluating BOT+BAL with agenT-797. See our presentation details below and in our press release: investor.agenusbio.com/news/default.aspx
-
Agenus reposted
Pashtoon Kasi MD, MS
@pashtoonkasi
What NEST taught us
Lesson 5: Feasibility
FOxTROT & groups outside of US have helped move neoadjuvant therapy forward, but not routinely used in US. Patients we saw had a surgery date that was rescheduled.
#nest3 now open for accrual! @OncoAlert
aacrjournals.org/clincancerres/article/doi/10.1158/1078-0… -
Agenus
@Agenus_Bio
Missed our September Stakeholder Webcast yesterday? 🎥Watch the replay: www.youtube.com/watch?v=Fq7JsqwEiWk
Hear updates on ROBBIN Phase 3 execution, BOT+BAL and the rationale for immunotherapy before surgery.
#agenus #botbal #colorectalcancer -
Agenus
@Agenus_Bio
Join us today at 4:30 p.m. ET for our September webcast featuring physician perspectives on treating earlier-stage disease with Dr. Benjamin Schlechter MD
Register and watch here: agenusbio.zoom.us/j/94988495639?pwd=VVFCWFpkdS5eTEohUrazY…
$AGEN -
Agenus
@Agenus_Bio
Agenus will present three-year overall survival data from the recurrent ovarian cancer cohort of the Phase 1b C-800-01 study evaluating BOT+BAL at #igcs2026.
Read the release: investor.agenusbio.com/news/default.aspx
#ovariancancer #immunooncology $AGEN -
Agenus
@Agenus_Bio
Agenus will participate in the Cantor Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference this September, including fireside chats and 1:1 investor meetings.
Learn more: investor.agenusbio.com/news/default.aspx
#agenus #biotech -
Agenus
@Agenus_Bio
New in Clinical Cancer Research: mature Phase 1b BOT+BAL data in MSS mCRC without active liver metastases show 21.2-mo median OS, 33% 3-year OS, and responses in low-TMB/PD-L1-negative tumors.
Read more: investor.agenusbio.com/news/default.aspx
#botbal #colorectalcancer -
Agenus
@Agenus_Bio
Updated Phase 2 NEST results with neoadjuvant BOT+BAL are now published in Clinical Cancer Research: no observed CRC recurrences at longer follow-up, 59% pathologic response in pMMR/MSS tumors and no surgery delays.
Read more: investor.agenusbio.com/news/default.aspx
$AGEN #coloncancer -
Agenus
@Agenus_Bio
Agenus will report Q2 2026 financial results and provide a development update before the market opens on Thursday, August 6.
Learn more: investor.agenusbio.com/news/default.aspx
$AGEN #bot #crc #immunotherapy #earnings -
Agenus
@Agenus_Bio
At #esmo26, 3 investigator-sponsored posters will highlight #bot+BAL in neoadjuvant CRC, refractory MSS mCRC and advanced sarcoma. NEOASIS adds to the evaluation of BOT+BAL before surgery as Agenus advances its neoadjuvant strategy.
-
Agenus
@Agenus_Bio
This work by @ben_schlechter, fellow investigators and pts helped challenge long-held assumptions about IO in MSS CRC—and is informing how IO treatment with BOT/BAL will be studied earlier in the disease in the neoadjuvant setting. Thank you for your contributions Dr. Schlechter.
VJ Oncology
@VJOncology
Benjamin Schlechter (@ben_schlechter) at #esmogi26 presents findings from extended follow-up of the Phase Ib C-800-01 study of botensilimab plus balstilimab in previously treated MSS metastatic #colorectalcancer without liver metastases 🩺💉
The combination showed durable responses, with 33% of patients alive at 3 years, and manageable toxicity 📊
Watch: www.vjoncology.com/video/ilh2zbm92-i-3-year-data-of-boten…
#oncology @myESMO #crcsm #immunoonc @DanaFarberNews #ctsm
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Gilead Sciences (Silver) and Revolution Medicines (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given. -
Agenus
@Agenus_Bio
Agenus announced an oversubscribed private placement of up to $340M to advance ROBBIN, its planned Phase 3 trial of neoadjuvant #bot+BAL in high-risk Stage II/III MSS colon cancer.
Webcast today at 8:30 a.m. ET: agenusbio.zoom.us/j/97333887478?pwd=3lV1hs2TBfQPb3ma02Pii…
Read release: investor.agenusbio.com/news/default.aspx
$AGEN -
Agenus
@Agenus_Bio
New at #esmogi26: Agenus reported 3-year follow-up data for investigational BOT+BAL in refractory MSS mCRC without active liver metastases, including 33% 3-year OS, 21.2-mo median OS and no new safety signals.
📎Release:investor.agenusbio.com/news/default.aspx
📰Poster: www.agenusbio.com/publications -
Agenus
@Agenus_Bio
At #esmogi26, Agenus will present updated 3-year survival from the 123-patient Phase 1b BOT/BAL cohort in MSS metastatic colorectal cancer without active liver metastases, reflecting an additional year of follow-up.
Watch below for details. #msscrc #crc -
Agenus
@Agenus_Bio
Not all “cold” tumors are the same.
New in Oncogene: Agenus and the Armenian Bioinformatics Institute show how transcriptomic profiling may help identify immune patterns linked to #bot/BAL outcomes in MSS #colorectal cancer.
Read more: www.nature.com/articles/s41388-026-03861-2 -
Agenus
@Agenus_Bio
This #nationalcancersurvivorsday, we celebrate the strength and resilience of people living with and beyond cancer, and recognize the work still ahead.
At Agenus, we remain committed to advancing science so more patients may have the opportunity to live longer, better lives. -
Agenus
@Agenus_Bio
A few great days in Chicago at #asco2026 connecting with IO experts, attending scientific sessions and reconnecting with colleagues across the oncology community.
We return energized and ready to get back to work advancing IO for patients.
visit: agenusbio.com/publications -
Agenus
@Agenus_Bio
At #asco26, Agenus + Noetik will present retrospective data on TARIO-2, an AI model analyzing routine H&E images from BOT+BAL-treated pts.
In refractory MSS mCRC NLM, the AI-identified subgroup had 64% response vs 9% in the remaining cohort.
Full release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
New Phase 2 #bot+BAL melanoma data will be presented at #asco26.
In heavily pretreated advanced checkpoint-refractory #melanoma, median OS was 16.6 months, 42% of patients were alive at 2 years, and median DOR was not reached.
Read the Release: investor.agenusbio.com/news/default.aspx -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
At #asgct2026, MiNK is presenting clinical evidence that agenT-797, our off-the-shelf allogeneic #inkt cell therapy, generated distinct immune responses in solid tumors and #ards.
The data support the potential of iNKT cells to drive context-dependent immune reprogramming.
Read more: investor.minktherapeutics.com/press-releases -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK and First Lviv Territorial Medical Union have initiated a randomized Phase 2 trial evaluating agenT-797 in severe acute lung injury and critical illness.
The study will assess clinically meaningful ICU outcomes, including survival, ventilator-free days, recovery and secondary infections.
Read more: investor.minktherapeutics.com/press-releases
$INKT #ards #celltherapy #criticalcare -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
🫁 Today - 11am at #ats2026, Dr. Terese Hammond presents new findings involving the combination of agenT-797 (@MiNK_iNKT) + Anktiva® (N-803) (@ImmunityBio) in persistent pulmonary fungal infection under complex pathogenic conditions.
#pulmonary #criticalcare #ards #immunotherapy #celltherapy -
Agenus reposted
Jennifer Buell
@jbuell01
🫁 Severe inflammatory lung disease driven by deadly pathogens and other fibrotic events is becoming an increasingly urgent global challenge in pulmonary medicine.
Today at #ats2026, Dr. Terese Hammond presents @MiNK_iNKT agenT-797 + @ImmunityBio Anktiva® data under complex pathogenic conditions. #inkt #pulmonary #ards #sepsis #hantavirüs #fungemia
MiNK Therapeutics
@MiNK_iNKT
🫁 Today - 11am at #ats2026, Dr. Terese Hammond presents new findings involving the combination of agenT-797 (@MiNK_iNKT) + Anktiva® (N-803) (@ImmunityBio) in persistent pulmonary fungal infection under complex pathogenic conditions.
#pulmonary #criticalcare #ards #immunotherapy #celltherapy -
Agenus
@Agenus_Bio
We will report Q1 2026 financial results before market open on Mon, May 11.
A June webcast, held with our Annual Meeting of Shareholders, will spotlight strategic priorities, data milestones and progress across the global BOT/BAL program.
Read Release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Agenus is heading to #asco2026 with 4 accepted abstracts, including the first Phase 2 presentation of #bot+/-BAL in advanced cutaneous #melanoma, plus #crc and translational research updates.
Read press release: investor.agenusbio.com/news/default.aspx
$AGEN #immunotherapy #biotech -
Agenus
@Agenus_Bio
Agenus and BAP Pharma announced an exclusive global partnership supporting authorized access programs for investigational BOT+BAL, including France’s AAC pathway and named-patient programs in select countries.
Read release:investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Our updated April 2026 corporate overview is now available, highlighting BOT+BAL #crc progress, Phase 3 BATTMAN rationale, expansion potential, and key 2026 catalysts.
Visit our IR site: investor.agenusbio.com/overview/default.aspx
View the deck: s202.q4cdn.com/949764554/files/doc_presentations/2026/Apr…
$AGEN #immunotherapy -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK is live in Los Angeles for #aacrio25.
Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with @Agenus_Bio's BOT/BAL & chemotherapy in refractory #gastriccancer.
Learn more: investor.minktherapeutics.com/news-releases/news-release-… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics announces abstract acceptance at American Thoracic Society (ATS) International Conference 2026 Featuring #agent-797 in a novel combo approach for persistent infection—highlighting the potential of iNKT cell therapy beyond oncology.📍
Poster #103 | May 20
Details: investor.minktherapeutics.com/press-releases
#ats2026 #immunotherapy #celltherapy -
Agenus
@Agenus_Bio
Agenus announces data from a Phase II investigator sponsored trial of #bot/BAL + @MiNK_iNKT agenT-797 in PD-1 refractory gastroesophageal cancer.
🔹Apr 20
🔹2–5 PM PT
🔹Poster 52 | CT166
#aacr25 #immunotherapy #oncology -
Agenus
@Agenus_Bio
First patient enrolled in our global Phase 3 #battman trial evaluating #bot+BAL in MSS/pMMR mCRC — a population historically resistant to immunotherapy.
A key step forward as we advance our registrational program.
🔗investor.agenusbio.com/news/default.aspx
#oncology #immunotherapy $AGEN -
Agenus
@Agenus_Bio
We’re live.
Join now for updates on #bot+BAL, #access programs, and 2026 priorities.
▶️ Watch: vimeo.com/event/5828543
#immunotherapy #crc #innovation -
Agenus
@Agenus_Bio
Reminder: Join our March Stakeholder Webcast today.
Updates on #bot+BAL, global #access, and 2026 priorities.
Register: vimeo.com/event/5828543
Submit Questions: app.sli.do/event/qBiptRwcnamAfzRhiQnExc -
Agenus
@Agenus_Bio
March is Colorectal Cancer Awareness Month.
But for patients, the need for better options doesn’t end on March 31.
Our focus continues on advancing #immunotherapy for those with the fewest options.
#crcawarenessmonth #innovation -
Agenus
@Agenus_Bio
Agenus announces March webcast on Tues, Mar 31st at 4:30EST
Updates on:
• Clinical progress
• Global access (France AAC + NPP)
• 2026 priorities
Live Q&A included.
Register: vimeo.com/event/5828543
Submit questions: app.sli.do/event/qBiptRwcnamAfzRhiQnExc
#immunotherapy #oncology #bot -
Agenus
@Agenus_Bio
At Agenus, we believe innovation should confront tumors historically resistant to #immunotherapy
and real progress means moving beyond incremental benefit.
#crcawarenessmonth #unmetneed #innovation -
Agenus
@Agenus_Bio
Every cancer treatment available today began in a clinical trial.
Patients who participate in research help bring tomorrow’s treatments to patients today.
#crcawarenessmonth #clinicaltrials -
Agenus
@Agenus_Bio
CRC is rising in younger adults.
Know the warning signs.
Awareness can save lives.
#crcawarenessmonth #crc #signs -
Agenus
@Agenus_Bio
27,000 blue flags on the National Mall.
Each represents a life that may be lost to #crc in 2030-- unless we ACT NOW.
Thank you to @FightCRC for honoring these lives and raising awareness of a disease that is now the leading cause of cancer death in people under 50 in the U.S. -
Agenus
@Agenus_Bio
At #aacr2026, prelim results from the investigator-sponsored #bbopco study led by Nicholas DeVito from Duke, will be presented evaluating #bot+BAL in 1L MSS #crc.
A shift toward using IO earlier to potentially reduce reliance on chemo + surgery.
Release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Innovation only matters if patients can access it.
We remain committed to expanding responsible global access pathways while advancing registrational trials.
Because time matters.
#crcawarenessmonth #accesstoinnovation -
Agenus
@Agenus_Bio
Innovation in cancer care cannot be incremental.
Agenus continues to build clinical evidence for #bot + BAL, while physician and patient interest grows globally. In parallel, we are strengthening manufacturing to support expanding clinical and access programs.
#immunotherapy -
Agenus
@Agenus_Bio
Agenus reports 2025 results and progress for BOT+BAL
• P3 BATTMAN trial underway in MSS mCRC
• 42% 2-year OS in heavily pretreated pts
• 200+ HCP access inquiries from 30+ countries
• $4.2M initial revenue from access programs
investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Agenus was founded on a simple belief: the immune system can be harnessed to fight cancer.
For 30+ years, we’ve advanced immuno-oncology science.
Today, that foundation drives our focus on areas of highest unmet need.
#crcawarenessmonth #immunotherapy -
Agenus
@Agenus_Bio
Agenus triggers first $20M contingent payment under Zydus collaboration.
Funds support manufacturing for #bot+BAL as enrollment advances in the #battman Phase 3 trial and global access programs expand.
Read the release: investor.agenusbio.com/news/default.aspx
#immunotherapy #access #bot #crc -
Agenus
@Agenus_Bio
~85–95% of metastatic colorectal cancer is MSS.
Historically resistant to immunotherapy.
Innovation must reach the majority — not just the minority.
#mssmcrc #immunotherapy #crcawarenessmonth -
Agenus
@Agenus_Bio
For many pts, survival comes with lasting side effects from conventional treatments like neuropathy, bowel dysfunction, fertility loss.
Extending life matters. Preserving quality of living matters.
The future must aim higher than incremental gains.
#crcawarenessmonth -
Agenus
@Agenus_Bio
Agenus will report Q4 and full-year 2025 financial results on March 16.
A stakeholder briefing later this month will highlight strategic priorities and progress across the global #bot/BAL development program.
Read the release: investor.agenusbio.com/news/default.aspx
#earnings $AGEN -
Agenus
@Agenus_Bio
Nearly 3 in 4 younger CRC patients are diagnosed at advanced stages.
Earlier awareness. Earlier screening. Faster innovation.
We must move on all three fronts.
#crcawarenessmonth #eocrc #immunotherapy -
Agenus
@Agenus_Bio
Colorectal cancer is now the #1 cause of cancer-related death in adults under 50.
Mortality from most major cancers has declined.
CRC mortality has increased 1.1% annually since 2005.
The status quo is not enough.
#crcawarenessmonth #crc #immunotherapy -
Agenus
@Agenus_Bio
At #aacrio, Agenus presented data showing integrated blood + tumor immune features identify biologically distinct MSS mCRC subgroups with differential survival.
Read release: investor.agenusbio.com/news/default.aspx
View Poster B036: www.agenusbio.com/publications
#immunotherapy #biomarker #bot #crc -
Agenus
@Agenus_Bio
Published by OncoDaily: Dr. Garo H. Armen’s op-ed, “The Old System Failed Patients.”
Disruption was necessary. Now reform must shorten timelines, modernize evaluation, and expand access for patients who can’t wait.
#access #innovation #immunotherapy
OncoDaily
@oncodaily
The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen
oncodaily.com/opinion/garo-armen-change-must-go-further2026
@garo_armen @Agenus_Bio
@HHSGov @SecKennedy @HHSResponse @FDA @US_FDA @FDAOncology @US_FDA @FDArecalls -
Agenus
@Agenus_Bio
Catch the 10-minute highlights from our first 2026 Stakeholder Webcast—covering the Zydus partnership, expansion of the French AAC #bot+BAL #immunotherapy program, and our focus for the year ahead.
📺 Watch the reel: youtu.be/NRP1nP7pwdw -
Agenus
@Agenus_Bio
Agenus will present a poster at #aacrio 2026 highlighting biomarker analyses from the investigational #bot +BAL program in immunologically “cold,” treatment-refractory cancers.
📅 Feb 19th @ 12:15-3:15PM PT / 3:15-6:15 PM ET
🔗to press release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
ICYMI: Our January 28th webcast is now live on YouTube.
French AAC expansion (now incl. three tumor types), the Zydus closing, and rising global interest in BOT+BAL—plus what it all means for patients in 2026.
🎥 here: youtu.be/gIGVEdHGRiM -
Agenus
@Agenus_Bio
Today at 4pm ET: Our first Stakeholder Webcast of 2026 brings together global oncology leaders to discuss #collaborations, expanded #patientaccess and #medicalaffairs to support BOT+BAL.
Register: vimeo.com/event/5673012/register -
Agenus
@Agenus_Bio
We’re LIVE!
Join our January 2026 Stakeholder Webcast featuring Dr. Jones, Dr. Iglesias, and Dr. Armen discussing expanding access and what to expect in 2026.
Register & join live event: vimeo.com/event/5673012/register -
Agenus
@Agenus_Bio
Join us tomorrow at 4pm ET for the first Agenus Stakeholder Webcast of 2026.
🔹Zydus Strategic Partnership Closure
🔹Global BOT+BAL Access
🔹Clinical Development and Operational Readiness
Register: vimeo.com/event/5673012/register
Questions: ask@agenusbio.com -
Agenus
@Agenus_Bio
#crc is now the leading cause of cancer death under 50, per @JAMA_current.
We’re advancing #bot+BAL to help move beyond treatments with long-term effects, including chemo, radiation, and radical surgery—especially for younger patients.
www.agenusbio.com
#immunotherapy
JAMA
@JAMA_current
Analysis of US mortality data indicates breast cancer, lung cancer, and leukemia deaths decreased in people younger than 50, while #colorectalcancer mortality rose to become the leading cancer death by 2023.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
Agenus
@Agenus_Bio
Agenus has expanded its global Medical Affairs infrastructure to support increasing physician-initiated requests for authorized access to investigational botensilimab + balstilimab (#bot+BAL) through established regulatory pathways outside the U.S.
🔗investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Join us Jan 28 at 4pm ET for the first Agenus Stakeholder Webcast of 2026.
🔷 Expanded Global Access to BOT+BAL
🔷 Clinical Dev and Partnership Update
🔷 2026 Preview
Register: vimeo.com/event/5673012
Questions: ask@agenusbio.com
Read full release: investor.agenusbio.com/news/default.aspx -
Agenus reposted
Jennifer Buell
@jbuell01
TODAY: @MiNK_iNKT is presenting at the inaugural USA–Saudi Biotech Alliance, participating in the global initiative designed to enable scale, accelerate access, and expand patient impact across borders. Brilliant leadership and vision, @PatrickSoonShiong, @DHSgov, Dr. Al Saud, Dr. Alknawy in convening this moment for global healthcare resilience and access.
Dr. Pat Soon-Shiong
@DrPatrick
A decade of work at Nant and @ImmunityBio to be unveiled at this historic summit of USA-Saudi Alliance we convened. Honored that very senior leadership are attending from both Saudi and USA to address healthcare resiliency and patient access. Addressing checkpoint failures soon
-
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
Proud to see @jbuell01 Jennifer Buell, PhD, represent MiNK Therapeutics at the USA–Saudi Biotech Alliance Global Health Summit, highlighting iNKT cell therapies within global immunotherapy platforms for U.S.–Saudi trials.
#inkt #immunotherapy #biotech -
Agenus reposted
Jennifer Buell
@jbuell01
MiNK-215 ⭐️"In the Spotlight"⭐️@AACR with expert commentary by Dr. Steven Albelda @PennMedicine
MiNK-215 shows how a multi-mechanism, allo-iNKT can remodel tumor microenvironment, overcome resistance, and activate durable #immunity in solid #cancer.
This is what "multiple shots on goal” looks like (IL-15-FAP-CAR-INKT; MINK-215)
doi.org/10.1158/2326-6066.CIR-25-1344
#immunotherapy #celltherapy #car #allogeneic #inkt #solidtumors #oncology #cancerresearch #biotech -
Agenus
@Agenus_Bio
When standard options are exhausted, access matters.
France has expanded compassionate access to #bot+ BAL for patients with colorectal cancer, certain ovarian cancers, and soft-tissue sarcomas—fully reimbursed and hospital-based under AAC.
Read Release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
Durable responses. Refractory disease. Few options.
New data published in JITC underscore the potential of botensilimab + balstilimab in platinum-refractory ovarian cancer.
📄press release: investor.agenusbio.com/news/default.aspx
📄pub: jitc.bmj.com/lookup/doi/10.1136/jitc-2025-013222
#immunotherapy #ovariancancer -
Agenus
@Agenus_Bio
Independent analyses help contextualize emerging data and guide future research.
A new ESMO publication compares #bot + BAL with current standards of care in refractory MSS metastatic colorectal cancer.
🔗www.sciencedirect.com/science/article/pii/S25900188250051…
#colorectalcancer #esmo #clinicalresearch -
Agenus
@Agenus_Bio
During his #esmoio25 spotlight lecture, Dr. Steven O’Day explained why CTLA-4 is re-emerging as a central driver of IO Revolution 2.0.
Read the full presentation: agenusbio.com/publications/
#immunooncology #ctla4 #cancerresearch #biotech -
Agenus reposted
Jennifer Buell
@jbuell01
🚨 Big move with @ZydusUniverse & Formycon deal - highlights serious scale-up in IO and biosimilar footprint — and having @Agenus_Bio state-of-the-art manufacturing behind Zydus provides even more strength for this growth! #agenus @MiNK_iNKT #globalmarkets
🔗 finance.yahoo.com/news/formycon-zydus-partner-exclusive-l… -
Agenus
@Agenus_Bio
ICYMI: Our End-of-Year Stakeholder Webcast replay is now on YouTube.
🎦Watch here: youtu.be/N4ST9r4iBac
Hear from Dr. Lieu, Dr. Loree & Dr. Johnson on #io in MSS #crc, Phase 3 BATTMAN momentum, global access progress, and powerful patient-centered perspectives.
#botbal -
Agenus
@Agenus_Bio
We’re LIVE!
Join our End-of-Year Stakeholder Webcast featuring Dr. Lieu, Dr. Loree, and Dr. Johnson discussing IO in CRC, the BATTMAN Phase 3 trial, and early-onset CRC.
Register to join live event: vimeo.com/event/5519294/efa702d111 -
Agenus
@Agenus_Bio
1 hour until we go LIVE.
Join us at 4pm ET for updates on IO in CRC, the global Phase 3 BATTMAN trial, and a powerful caregiver perspective.
Register now: vimeo.com/event/5519294/efa702d111 -
Agenus
@Agenus_Bio
Today at 4pm ET: Our End-of-Year Stakeholder Webcast brings together GI oncology leaders + a caregiver/physician perspective on early-onset CRC.
Agenda includes IO in CRC, global Phase 3 BATTMAN update, and more.
Register: vimeo.com/event/5519294/efa702d111 -
Agenus
@Agenus_Bio
Join us Dec 3 at 4pm ET for the Agenus End-of-Year Stakeholder Webcast.
• Phase 3 BATTMAN study
• Evolving IO approaches in MSS CRC
• A caregiver–physician perspective
Register: vimeo.com/event/5519294/efa702d111
Questions: ask@agenusbio.com
Real full release: investor.agenusbio.com/news/default.aspx -
Agenus
@Agenus_Bio
BOT/BAL continues to redefine what’s possible in immunotherapy showing durable survival across multiple tumor types, regulatory progress, and growing access for patients worldwide.
Read more on our Q3 2025 milestones: investor.agenusbio.com/news/default.aspx
#immunooncology #botbal #crc -
Agenus
@Agenus_Bio
“Start with what can last.”
Great perspective from Dr. Nicholas DeVito on teaching the immune system to remember—and why challenging the sequence of therapy could reshape outcomes.
Exclusive Conversation with Dr. Nicholas DeVito in @Oncodaily
oncodaily.com/magazine/immune-system-nicholas-devito-395036 -
Agenus
@Agenus_Bio
At @GatewayCR’s Annual Gala, Dr DeVito was recognized for leading an investigator-initiated study of #bot/ BAL given before chemo + surgery in #crc — a bold step toward reducing treatment burden.
🎥patient video: www.youtube.com/watch?v=4pSiTI-nodY
#immunotherapy #gatewayforcures -
Agenus
@Agenus_Bio
Within 5 years, #crc is projected to be the #1 cancer killer under 50.
Agenus CEO Dr. Garo Armen urges the FDA to match the pace of science and bring next-gen immunotherapies to patients faster.
🔗 dcjournal.com/fda-must-keep-up-with-science-on-cancer/
#cancercare #fda #innovation #immunotherapy -
Agenus
@Agenus_Bio
ICYMI: Prof. Alexander Eggermont shared how France’s AAC program gives patients access to #botbal—“a unique combo with efficacy across multiple tumor types.”
Watch his full remarks on global impact ▶️ youtu.be/N0BUNU87crs
#immunotherapy #cancercare #globalaccess -
Agenus
@Agenus_Bio
ICYMI: At our October Stakeholder Webcast, Dr. Michael Gordon shared new 400+ patient pan-tumor data from #esmo2025 showing how #bot + #bal are challenging long-held limits in immuno-oncology.
▶️ Watch the replay: youtu.be/N0BUNU87crs
#oncology #immunotherapy #cancerresearch -
Agenus
@Agenus_Bio
We’re LIVE! #agenus Stakeholder Briefing on #botbal: post-ESMO data + France’s AAC inclusion, moderated by Dr. Garo Armen.
🎥 Join now: riverside.fm/studio/agenus-presentation
#immunooncology -
Agenus
@Agenus_Bio
Today, 4 PM ET: #agenus Stakeholder Briefing on #botbal global momentum + post-#esmo2025 insights.
With Dr. Michael Gordon & Prof. Alexander Eggermont.
🎥 Watch live: riverside.fm/studio/agenus-presentation
#immunooncology -
Agenus
@Agenus_Bio
Emerging survival plateaus with BOT/BAL across advanced solid tumors.
Presented by Dr. Michael Gordon at #esmo2025 from a 400+ patient Phase 1b study of refractory cancers.
See the full presentation → www.agenusbio.com/publications
#botbal #immunooncology -
Agenus
@Agenus_Bio
New #esmo2025 data: BOT/BAL shows 39% of patients alive at 2 years across multiple refractory tumors, including those who failed prior IO. Durable hope for patients left behind by first-gen immunotherapy.
Read the release: investor.agenusbio.com/news/default.aspx
#immunooncology #botbal -
Agenus
@Agenus_Bio
Join us Oct 21, 4PM ET for the next #agenus Stakeholder Briefing—moderated by Dr. Garo Armen.
Hear from industry leaders report post #esmo2025 BOT/BAL data and learn about expanding access.
🎥 Watch live → riverside.fm/studio/agenus-presentation
#botbal #immunooncology -
Agenus
@Agenus_Bio
Proud of the work @CCAlliance is doing with @katiecouric and @VancityReynolds to bring CRC to the forefront. By 2030, CRC is estimated to be the #1 cause of cancer related death in people under 50! Get Screened!
youtu.be/gvhKiFq4Oes
#leadfrombehind #crc -
Agenus
@Agenus_Bio
Missed the Agenus Stakeholder Briefing?
Catch the highlights in 4 minutes:
✔️ CRC crisis & urgent patient needs
✔️ Our bold vision for IO
✔️ BOT/BAL & Phase 3 BATTMAN
✔️ Partnership momentum
Watch below:
#immunooncology #crc #biotech #botbal #agenusThis media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
France grants reimbursed early access to BOT/BAL for patients with metastatic MSS colorectal cancer under its Accès Compassionnel (AAC) program.
Read More: investor.agenusbio.com/news/news-details/2025/France-Gran…
#colorectalcancer #immunotherapy #botbal #france #aac #oncology -
Agenus
@Agenus_Bio
Agenus @ H.C. Wainwright 27th Global Investment Conference
Fireside chat: Tue, Sept 9 • 10:00 AM EST
With Dr. Richard Goldberg (CDO) & Robin Taylor, PhD (CCO)
In person: Lotte NY Palace, Kennedy II – 4th Fl
Live Webcast: journey.ct.events/view/967c04b3-6f9c-484b-8810-f0eedfc11078
#biotech #immunooncology $AGEN -
Agenus
@Agenus_Bio
Last night we hosted a Virtual Stakeholder Briefing with global leaders on strategic and financial updates, calling upon @HHSgov and @FDA to lower recommended screening ages for patients.
WATCH: investor.agenusbio.com/events-and-presentations/default.aspx
#immunooncology #biotech #cancerresearch #innovation #crc -
Agenus
@Agenus_Bio
Today @ 4PM ET 🚨
Join our Stakeholder Webcast
Don’t miss it.
Link: riverside.fm/studio/agenus-presentation
#biotech #io #crc -
Agenus
@Agenus_Bio
📢 NEW LINK: Don’t miss our Virtual Stakeholder Briefing on Aug 27 @ 4PM ET!
riverside.fm/studio/agenus-presentation
We'll cover our progress, BOT/BAL data, BATTMAN trial preview + more.
#immunooncology #botbal #biotech $AGEN -
Agenus
@Agenus_Bio
Join us for Agenus’s Virtual Stakeholder Briefing on Wed, Aug 27, 2025, at 4:00 PM ET!
Hear from our CEO Garo Armen & leading oncology experts on BOT/BAL advancements, the Zydus partnership and Phase 3 BATTMAN study in #mcrc.
Register: registrations.events/direct/Q4I7324292 -
Agenus
@Agenus_Bio
Agenus Announces Q2 2025 Financial Results this morning.
Join us at the end of August for a virtual meeting where we’ll share key strategic progress.
Read more: investor.agenusbio.com/news/news-details/2025/Agenus-Anno…
#agenus #biotech #financialresults #immunooncology #q22025 -
Agenus
@Agenus_Bio
Your immune system can fight more than germs—it can fight cancer.
#immunooncology (IO) therapies supercharge your natural defenses to detect, attack & remember cancer.
Learn why IO is different from chemo & radiation.
#immunotherapy #cancerresearch -
Agenus
@Agenus_Bio
In 2022, colorectal cancer (#crc) was the leading cause of cancer-related death in men and 2nd in women ages 20–49.
A study in @JAMA highlights rising early-onset CRC, why it’s happening & the need for better treatments.
Read more: jamanetwork.com/journals/jama/article-abstract/2836671 -
Agenus
@Agenus_Bio
Colorectal cancer cases are rising, underscoring the need for innovative research. Emerging #immunooncology (IO) strategies are being studied for their potential to improve outcomes. Watch this series from @TargetedOnc with Dr. Schlechter of @DanaFarber.
Targeted Onc
@TargetedOnc
WATCH: @ben_schlechter discusses the unmet needs and advent of immunotherapy in colorectal cancer treatment www.targetedonc.com/view/beyond-the-breakthroughs-unmet-n…
-
Agenus
@Agenus_Bio
Agenus abstracts accepted for #esmo25 including an oral presenting emerging survival plateaus with BOT + BAL in 343 evaluable refractory patients across 5 tumor types. Additional IST abstracts in cervical, MSS CRC & skin cancers.
Details: investor.agenusbio.com/news/news-details/2025/Agenus-to-H…
#immunotherapy -
Agenus
@Agenus_Bio
Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer. Curious about how this approach has the potential to change the future of #cancercare?
Learn more at: www.agenusbio.com/wp-content/uploads/2024/02/what_is_IO_i… -
Agenus
@Agenus_Bio
Colon cancer affects more than just the body—it disrupts work, daily life, and family. @DanaFarber’s Dr. @ben_schlechter explains the full impact on families. Watch now + explore resources: agenusbio.com/patients-care-partners/ #coloncancer
-
Agenus
@Agenus_Bio
On @CNBC 's Squawk Box, Dr. @MartyMakary spotlighted @US_FDA 's push to cut conflicts of interest & speed #cancer innovation. We've submitted request to join the National Priority Voucher Program and look forward to advancing chemo- & radiation-free GI cancer therapies. #crc
-
Agenus
@Agenus_Bio
Thank you to @myESMO, @ben_schlechter and @DanaFarber for presenting new results of #bot/BAL in refractory MSS #colorectalcancer.
#cancerresearch #immunooncology #esmogi2025This media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
Over the weekend at #esmogi25, our botensilimab/balstilimab investigational combo presented new MSS #colorectalcancer data, showing consistent results over extended follow-up. See the full presentation here: www.agenusbio.com/publications #immunotherapy #cancerresearch
-
Agenus
@Agenus_Bio
Wishing everyone a happy and healthy Fourth of July! May this holiday bring us together as a national community and provide support for all Americans, especially those battling #cancer.
-
Agenus
@Agenus_Bio
Our goal is to expand the patient population that can benefit from immunotherapy-based cancer treatments. Watch CDO Dr. Richard Goldberg explain below.
Learn more about #immunotherapy and our pipeline on our website: agenusbio.com -
Agenus
@Agenus_Bio
Current options for colorectal & rectal cancers are invasive, taxing & can lead to lasting complications. In this video, Agenus CEO Dr. Garo Armen shares a personal story that fuels his drive to bring more humane, effective treatments to patients. #cancersurvivormonth
This media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
Stop by our poster next week at #esmogi25 as new data from our Phase 1 #clinicaltrial focused on MSS metastatic #colorectalcancer cohort, presented by @ben_schlechter of @DanaFarber.
Learn more: cslide.ctimeetingtech.com/coasis_21393/attendee/confcal/p… -
Agenus
@Agenus_Bio
Thank you @FightCRC and the global experts who came together to ignite progress for early-onset colorectal cancer. At Agenus, we stand with this community—driven to bring innovation that can change the future for those impacted by this growing and urgent health challenge.
Fight Colorectal Cancer
@FightCRC
That’s a wrap on the first-ever Global Early Onset Colorectal Cancer Think Tank! 🌍 Leaders from 22+ countries came together to accelerate progress against EOCRC. The event may be over, but the commitment is just beginning. The future of CRC care is global, and it starts now.
-
Agenus
@Agenus_Bio
Agenus CDO Dr. Richard Goldberg has dedicated 40+ years to advancing #colorectalcancer treatment.
He says "we have to go farther" to meet the unmet need for CRC patients through academia, research, and #patientadvocacy with @FightCRC.
Watch 👇 and visit: agenusbio.comThis media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
After decades advancing #immunotherapy, @ODayMD now focuses on early-stage #colorectalcancer—guiding next-generation of oncologists and developing treatment strategies as CMO at @Agenus_Bio.
Hear his insights on shifting clinical trends 👇
#oncology #immunotherapy #cancerresearch -
Agenus
@Agenus_Bio
#colorectalcancer is on track to become the leading cause of cancer deaths in adults under 50 by 2030.
Agenus CDO Dr. Richard Goldberg outlines key clinical trends and therapeutic responses to this rising public health concern.
#colorectalcancer #oncology #immunooncology -
Agenus
@Agenus_Bio
Agenus announced #cancerresearch collaboration w/ @NOETIK_ai – the partnership leverages AI-powered virtual cell models to advance precision #immunotherapy and identify people that may benefit most to #bot/BAL treatment.
Read more: investor.agenusbio.com/news/news-details/2025/Agenus-and-…
#immunooncology -
Agenus
@Agenus_Bio
Dr. Richard Goldberg highlights a troubling trend: colorectal cancer is rising among younger adults. Early screening can catch cancer before it spreads—not just for colorectal, but other cancers as well.
#colorectalcancer #earlydetection #cancerscreening #preventivecare #oncology
Chicago Tribune Opinion
@chitribopinions
Dr. Richard Goldberg: Preventive care and cancer screenings are critical to your health www.chicagotribune.com/2025/06/09/opinion-joe-biden-prost…
-
Agenus
@Agenus_Bio
Hear from Agenus CEO Garo Armen on our recent partnership with @ZydusUniverse —an aligned collaborator positioned to help expand our clinical trial efforts in India and accelerate data generation for our #immunotherapy programs.
Learn more: investor.agenusbio.com/news/news-details/2025/Agenus-and-… -
Agenus
@Agenus_Bio
Agenus & @ZydusUniverse announce a $141M partnership to advance BOT/BAL, combining IO innovation with global manufacturing to expand cancer immunotherapy access in India & beyond.
Read more: investor.agenusbio.com/news/news-details/2025/Agenus-and-….
#immunooncology #globalhealth #manufacturing #cancerresearch -
Agenus
@Agenus_Bio
At #asco25, we shared new data highlighting botensilimab’s immune activation in MSS #colorectalcancer—a common, treatment-resistant form of the disease. These findings offer new insight into how these patients may respond at the immune level.
Learn more: investor.agenusbio.com/news/news-details/2025/Agenus-Pres… -
Agenus
@Agenus_Bio
Agenus will present new data from its expanded MSS metastatic colorectal cancer cohort at #esmogi25.
Access full details: investor.agenusbio.com/news/news-details/2025/Agenus-Anno….
#colorectalcancer #immunotherapy #oncology #clinicaltrials -
Agenus
@Agenus_Bio
We are pleased to welcome Dr. Richard Goldberg to Agenus as Chief Development Officer.
A pioneer in gastrointestinal oncology, Dr. Goldberg will guide the advancement of our immuno-oncology programs.
Read the full announcement: investor.agenusbio.com/news/news-details/2025/Renowned-GI…. -
Agenus
@Agenus_Bio
Today we shared our Q1 2025 financial results and highlighted key updates from our immuno-oncology pipeline.
We remain committed to advancing the next generation of immunotherapies for individuals living with cancer.
Access the Q1 report: investor.agenusbio.com/news/news-details/2025/Agenus-Repo…. -
Agenus
@Agenus_Bio
At #aacr25 Dr. Chalabi participated in the session “Neoadjuvant Treatment Across Tumor Types: One Size Does Not Fit All,” discussing the current landscape and promising role of IO—including BOT/BAL studies.
Learn more & view her NEOASIS presentation: www.agenusbio.com/publications. -
Agenus
@Agenus_Bio
As Dr. Goldberg eloquently states, the time is now to evolve how we develop and assess innovative treatments. At Agenus, our mission is rooted in bringing potential life-changing therapies—like BOT/BAL—to patients who have long been underserved.
#colorectalcancer #immunotherapy
The Cancer Letter
@TheCancerLetter
Richard M. Goldberg: "My hope for Makary’s new role is that he will embrace new models in drug development to make sure that we are properly evaluating the benefits of the new tools we have in our toolbox."
cancerletter.com/guest-editorial/20250425_6/ -
Agenus
@Agenus_Bio
Today at #aacr25, Dr. @MyriamChalabi presented the first results from the NEOASIS study, evaluating neoadjuvant botensilimab/balstilimab in early-stage MSS and MSI-H cancers, including colorectal and breast cancers.
Learn more: investor.agenusbio.com/news/news-details/2025/Agenus-BOTB….
#oncology #clinicaltrial -
Agenus
@Agenus_Bio
Looking ahead to #aacr25: Dr. @MyriamChalabi will present the first results from the NEOASIS trial, evaluating neoadjuvant botensilimab/balstilimab in MSI-H and MSS solid tumors.
Learn more about the presentation: investor.agenusbio.com/news/news-details/2025/Agenus-to-P….
#immunotherapy #oncology -
Agenus
@Agenus_Bio
Stay tuned for #aacr25, where @DrElkhoueiry will present data from our Phase 1 trial evaluating botensilimab/balstilimab in treatment-refractory hepatocellular carcinoma (HCC).
Learn more: investor.agenusbio.com/news/news-details/2025/Agenus-to-P….
#immunotherapy #cancerresearch #oncology -
Agenus
@Agenus_Bio
Tune in to "The Top Line" by @FierceBiotech! Our Chief Medical Officer, Dr. Steven O'Day, shares his insights on the latest innovations and the future of immunotherapy in colorectal cancer care.
Listen here: www.fiercebiotech.com/sponsored/agenus-cmo-touts-immunoth…
#oncology #cancerresearch #colorectalcancer -
Agenus
@Agenus_Bio
Colorectal cancer is the 2nd leading cause of cancer-related deaths worldwide. As we recognize #colorectalcancerawarenessmonth, we reaffirm our commitment to raising awareness, advancing education, and driving innovation in treatment options for those impacted by this disease.
-
Agenus
@Agenus_Bio
Yesterday at #aacrio25, we presented new translational insights demonstrating the strong immune activation driven by BOT/BAL in combination with chemotherapy and MiNK Therapeutics' allo-iNKTs in refractory #gastriccancer.
Read more about the data: investor.agenusbio.com/news/news-details/2025/Agenus-Pres… -
Agenus
@Agenus_Bio
Join us today at #aacrio25. We’re presenting new translational data from the ongoing Ph2 study in refractory #gastriccancer, evaluating BOT/BAL in combination with chemotherapy & @MiNK_iNKT allo-iNKTs (agenT-797).
Learn more and view presentation details: investor.agenusbio.com/news/news-details/2025/Agenus-Pres… -
Agenus
@Agenus_Bio
Our CEO, Dr. Garo Armen, was honored to speak at the Second Annual Oncothon this past weekend, where he shared insights and a call to action for advancing innovation in pediatric cancer care.
Hear more from @oncodaily: oncodaily.com/opinion/garo-armen-innovation-pediatric-can…
#oncothon2025 -
Agenus
@Agenus_Bio
Our CMO @ODayMD sat down with @statnews to make the case for redefining how we measure success in #cancer treatment. www.statnews.com/sponsor/2024/12/13/is-it-time-to-rethink…
-
Agenus
@Agenus_Bio
#breakingnews: Today, we announced the publication of new data in the Journal of Clinical Oncology. Read more about the findings here: investor.agenusbio.com/news/news-details/2025/Agenus-Anno… #immunooncology #sarcomas
-
Agenus
@Agenus_Bio
#breakingnews: Today, we announced new data highlighting BOT/BAL across multiple lines of treatment in #colorectalcancer. Find the details of our five #ascogi presentations here: investor.agenusbio.com/news/news-details/2025/Agenus-Pres…
#gi25 -
Agenus
@Agenus_Bio
Our team is looking forward to attending the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. It’s always a pleasure connecting with our peers and industry leaders from around the globe.
-
Agenus
@Agenus_Bio
As the year comes to a close, we are reflecting on both our accomplishments, and the opportunities ahead of us in 2025! Thank you to our talented team and dedicated partners for your continued commitment and support. Here’s to a great year ahead!
-
Agenus
@Agenus_Bio
We’re proud of our cutting-edge manufacturing facilities, including our newest facility in California, designed to accelerate the commercialization of innovative therapies. Read more: magazine.manufacturing-today.com/mag/0392452001734621977/…
-
Agenus
@Agenus_Bio
We’re excited to announce five presentations highlighting new data at the 2025 ASCO GI Symposium next month in San Francisco. Learn more: investor.agenusbio.com/news/news-details/2024/Agenus-Anno…
-
Agenus
@Agenus_Bio
We were honored to join the Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer, hosted by @OncoDaily. Our VP of Research, Dhan Chand, joined leaders to share insights and drive innovation in advancing #colorectalcancer care. Watch now: www.youtube.com/watch?v=cR7Yim2oAW0
-
Agenus
@Agenus_Bio
Agenus is proud to announce a collaboration with @TannerPharma to provide expanded access to our investigational immunotherapies through a Named Patient Program.
Tanner Pharma Group
@TannerPharma
#tannerpharma partners with @Agenus_Bio to expand access to botensilimab & balstilimab for MSS CRC & other #cancers, offering new opportunities for patients. www.businesswire.com/news/home/20241211536801/en/Tanner-P…
-
Agenus
@Agenus_Bio
At @sitcancer #sitc24 we are presenting new data from our investigational immunotherapy programs, including botensilimab and AGEN1721. Explore our latest advancements in cancer research here: investor.agenusbio.com/news/news-details/2024/Agenus-to-P…
-
Agenus
@Agenus_Bio
Receiving a #cancer diagnosis can be overwhelming and filled with uncertainties. We’re here to share knowledge, including providing you with information about our research in #immunotherapy, finding clinical trials, and more: www.agenusbio.com/patients
-
Agenus
@Agenus_Bio
Thank you, @statnews, for a great summit! Our team enjoyed hearing from top voices in the industry, as well as policymakers and advocates. We were proud to sponsor this year’s event and have our Chief Medical Officer, @ODayMD, share his insights on cancer #immunotherapy.
-
Agenus
@Agenus_Bio
Congratulations to our Chairman & CEO, Dr. @garo_armen, on being awarded @WITSA1’s Eminent Person Award. This well-deserved honor recognizes his pioneering work in #immunotherapy and its role in transforming #cancer treatment.
-
Agenus
@Agenus_Bio
We’ll be attending @sitcancer’s 39th Annual Meeting in Houston, TX next month! We look forward to connecting with researchers, clinicians, and other industry leaders driving #immunotherapy R&D. www.sitcancer.org/2024/home
#sitc24 -
Agenus
@Agenus_Bio
The @NBCF reports that more than 360,000 people will be diagnosed with breast cancer in 2024. This #breastcancerawarenessmonth and every month, we support efforts to advance early detection methods and innovative treatment options that can help increase chances of survival.
-
Agenus
@Agenus_Bio
We’re proud to sponsor this year’s #statsummit, focused on delivering meaningful impacts in health and medicine and bringing breakthroughs to patients — all while convening decision makers in one place.
-
Agenus
@Agenus_Bio
That’s a wrap on #esmo2024. Our team had a great time connecting with leaders and advocates from around the world as we explored the future of immuno-oncology together. Thank you for another inspiring annual meeting.
-
Agenus reposted
OncLive.com
@OncLive
WATCH: Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma @breelynwilkyMD @CUCancerCenter @myesmo #esmo2024 #esmo24 #scmsm
www.onclive.com/view/dr-wilky-on-a-study-of-botensilimab-… -
Agenus
@Agenus_Bio
The Agenus team is headed to Barcelona for #esmo24. This Friday, catch the latest data from our clinical trial of botensilimab and balstilimab in refractory sarcomas. View the presentation details here: investor.agenusbio.com/news/news-details/2024/Botensilima…
-
Agenus
@Agenus_Bio
Attending #esmo24 in Barcelona from September 13-17? Our Medical Affairs team welcomes physicians to connect and explore the future of immuno-oncology. Schedule a meeting here: agenusbio.com/medical-affairs/
-
Agenus
@Agenus_Bio
Michael Sapienza, CEO of @CCAlliance, highlights the urgent need for new treatments to tackle MSS #colorectalcancer. Together, we are committed to driving change and innovation to bring hope to patients living with CRC.
-
Agenus
@Agenus_Bio
Today we released our Q2 2024 operational and financial results - get the latest here: investor.agenusbio.com/news/news-details/2024/Agenus-Repo…
-
Agenus
@Agenus_Bio
We’re pleased to share our latest study in @CD_AACR on botensilimab’s mechanism of action and its potential in addressing treatment-resistant cancers. Read more: investor.agenusbio.com/news/news-details/2024/Agenus-Publ… #cancerresearch #immunotherapy #cancertreatment
-
Agenus reposted
Cure GI Cancers
@RueschCenter
CRC in Adolescents and Young Adults: An Emerging Entity. @marshalj23 discusses the noticeable trend in colorectal cancer cases shifting to younger age groups, even to adolescents and young adults. @LombardiCancer @Medscape
decisionpoint.medscape.com/oncology/viewarticle/1001329?c… -
Agenus
@Agenus_Bio
Our own Nils Eckardt MD MSc shares his perspectives on driving change in #oncology via @oncodaily
OncoDaily
@oncodaily
Driving Change in Oncology: the Vision of the Chief Medical Affairs Officer of @Agenus_Bio
oncodaily.com/115149.html
@ASCO @shhovsepyan
#cancer #asco24 #agenus #immunotherapy #healthcareinnovation #oncodaily #oncology -
Agenus
@Agenus_Bio
Colorectal cancer is the second leading cause of cancer death in the United States. Marianne Pearson, Senior Director of Patient Navigation at @CCAlliance, highlights the urgent need for innovative treatment options for these patients.
-
Agenus
@Agenus_Bio
Dr. Benny Johnson shares his journey from medical oncologist to caregiver for his wife battling #colorectalcancer with @oncodaily . Discover his insights on balancing professional expertise with personal care, and the hope found in innovative treatments: oncodaily.com/url/103977
-
Agenus
@Agenus_Bio
Today, we announced the outcomes of our End-of-Phase 2 meeting and shared the topline interim Phase 2 data for BOT/BAL in MSS colorectal cancer. Get the latest: investor.agenusbio.com/news/news-details/2024/Agenus-Anno…
-
Agenus reposted
OncoDaily
@oncodaily
Alexa Buffa named one of 2024's Industry Rising Stars by @LifeSciEvents
@Agenus_Bio @abuffa9
oncodaily.com/positive/102377.html
#agenus #cancer #oncodaily #oncology #leadership -
Agenus reposted
OncoDaily
@oncodaily
Discover the most promising cancer drugs in 2024 and learn key terms to help you understand your treatment options better with this patient-friendly overview of groundbreaking cancer therapies.
@US_FDA @AstraZeneca @DaiichiSankyo @Agenus_Bio @Dizal_Global @genentech @Amgen @MerusNV @moderna_tx @Merck
oncodaily.com/insight/100959.html
#newcancerdrugs #immunotherapy #cancercare #patienteducation #cancerresearch #oncology #cancer #oncodaily #cancerdrugs #promisingcancerdrugs #cancerdrugs2024 #fda #cancerpatient -
Agenus
@Agenus_Bio
Thanks to @OncLive for sharing the important work being done in #colorectalcancer by @ben_schlechter and @DanaFarber #cancerresearch #oncology
OncLive.com
@OncLive
Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal Cancer @ben_schlechter @DanaFarber #crcsm #oncology
www.onclive.com/view/researchers-report-first-effective-u… -
Agenus
@Agenus_Bio
Did you know #immunotherapy activates the body’s own immune system to fight cancer? Agenus Chief Medical Officer, Dr. Steven O'Day, explains why this innovative approach stands apart from traditional chemotherapy.
-
Agenus
@Agenus_Bio
Thank you to @GiOncNow, @ben_schlechter and @DanaFarber for giving this incredible overview of botensilimab's role in treating MSS #colorectalcancer.
#cancerresearch #immunotherapy
GI Oncology Now
@GiOncNow
⭐ We spoke with @ben_schlechter of @DanaFarber on the unique mechanisms of action of botensilimab, and how this therapy is well-suited to treat microsatellite stable colorectal cancer, particularly in non-liver metastatic sites: www.gioncologynow.com/videos/bot-bal-in-mss-crc-efficacy-…
-
Agenus
@Agenus_Bio
As shown last week at #esmogi24, our botensilimab/balstilimab investigational therapy offered new hope for this MSS-#colorectalcancer patient, achieving a complete response in seven weeks. See the full presentation here: www.agenusbio.com/wp-content/uploads/2024/06/240624.ESMO_… #immunotherapy #cancerresearch
-
Agenus reposted
OncLive.com
@OncLive
Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status #oncology #crcsm #esmogi24 @myESMO @D_JafariMD
www.onclive.com/view/neoadjuvant-botensilimab-balstilimab… -
Agenus
@Agenus_Bio
That's a wrap on @myESMO #esmogi24! Our team was inspired by engaging with the GI community and sharing the latest advancements from our BOT/BAL therapy, including new data in neoadjuvant colon cancer. Exciting times ahead for the future of cancer care. #oncology #cancerresearch
-
Agenus reposted
Dr. Cathy Eng
@CathyEngMD
Bot/Bal #immunotherapy in #coloncancer #nest 1/2 @Agenus_Bio with very promising data in early MSI-s/MSI-H #coloncancer ! @myESMO #esmogi24 #esmoambassadors @OncoAlert #cancerresearch #cancer
-
Agenus
@Agenus_Bio
New data from the NEST clinical trial was presented at
@myESMO's #esmogi24 - results demonstrated significant tumor reductions in MSS #coloncancer patients treated with botensilimab/balstilimab in the #neoadjuvant setting. Learn more: investor.agenusbio.com/news/news-details/2024/Significant… -
Agenus
@Agenus_Bio
The Agenus team is in Munich for @myESMO's #esmogi24 annual meeting. Stay tuned tomorrow for new data from the NEST clinical trial on our botensilimab/balstilimab #immunotherapy combination in #neoadjuvant colon cancer.
See the schedule: cslide.ctimeetingtech.com/esmogi24hybrid/attendee/confcal… -
Agenus
@Agenus_Bio
The @theNCI's Cancer Therapy Evaluation Program (CTEP) has announced the availability of our therapy, botensilimab, for clinical studies. Get the details here: investor.agenusbio.com/news/news-details/2024/Cancer-Ther…
-
Agenus
@Agenus_Bio
If you are a physician attending #esmogi24 in Munich from June 26-29, our Medical Affairs team would welcome the opportunity to discuss the future of immuno-oncology with you. Schedule a meeting here: www.agenusbio.com/medical-affairs
-
Agenus
@Agenus_Bio
We are proud to support @FightCRC ’s latest webinar. Tune in tomorrow at 1:00 p.m. ET to hear @smitha42 discuss how to navigate the clinical trial landscape and explore treatment options for #colorectalcancer.
Register to attend: fightcolorectalcancer.org/event/clinical-trials-how-do-i-… -
Agenus
@Agenus_Bio
Are you a physician attending #esmogi24? Join us in Munich from June 26-29 to discuss the future of immuno-oncology with our Medical Affairs team. Schedule a meeting here: www.agenusbio.com/medical-affairs
-
Agenus reposted
The Mirror
@DailyMirror
New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
www.mirror.co.uk/news/health/new-bowel-cancer-treatment-s… -
Agenus
@Agenus_Bio
Results from our Phase 1 clinical trial on the combination of botensilimab and balstilimab for MSS mCRC have been published in @NatureMedicine. Read the full publication here: go.nature.com/4enyRla
-
Agenus
@Agenus_Bio
Yesterday, Dr. Steven O’Day, shared the latest data on our botensilimab programs at @NatureConf’s Cancer Immunotherapy conference in Boston. Thanks to all for the impactful discussion as we advance immunotherapy together. #cancerresearch #immunotherapy
-
Agenus
@Agenus_Bio
Join us at the @GoldmanSachs 45th Annual Global Healthcare Conference for our fireside chat on June 12th at 8:00 a.m. ET. Catch the live webcast: event.webcasts.com/starthere.jsp?ei=1673793&tp_key=7ef0fb…
-
Agenus
@Agenus_Bio
Tomorrow, Dr. Steven O’Day will be speaking at @NatureConf’s #cancerimmunotherapy event, presenting an update on our botensilimab programs. Learn more: conferences.nature.com/event/7d8defc1-4522-41e2-955b-2884…
-
Agenus
@Agenus_Bio
We’ve been inspired and energized by our time at #asco2024, where we had the opportunity to engage with clinicians, advocates, and the oncology community in our partnership to transform the lives of individuals living with cancer.
-
Agenus
@Agenus_Bio
Thank you to @GiOncNow for sharing data from our #asco24 poster presentation.
GI Oncology Now
@GiOncNow
🔬 At #asco24, Dr. @mgfakih of @cityofhope presented a poster showcasing the efficacy of #botensilimab plus #balstilimab for the treatment of microsatellite stable #colorectal cancer.
📋 Learn how the combination differs from previous I-O combinations: www.gioncologynow.com/post/efficacy-of-botensilimab-balst… -
Agenus
@Agenus_Bio
Congrats to Dr. @pashtoonkasi on receiving the Yvonne Award from @oncodaily @ #asco24. The "Challenging the Status Quo" award recognizes those advancing cancer care, exemplified by his leadership of the NEST trials of botensilimab/balstilimab in neoadjuvant colorectal cancer.
-
Agenus
@Agenus_Bio
Thanks to @BioCentury for including our #asco24 data as we continue our mission to expand treatment options for individuals living with cancer.
BioCentury
@BioCentury
New data at #asco24 shows companies haven't given up on immunotherapy for cold tumors. BioCentury analyzes the therapeutic strategies demonstrating early efficacy signals in genetically stable colorectal cancers. www.biocentury.com/article/652573/immunotherapies-break-i…
-
Agenus
@Agenus_Bio
Yesterday, Dr. @mgfakih shared an analysis from our botensilimab/balstilimab MSS colorectal cancer program at #asco24. Learn more about BOT/BAL’s activity in difficult-to-treat metastatic sites of disease in the presentation: www.agenusbio.com/wp-content/uploads/2024/05/219_Fakih-MS…
-
Agenus
@Agenus_Bio
Are you a physician attending #asco24 ? Join us in Chicago to discuss the future of immuno-oncology with our Medical Affairs team. Schedule a meeting here: agenusbio.com/medical-affairs-chicago-2024/
-
Agenus
@Agenus_Bio
#colorectalcancer's continued rise among young adults drives our focus on increasing #crcawareness and patient-centric innovation to expand treatment options for individuals living with cancer. See @NYTHealth's latest to learn more.
NYT Health
@NYTHealth
A new analysis of dozens of studies has identified the most common warning symptoms in adults under 50, whose rates of colon and rectal cancer are on the rise. www.nytimes.com/2024/05/24/health/colon-cancer-warning-si…
-
Agenus
@Agenus_Bio
Agenus is headed to #asco24 where Dr. Marwan Fakih will share a new analysis that highlights botensilimab/balstilimab’s activity across challenging metastatic disease sites in MSS colorectal cancer. Learn more about the data and upcoming presentation: investor.agenusbio.com/news/news-details/2024/Breakthroug…
-
Agenus
@Agenus_Bio
Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer.
Learn more: investor.agenusbio.com/news/news-details/2024/FDA-Grants-… -
Agenus
@Agenus_Bio
Yesterday, we announced our Q1 report, inclusive of our strategic partnership with @Ligand_LGND - validating our advancements in investigational immunotherapy BOT/BAL programs, deep partnership pipeline, and commercial readiness. Learn more: investor.agenusbio.com/news/news-details/2024/Agenus-Repo…
-
Agenus
@Agenus_Bio
Today we announced a royalty financing agreement with @Ligand_LGND. This collaboration enables Agenus to accelerate our efforts to bring botensilimab/balstilimab to patients. Learn more here: investor.ligand.com/news-and-events/press-releases/news-d…
-
Agenus
@Agenus_Bio
May 1st marks #cancerresearchmonth. Join us as we recognize the strides in cancer care and raise awareness to support millions worldwide affected by this disease. We extend our gratitude to our scientists and the research community who drive progress every day.🔬#cancerawareness
-
Agenus
@Agenus_Bio
Stop by our poster on June 1st as we present a sub-analysis of the MSS colorectal cancer cohort from our Phase 1b study of botensilimab and balstilimab at the @ASCO Annual Meeting #asco2024.
Learn more: investor.agenusbio.com/news/news-details/2024/Botensilima… -
Agenus
@Agenus_Bio
Today we announced updated Phase 1 data and progress on our investigational botensilimab/balstilimab combination in patients with metastatic MSS colorectal cancer. Get the latest: investor.agenusbio.com/news/news-details/2024/Agenus-Anno…
#colorectalcancer #botensilimab #immunotherapy #clinicaltrials -
Agenus
@Agenus_Bio
We’ve been energized and inspired by our time at #aacr2024. Yesterday @dhanschand, presented preclinical data on the activity of BMS-986442, @bmsnews bispecific TIGIT program that was licensed from Agenus in 2021 (formerly AGEN1777). View the presentation www.agenusbio.com/publications.
-
Agenus reposted
Jennifer Buell
@jbuell01
I ride in the @PanMass for our brave fighters, our warriors, our purpose. profile.pmc.org/JB1092 @DanaFarber #pmc2024 @MiNK_iNKT @Agenus_Bio
-
Agenus reposted
OncoDaily
@oncodaily
I ride in the Pan Mass Challenge to eliminate the premature loss of so many important lives, to stand with our fighters, to illuminate hope - Jennifer S. Buell
@jbuell01 @MiNK_iNKT @Agenus_Bio @DanaFarber
oncodaily.com/blog/43355.html
#oncology #cancer #motivation #leadership #oncodaily -
Agenus
@Agenus_Bio
Today we announced Q4 & year-end 2023 results. The year was marked by significant progress with our investigational immunotherapy BOT/BAL programs. We are committed to advancing BOT/BAL with the goal of transforming clinical practice and patient outcomes. investor.agenusbio.com/news/news-details/2024/Agenus-Repo…
-
Agenus
@Agenus_Bio
We are proud to support @FightCRC's #unitedinblue- an installation of 27,400 flags on D.C.’s National Mall, representing people under age 50 projected to be diagnosed with CRC in 2030. Agenus’ Dr. Joe Grossman spoke to volunteers and joined with his family to plant flags.
-
Agenus
@Agenus_Bio
Today we honor the achievements and contributions of #women worldwide.
We are proud to recognize and celebrate our female employees on International Women’s Day and every day. Thank you for your commitment and dedication to our mission of transforming #cancer care. #iwd2024 -
Agenus
@Agenus_Bio
At #aacr on April 8, our Vice President of Research, Dhan Chand, will present preclinical data from BMS-986442. This is @bmsnew’s bispecific TIGIT program that was licensed from Agenus in 2021 (formerly AGEN1777). Learn more: investor.agenusbio.com/news/news-details/2024/Agenus-Anno…
#immunotherapy #cancerresearch -
Agenus
@Agenus_Bio
In the latest episode of "The Immuno-Oncology Curve," Dr. Steven O'Day talks with Agenus colleagues Dr. Joseph Grossman and Dr. Benny Johnson.
Learn about their journey from the clinic and the current opportunities and challenges in GI cancers: theimmunooncologycurve.substack.com/p/episode-3-from-prac… -
Agenus
@Agenus_Bio
Proud of our @saponiQx team on this important milestone for the discovery and development of next-generation vaccine adjuvants.
SaponiQx
@saponiQx
We’re pleased to announce that SaponiQx and @Ginkgo have been awarded a 5-year contract totaling up to $31 million from the U.S. Government’s @DeptofDefense to discover and develop next-generation saponin-based vaccine adjuvants. Learn more: www.prnewswire.com/news-releases/ginkgo-bioworks-and-sapo…
-
Agenus
@Agenus_Bio
Agenus joined oncology leaders at @ASCO #gi24.
We are proud to partner with @pashtoonkasi who presented data from neoadjuvant BOT/BAL in colorectal cancer. The findings underscore the potential to help #patients in earlier stages of #crc.
Learn more: investor.agenusbio.com/news/news-details/2024/Botensilima… -
Agenus
@Agenus_Bio
On the second episode of "The Immuno-Oncology Curve," @ODayMD sits down with members of the colorectal cancer community. Together, they delve into the current treatment landscape, the rising trend of early-onset diagnoses, and more.
Listen and subscribe: theimmunooncologycurve.substack.com/p/igniting-change-per… -
Agenus reposted
Pashtoon Kasi MD, MS
@pashtoonkasi
Our📝paper with more than 10,000 accesses ranks at🥇@oncogenejournal.
Neoadjuvant #botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient (pMMR/MSS) colorectal cancer.
Link✍🏽: www.nature.com/articles/s41388-023-02835-y
#gi24 will present full NEST-1 cohort. -
Agenus
@Agenus_Bio
Agenus is a proud member of @MassBio and we are excited to be featured in this month’s member spotlight. Our CEO Garo Armen, Ph.D., speaks to Agenus’ commitment to patients and our goal of transforming cancer care through a second revolution in I-O. www.massbio.org/news/recent-news/member-spotlight-qa-with…
-
Agenus
@Agenus_Bio
Introducing “The Immuno-Oncology Curve,” an Agenus podcast hosted by @ODayMD. On this platform, Dr. O’Day will share the mic with oncologists, advocates, patients, and colleagues to keep you ahead of the curve on the latest in immunotherapy.
Listen here: theimmunooncologycurve.substack.com/p/episode-1-sending-t… -
Agenus
@Agenus_Bio
Today, on #worldpancreaticcancerday, we join communities around the globe to raise awareness for this disease. Agenus is committed to developing new treatment options, including #botensilimab, which is under investigation to potentially help patients with pancreatic cancer.
-
Agenus
@Agenus_Bio
Today Agenus announced its third quarter 2023 financial results and shared the latest data, plans, and achievements in our ongoing investigational botensilimab programs.
Hear more about our progress: investor.agenusbio.com/news/news-details/2023/Agenus-Repo…
#agenus #botensilimab #immunotherapy -
Agenus
@Agenus_Bio
That’s a wrap on #esmo2023. We enjoyed our engagements with oncology leaders and advocates across the globe, where we had the opportunity to share new data from our investigational BOT/BAL programs.
Hear more about these results in our webcast replay at: vimeo.com/878039927/f11bce4f16?ts=0 -
Agenus
@Agenus_Bio
Agenus is proud to unveil the latest research from our investigational #botensilimab programs, showcasing significant advancements across our colorectal, pancreatic, lung, melanoma, and sarcoma studies. #esmo2023
A live webcast will be hosted at 1 pm EDT: investor.agenusbio.com/news/news-details/2023/Agenus-Unve… -
Agenus
@Agenus_Bio
At #esmo2023 Dr. @breelynwilkyMD presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma, which showed durable responses across multiple subtypes.
Learn more: investor.agenusbio.com/news/news-details/2023/ESMO-2023-A… -
Agenus reposted
Dana-Farber's Young-Onset Colorectal Cancer Center
@DFarberYoungCRC
If you're free October 18th, please join our own Dr. Schlechter and this distinguished panel at 1PM EST for a virtual discussion of the growing immuno-oncology revolution against cancer!
webinars.endpts.com/re-activating-the-immune-system-again… -
Agenus
@Agenus_Bio
Agenus completed the planned patient enrollment of its Phase 2 clinical trial evaluating investigational agents botensilimab (BOT) and balstilimab (BAL) in advanced colorectal cancer. Learn more: investor.agenusbio.com/news/news-details/2023/Agenus-Comp…
#colorectalcancer #immunotherapy #botensilimab -
Agenus
@Agenus_Bio
Join us on October 18th for a dynamic #immunotherapy webinar with @endpts. Our Chief Medical Officer, Dr. Steven O'Day, will speak alongside Dr. @ben_schlechter, Dr. @pashtoonkasi, and @CancerInsider to examine the "The Next I-O Revolution.”
Register at: webinars.endpts.com/re-activating-the-immune-system-again… -
Agenus
@Agenus_Bio
We are pleased to announce our second quarter 2023 financial results and provide an update on our exciting progress. Read more about our developments this quarter: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
We look forward to participating in the upcoming @ThisIsBTIG Virtual Biotechnology Conference on Monday, August 7th, at 3:00 PM ET. Tune in for a fireside chat with Dr. Garo Armen, Chairman and CEO of Agenus, as he discusses the latest progress across our portfolio.
-
Agenus
@Agenus_Bio
Did you know? About 127,000 Americans lose their lives to lung cancer each year. Today we honor #worldlungcancerday to magnify the importance of cancer research. Agenus is committed to improving treatment options for these patients. Learn more at: www.lungcancerresearchfoundation.org/lung-cancer-facts/
-
Agenus
@Agenus_Bio
Agenus to provide second quarter 2023 financial report and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 7th, at 3:00 PM ET.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus is thrilled to welcome the newest members of our executive leadership team: Robin Taylor, Chief Commercial Officer; Homa Yeganegi, Chief Product Strategy and Global Medical Affairs Officer; and @faganstephanie, Chief Communications Officer.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus’ latest Phase 1b data demonstrated positive overall survival in advanced #colorectalcancer patients.
Learn more about our recent findings here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
Biotech2050 Podcast
@Biotech2050Pod
Garo Armen, Chairman & CEO, @Agenus_Bio: www.biotech2050.com/episodes/leadership-in-revolutionizin…
-
Agenus
@Agenus_Bio
July is UV Awareness Month, reminding us that ultraviolet rays are the root cause of most skin cancers. Protect yourself this summer and practice important sun safety. #uvawarenessmonth #skincancer
Learn more: www.aad.org/member/advocacy/promote/uv-awareness
@AADskin -
Agenus
@Agenus_Bio
#sarcomas are rare cancers that develop in bones & soft tissues. Join us this #sarcomaawarenessmonth as we raise awareness and support cancer patients worldwide. Learn more about #sarcoma at
@CureSarcoma. Together, let's make a difference.
www.curesarcoma.org/sarcoma-resources/ -
Agenus
@Agenus_Bio
What an inspiring #wcgic23. Agenus was honored to join global oncology leaders to share our latest data on botensilimab & balstilimab's survival benefit in #patients with advanced #colorectalcancer. Learn more: www.agenusbio.com/publications.
Thank you, @WCGIC. -
Agenus
@Agenus_Bio
Today, Dr. Andrea Bullock presented positive data showing the survival benefit of botensilimab & balstilimab in #patients with advanced #colorectalcancer.
Learn more here: investor.agenusbio.com/news-releases/news-release-details…
@BIDMChealth #wcgic23 -
Agenus
@Agenus_Bio
ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer.
Read more: investor.agenusbio.com/news-releases/news-release-details…
#wcgi23 #colorectalcancer -
Agenus
@Agenus_Bio
Agenus is back at #wcgic23 in Barcelona, Spain. Join us as global experts and advocates come together to revolutionize #gicancer care. Stop by our booth and stay tuned tomorrow to hear our late-breaking data in #crc. Together, let's make a difference.
www.worldgicancer.com -
Agenus
@Agenus_Bio
We had a fantastic time with our Medical Affairs team at Agenus HQ in Lexington, MA, as we gear up for @WCGIC next week, where we will present the latest data from botensilimab in MSS #crc. We're looking forward to sharing this data & engaging with GI oncology leaders worldwide.
-
Agenus
@Agenus_Bio
We are thrilled to be back for another year at @WCGIC in Barcelona, Spain, from June 28 to July 1st. Stay tuned to hear from Dr. Andrea Bullock on the late-breaking data of botensilimab & balstilimab in heavily pretreated colorectal cancer #wcgi2023.
-
Agenus
@Agenus_Bio
Agenus Chairman and CEO, Dr. Garo Armen, will participate in a fireside chat at the #jefferieshealthcare Conference at the Marriott Marquis in New York City tomorrow at 1 PM EST. Tune in at investor.agenusbio.com/events-and-presentations.
-
Agenus
@Agenus_Bio
That’s a wrap on #asco23. Our time in Chicago was full of engaging discussions with expert oncologists, an insightful presentation of positive data from our phase 1 study of AGEN2373, and meaningful conversations with #patient advocates across the globe. Thank you @ASCO.
-
Agenus
@Agenus_Bio
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Announces Virtual Annual Shareholders Meeting.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Today, Agenus stands with @SurvivorsDay in honoring and celebrating cancer survivors' resilience, courage, and strength. Let’s raise awareness & celebrate life.
#nationalcancersurvivorsday #ncsd -
Agenus
@Agenus_Bio
Exciting day at #asco23. We enjoyed discussing data from our Phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in #patients with advanced solid tumors.
You can view the presentation at agenusbio.com/publications/. -
Agenus
@Agenus_Bio
Agenus is live in Chicago for #asco23. We are looking forward to an insightful conference and engagement with #oncology experts from across the globe.
-
Agenus
@Agenus_Bio
Today marks the 11th Annual #cancerimmunotherapymonth. This June, we join @CancerResearch & @NCIResearchCtr in raising awareness and highlighting the incredible breakthroughs in cancer research & treatment. Together, we can make a difference for cancer patients everywhere.
-
Agenus
@Agenus_Bio
Agenus to Participate in Jefferies Healthcare Conference.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
We're proud to be a platinum sponsor of the @SiopAsia2023 XV Congress in Yerevan, Armenia, on May 18-21st. Join us and the International Society of Pediatric Oncology in advancing pediatric cancer research and treatments worldwide.
#siop2023
www.siopasia2023.am -
Agenus
@Agenus_Bio
Today and every day, we're grateful for the incredible work of nurses worldwide. Agenus joins @ICNurses in celebrating #internationalnursesday and recognizing the life-changing impact of their dedication and compassion. Thank you for all that you do.
#nursesareheroes #ind2023 -
Agenus
@Agenus_Bio
Agenus Provides Corporate Update and First Quarter 2023 Financial Results.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus is proud to support the ovarian cancer community this #worldovariancancerday. There remains a global need for greater awareness and commitment. By taking action together, we can make a positive impact on #patients lives. #wocd2023
-
Agenus
@Agenus_Bio
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Skin cancer is a serious health issue, and at Agenus, we're doing our part to raise awareness about melanoma. This May, join us in spreading the word about prevention, early detection, and treatment by visiting www.curemelanoma.org.
#stopmelanoma
@MelanomaReAlli -
Agenus
@Agenus_Bio
Tomorrow Agenus Chairman & CEO Dr. Garo Armen will be speaking at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 3:30 PM ET at NASDAQ HQ in NYC. #bioconnect2023 #industryleadership
-
Agenus
@Agenus_Bio
Cancer research is vital to improving patient outcomes. This #nationalcancerresearchmonth, Agenus is proud to stand with @AACR and the 18 million people impacted by cancer worldwide.
Learn more: www.aacr.org/patients-caregivers/awareness-months/nationa…
#cancerresearch #ncrm23 -
Agenus
@Agenus_Bio
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
SaponiQx
@saponiQx
This #worldimmunizationweek, we collectively support @WHO's mission of accelerating rapid progress in restoring essential vaccine coverage to protect children and adults worldwide, to allow them to live happier and healthier lives.
www.who.int/campaigns/world-immunization-week/2023
#thebigcatchup -
Agenus reposted
Biotech2050 Podcast
@Biotech2050Pod
Hear @garo_armen of @Agenus_Bio discuss his approach to #teambuilding and how he’s adapted his #hiring approach given the current environment.
Listen now: podcasts.apple.com/us/podcast/leadership-in-revolutionizi…
$AGEN #biotech #podcast #cancer #immunotherapy #immunology #oncology #talent #immunotherapies -
Agenus
@Agenus_Bio
Congratulations to our collaborator @oxfordbio on their collaboration with GORTEC to investigate OBT076 as monotherapy and in sequence with #balstilimab in patients with Adenoid Cystic Carcinoma (ACC).
#immunotherapy
www.biospace.com/article/releases/oxford-biotherapeutics-… -
Agenus
@Agenus_Bio
Chairman & CEO Dr. Garo Armen recently discussed his career in biotech & his plans for Agenus to lead the next wave of #immunooncology therapies.
Biotech2050 Podcast
@Biotech2050Pod
We're celebrating our 150th #podcast episode with @garo_armen, Chairman & CEO of @Agenus_Bio! Hear Garo discuss their work developing #immunotherapies for #cancer.
Tune in: podcasts.apple.com/us/podcast/leadership-in-revolutionizi…
Hosted by @rahulc @MeetClora
$AGEN #biotech #pharma #immunology #oncology #io -
Agenus
@Agenus_Bio
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
30% of the global population lacks essential healthcare. Agenus & subsidiaries @MiNK_iNKT and @saponiQx support @WHO #healthforall initiative for all people to have good health and a fulfilling life in a peaceful, prosperous, and sustainable world. #who75
-
Agenus
@Agenus_Bio
Our CMO @ODayMD, reflects on #colorectalcancerawarenessmonth, recent #news for #botensilimab in #ovariancancer, and our mission to develop an arsenal of #immunotherapy treatments.
#colorectalcancer #oncology
www.linkedin.com/posts/steven-o-day-00792a3a_activity-704… -
Agenus
@Agenus_Bio
Thank you @FierceBiotech for reporting on meaningful #botensilimab news for patients with #ovariancancer.
#immunotherapy #oncology #gyneoncology #gynecologiconcology
FierceBiotech
@FierceBiotech
After Agenus withdrew its accelerated approval filing for cervical cancer drug balstilimab, the biotech has provided new combo data in ovarian cancer.
www.fiercebiotech.com/biotech/new-data-gives-agenus-anoth… -
Agenus reposted
OncLive.com
@OncLive
Thank you to @BrunoBockorny of @BIDMChealth for talking with us during #sgomtg about the combination of botensilimab and balstilimab in ovarian cancer! Check out our site for more exclusive meeting updates! @SGO_org #gyncsm
www.onclive.com/conference/sgo -
Agenus
@Agenus_Bio
We’re proud to announce positive data showing a 33% overall response rate for our novel multifunctional #ctla4 #botensilimab in combination with #balstilimab in recurrent platinum refractory/resistant #ovariancancer.
Learn more: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Join us at @SGO_org to hear @BrunoBockorny present updated data on #botensilimab in patients with recurrent/refractory #ovariancancer on Monday, March 27 at 9 am EST in East Hall.
Learn more: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
"#colorectalcancer (CRC) has become the deadliest cancer in men ages 20-49 years."
New data underscores the urgent need to raise awareness among young people.
Learn more: @CCAlliance
#crcscreening #colorectalcancerawarenessmonth
Colorectal Cancer Alliance
@CCAlliance
Alarming new data show colorectal cancer as the deadliest cancer in men ages 20-49.
Read more about this trend and what we can do to change outcomes. colorectalcancer.org/article/colorectal-cancer-becomes-de… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results.
Read here: investor.minktherapeutics.com/news-releases/news-release-… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting.
Read here: investor.minktherapeutics.com/news-releases/news-release-… -
Agenus
@Agenus_Bio
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Yesterday Agenus and @jbuell01 proudly joined @FightCRC, #colorectalcancer survivors and advocacy partners from across the U.S. to create awareness at the United in Blue Rally. We are inspired every day by #relentlesschampions.
Jennifer Buell
@jbuell01
We @Agenusbio & @MiNK_iNKT stand with @FightCRC & our champions #unitedinblue to bring new treatments for #msscrc; tracking as leading death in<45y by 2030. #colorectalcancerawarenessmonth #notimetowait @FightCRC #fightcolorectalcancer #strongarmselfie. @FightCRC.org/March
-
Agenus
@Agenus_Bio
We are pleased to see this interview by @ASCOPost with @DrElkhoueiry of @uscnorris spotlighting our data showing novel treatment of #botensilimab/balstilimab resulted in a 12-month OS rate of 63% in patients with metastatic #colorectalcancer.
Read here: ascopost.com/issues/march-10-2023/novel-immunotherapy-com… -
Agenus
@Agenus_Bio
Agenus celebrates #internationalwomensday. Today we recognize & celebrate women around the globe and their achievements. #womeninstem #embraceequity
-
Agenus
@Agenus_Bio
March is #colorectalcancer Awareness Month! Did you know that 1 in 3 people are not up-to-date with colorectal cancer screening? Affordable, take-home screening options exist. Don't wait. Get screened. fightcrc.org/screening @FightCRC
-
Agenus
@Agenus_Bio
March is #colorectalcancerawarenessmonth. We appreciate all who continuously advocate and care for patients, and we remain committed to supporting them.
-
Agenus
@Agenus_Bio
Agenus to Present Botensilimab Data in Oral Plenary Session at the @SGO_org 2023 Annual Meeting on Women’s Cancer on March 27. #sgomtg
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report. Read here: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Congrats to our partner @GSK on publication of the positive PH 3 trial results for its RSV vaccine candidate containing QS-21 STIMULON™. Agenus’ subsidiary, @saponiQx, is pursuing scalable, sustainable, and cost-effective production of adjuvants, including QS-21 STIMULON.
-
Agenus
@Agenus_Bio
Agenus CEO Dr. Garo Armen and Chief Medical Officer Dr. Steven O’Day will participate in a fireside chat at SVB Securities’ 2023 Global Biopharma Conference on February 16 at 10 AM EST. Learn more: wsw.com/webcast/svb8/register.aspx?conf=svb8&page=agen&ur…
#immunooncology #biotechnology #gbc -
Agenus
@Agenus_Bio
At Agenus, we're looking for exceptional talent to join us! Meet our next #employeespotlight, Jeff Tan. Jeff is proud of our culture. He enjoys our entrepreneurial mindset & his intellectually stimulating colleagues. Learn more & check out how to join us: agenusbio.com/join-us/
-
Agenus reposted
Sameh @ VuMedi
@Sameh_VuMedi
Check out Dr. Anthony El-Khoueiry @DrElkhoueiry @uscnorris discussing ASCO #gi23 Results From a Phase 1a/1b Study: #botensilimab, a Novel Innate/Adaptive Immune Activator, + #balstilimab in Metastatic Heavily Pretreated MSS CRC
#mcrc #gicsm #crcsm #meded
www.vumedi.com/video/asco-gi-2023-results-from-a-phase-1a… -
Agenus
@Agenus_Bio
ICYMI: We are encouraged our phase 1a/1b study of #botensilimab (novel innate/ adaptive immune activator) + balstilimab (anti-PD-1-antibody) shows promise in heavily pretreated patients with #msscrc. #gi23
-
Agenus reposted
Ben Schlechter
@ben_schlechter
-
Agenus reposted
SIOP Asia 2023
@SiopAsia2023
👋Get to know AGENUS/ @Agenus_Bio !
🔰AGENUS is the General (Platinum) sponsor of the SIOP Asia 2023 XV
congress, which will take place in Yerevan, Armenia🇦🇲
🔰We’d like to thank AGENUS for being our pillar for this incredible event
@SIOPEurope @WorldSIOP -
Agenus
@Agenus_Bio
At ASCO #gi23, we had the opportunity to share our late-breaking clinical trial data in MSS-CRC! Here are some exciting highlights from our presentation by @DrElkhoueiry.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Participate in February Investor Conferences.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
Court
@_shortcourtney_
Last week I had the honor of representing @EmeryvilleCA at the ribbon cutting for the @Agenus_Bio facility. Agenus produces immunotherapies that fight cancers by strengthening the response of the immune system. We’re excited to welcome an innovative company to town!
-
Agenus
@Agenus_Bio
#recap! We were honored to present at ASCO GI #gi23. Check out our latest press release to read more about the late-breaking clinical data from our phase 1 trial in MSS CRC, presented by @DrElkhoueiry. investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Thank you for the feature @ASCOPost !
Read more on the latest results from our clinical trial of botensilimab/balstilimab in MSS-CRC: ascopost.com/news/january-2023/combination-of-botensilima… -
Agenus
@Agenus_Bio
Meet Jimmie Pagsolingan, a Senior Manufacturing Manager at Agenus! Jimmie is one of the many leaders involved in launching our new manufacturing facility in Emeryville, CA. Read more about Jimmies experience here: www.linkedin.com/feed/update/urn:li:activity:702401328133…
-
Agenus reposted
Garo Armen
@garo_armen
Combination of Botensilimab & Balstilimab Shows Activity in MSS Colorectal Cancer - The ASCO Post ascopost.com/news/january-2… @Agenus_Bio is committed to enable access to all who need it. live-agenus.pantheonsite.io/wp-content/uploads/2022/09/ac…
-
Agenus
@Agenus_Bio
We are excited to be featured in Biotechnology News Magazine today! Check out this article to learn more about our late-breaking clinical data presented at ASCO #gi23 in Metastatic Microsatellite Stable Colorectal Cancer.
biomag1.com/agenus-presents-clinical-data-demonstrating-d… -
Agenus
@Agenus_Bio
Check out this piece from @DanaFarber featuring Agenus' next-generation immunotherapies, botensilimab and balstilimab in colorectal cancer. Read more about the latest data from our clinical trial, which we presented at ASCO GI #gi23: www.dana-farber.org/newsroom/news-releases/2023/immunothe…
-
Agenus
@Agenus_Bio
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
The possibilities are so exciting!! @MiNK_iNKT #immunotherapy #gi23 #celltherapy + #botensilimab
MiNK Therapeutics
@MiNK_iNKT
Outstanding data @DrElkhoueiry! Looking forward to the possibilities with our combinations! #inkt @Agenus_Bio agenusbio.com/wp-content/uploads/2022/06/Poster_AACR_2020…
Jennifer Buell
@jbuell01
WOW! @DrElkhoueiry presents BOTENSILMAB and survival in patients with MSS CRC! #gi23 @ASCO @Agenus_Bio @MiNK_iNKT
-
Agenus reposted
Jennifer Buell
@jbuell01
WOW! @DrElkhoueiry presents BOTENSILMAB and survival in patients with MSS CRC! #gi23 @ASCO @Agenus_Bio @MiNK_iNKT
-
Agenus reposted
Jennifer Buell
@jbuell01
#thelegend @DrElkhoueiry #gi23 Botensilimab in MSS CRC median overall survival NOT reached!. Pathbreaking. @Agenus_Bio @MiNK_iNKT
-
Agenus
@Agenus_Bio
Don't miss Agenus at the ASCO Gastrointestinal Cancers Symposium #gi23. Join us TOMORROW to see the latest results from our clinical trial of botensilimab & balstilimab in MSS-CRC.
More info at: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
#recap: Yesterday, the Mayor of Vacaville, John Carli, and city team members, Don Burris & Aaron Busch, joined the ribbon-cutting ceremony of our new manufacturing facility in Emeryville, CA. We are thrilled to continue to build our capabilities out West! #agenusemeryville
-
Agenus
@Agenus_Bio
Don't miss our fireside chat with Chairman & CEO Dr. Garo Armen and CMO Dr. Steven O'Day TODAY at 11:30 AM EST! Register to watch at the B. Riley Securities Oncology conference: brileyoncology22.sequireevents.com
-
Agenus
@Agenus_Bio
LIVE from the ribbon cutting of our new manufacturing facility in Emeryville, CA! We are thrilled to launch the grand opening of this location as we continue to expand our manufacturing capabilities at Agenus. #agenusemeryville
-
Agenus reposted
Jennifer Buell
@jbuell01
Congratulations @Agenus_Bio @MiNK_iNKT @saponiQx opening our revolutionary commercial manufacturing center. #immunotherapy @EmeryvilleCA
-
Agenus
@Agenus_Bio
Join us on January 21 at 10:00 AM ET & hear Dr. Anthony El-Khoueiry present data from Agenus' study of botensilimab AND balstilimab in colorectal cancer (MSS-CRC)at #gi23 @ASCO!
-
Agenus reposted
Garo Armen
@garo_armen
#botensilimab activity is very exciting; updates #ascogi23 @ASCO
Agenus
@Agenus_Bio
Another exciting moment for Agenus & botensilimab! As we welcome 2023, we are thrilled to present updated data since ESMO GI at ASCO Gastrointestinal Cancers Symposium #gi23. Tune in January 19-21, 2023!
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus is proud to support #cervicalcancerawarenessmonth as we continue our mission to help these patients in need. Let's raise awareness. To learn more, visit: www.aacr.org/patients-caregivers/awareness-months/cervica…
-
Agenus
@Agenus_Bio
Thank you for following #our2022moments series! We look forward to 2023 & can't wait to continue to share our innovations and developments with you.
Watch here: vimeo.com/770531071/c6d6b26691 -
Agenus
@Agenus_Bio
Meet Senior Manager External Innovation, Angela Hafner, Ph.D. She is passionate about our team & committed to our mission to make a difference in cancer patients' lives.
Check out our website: agenusbio.com/join-us/
#weareagenus #immunotherapy #employeespotlight -
Agenus
@Agenus_Bio
Botensilimab is advancing across multiple clinical trials, including MSS-CRC, melanoma, & more. Our data at #sitc and #ctos demonstrated botensilimab's activity across several cold and I-O refractory solid tumors. You can find these latest updates at www.agenusbio.com.
-
Agenus
@Agenus_Bio
Another exciting moment for Agenus & botensilimab! As we welcome 2023, we are thrilled to present updated data since ESMO GI at ASCO Gastrointestinal Cancers Symposium #gi23. Tune in January 19-21, 2023!
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Join our Fireside chat at the B. Riley Securities 3rd Annual Oncology Conference! Tune in to learn more about Agenus' latest clinical data, development, and plans for this year.
Register here: brileyoncology22.sequireevents.com -
Agenus
@Agenus_Bio
Check out another one of #our2022moments! We presented data at #sitc2022, which highlighted responses to botensilimab across nine treatment-resistant cancers.
Learn more here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
We are excited to announce the grand opening of our new fully integrated manufacturing facility at Emeryville, CA on January 17th. Stay tuned for more!
-
Agenus
@Agenus_Bio
Save the date for ASCGO GI 2023! On January 19-21 Agenus will be live in San Francisco, CA, with Dr. Anthony El-khoueiry.
-
Agenus
@Agenus_Bio
Time for another one of #our2022moments! In 2022 we cleared our IND for AGEN1571 and presented data on this program at #aacr.
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Welcome to #ourmoments series, where we will share some of our favorite moments from 2022. Tune in this week for a new highlight as we welcome 2023!
First, was the initiation of our phase 2 ACTIVATE trials, which you can learn more about here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
Wishing you a happy New Year from all of us at MiNK & @Agenus_Bio!!🎉We look forward to exciting progress, innovation, and further advancing our therapies for patients in 2023.
-
Agenus
@Agenus_Bio
Coming soon! Agenus is joining @instagram. Follow us at agenus_bio. www.instagram.com/p/CmcIOvHuhbi/
-
Agenus
@Agenus_Bio
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Botensilimab was uniquely designed to optimally empower the immune system to target cancer. For more information about botensilimab, visit our website! agenusbio.com
-
Agenus
@Agenus_Bio
Meet another #employeespotlight: Maggie Wilkens! Maggie is passionate about the opportunities at Agenus & how we strive to make a difference for cancer patients. Check out the people behind our purpose & opportunities to join our team at: agenusbio.com/join-us/
-
Agenus
@Agenus_Bio
Check out Agenus' next-generation CTLA-4 antibody: Botensilimab! Learn more about the activity & tolerability of Botensilimab across multiple advanced solid tumors by visiting our website: agenusbio.com 🔬
#botensilimab #immunotherapy #agenus -
Agenus
@Agenus_Bio
Meet: Aashna Gupta! Aashna takes pride in the Agenus pipeline & mission. She is driven & supported by her innovative colleagues, who help her achieve her goals. Interested in learning more and joining? Browse our website & open positions agenusbio.com/join-us/ #employeespotlight
-
Agenus
@Agenus_Bio
Check out Agenus' feature on this week's episode of the "Talking With Cancer" Podcast. Our chairman and CEO Dr. Garo Armen joined host Katie Phillips to discuss Agenus' history & our mission to pioneer the next generation of cancer treatments. www.talkingwithcancer.com
-
Agenus
@Agenus_Bio
We enjoyed attending this year's Evercore ISI #healthconx Conference! In case you couldn't join live, watch our fireside chat replay with CEO Dr. Garo Armen and CMO Dr. Steven O'Day to hear about the latest data & plans across the Agenus pipeline: wsw.com/webcast/evercore29/agen/2333250
-
Agenus
@Agenus_Bio
Tune into the 5th Annual Evercore ISI HealthCONx Conference on November 30th! Register to hear from Chairman & CEO Dr. Garo Armen and CMO Dr. Steven O’Day on the latest clinical data and progress at Agenus: investor.agenusbio.com/news-releases/news-release-details…
Agenus
@Agenus_Bio
Don’t miss Chairman & CEO Dr. Garo Armen and CMO Dr. Steven O’Day TODAY at 12:35 PM ET at the 5th Annual Evercore ISI HealthCONx Conference! To hear more about our latest clinical data and more, register here: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
We are excited to participate at the 5th Annual Evercore ISI HealthCONx Conference tomorrow! Join to hear a fireside chat with CMO, @ODayMD and learn more about our latest clinical data and expanding experience with botensilimab! investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
At Agenus we strive to harness the power of the immune system to bring curative treatment options for cancer patients. Hear from our Chairman & CEO Dr. Garo Armen at the 5th Annual Evercore ISI HealthCONx Conference November 30th! investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Join us TOMORROW at #ctos2022 & listen to @breelynwilkyMD present on her clinical experience with botensilimab plus balstilimab in sarcomas.
investor.agenusbio.com/news-releases/news-release-details…
Agenus
@Agenus_Bio
Tune into CTOS today & watch @breelynwilkyMD joined by other sarcoma leaders in Vancouver, Canada. Register to watch: www.ctos.org/Home.aspx
-
Agenus
@Agenus_Bio
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference - Wednesday, November 30th at 12:35pm ET.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
#tbt to our R&D Day last week! Thank you to all who joined at #theroadtaken to hear from leaders in oncology such as Dr. Michael Atkins, Dr. Larry Norton, Dr. Alexander Eggermont and more. Watch the replay: investor.agenusbio.com/events/event-details/road-taken-ag…
-
Agenus reposted
Alexa Buffa
@abuffa9
Proud to represent team @Agenus_Bio !! Agenus was recognized as one of the top 500 Fastest Growing Companies in North America by @DeloitteTMT #fast500
-
Agenus
@Agenus_Bio
Did you know lung cancer is the second most common cancer in the US? At Agenus, we are proud to support #lungcancerawarenessmonth & continue our mission to harness the power of the immune system to bring affordable, curative therapies to cancer patients. www.cancer.org/cancer/lung-cancer/about/key-statistics.html
-
Agenus
@Agenus_Bio
We are proud to announce that Agenus has been recognized as one of the Top Fastest Growing Companies in North America by @DeloitteTMT for 2022! Ranked 215 out of 500. Thank you to @DeloitteTMT #fast500 for the recognition & congratulations to the other winners.
-
Agenus
@Agenus_Bio
Save the date! Dr. Breelyn Wilky will present at CTOS on November 18th: Phase IA/IB Study of Botensilimab, A Novel Innate/Adaptive Immune Activator, Plus Balstilimab for the Treatment of Patients with Sarcoma www.ctos.org/Home.aspx
-
Agenus
@Agenus_Bio
What a fantastic week #sitc2022! Our team was honored to present our latest clinical data & growing experience with botensilimab. ICYMI take a look at this year’s presentation by @breelynwilkyMD . Thank you @sitcancer !
agenusbio.com/publications/ -
Agenus
@Agenus_Bio
Be sure to watch the replay of our R&D Day event this weekend! Hear from experts in I-O and Agenus leadership on their #roadtaken, and the latest data and plans for botensilimab.
investor.agenusbio.com/events/event-details/road-taken-ag… -
Agenus
@Agenus_Bio
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
Read here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Thank you to our audience & insightful speakers for joining us at yesterday's R&D Event! We were thrilled to present data on botensilimab and show you our path forward in the next generation of cancer treatments. We were honored to share our stories and hear from pioneers in IO.
-
Agenus
@Agenus_Bio
Live at #sitc2022! @breelynwilkyMD presenting the latest botensilimab clinical data at the Thomas Waldmann Memorial Plenary Session: New Immunotherapies.
-
Agenus
@Agenus_Bio
Join us TOMORROW at #theroadtaken! We can’t wait to discuss our latest clinical data on botensilimab & hear from our incredible lineup of featured speakers, including Michael Atkins, MD, Recipient of the SITC 2022 Lifetime Achievement award.
Agenus
@Agenus_Bio
Don’t miss #theroadtaken TODAY! To hear more about our novel insights into botensilimab and the Agenus pipeline.
-
Agenus reposted
Jennifer Buell
@jbuell01
#sitc22 plenary begins as @breelynwilkyMD readies to present on Botensilimab, Innate/Adaptive Immune Activator +\- Balstilimab in “Cold” I-O Refractory Tumors @sitcancer @Agenus_Bio
-
Agenus reposted
Jennifer Buell
@jbuell01
Morning coffee enveloped by @Agenus_Bio before BOTENSILIMAB takes center stage @sitcancer #sitc22
-
Agenus
@Agenus_Bio
Come listen to our new member of the Agenus team, Patricia Carlos, at our #theroadtaken! With over 20 years of experience in regulatory affairs leadership & will give her insights and discuss our paths forward with botensilimab.
Register at: agenusbio.zoom.us/webinar/register/WN_jBD6qVO2R62ia6FKUHm4Pw -
Agenus
@Agenus_Bio
We are excited for you to hear from our talented group of presenters and to tell you more about our growing clinical experience with botensilimab. Save the date on November 12th to hear the #sitc2022 plenary session featuring Dr. Bree Wilky and botensilimab.
-
Agenus
@Agenus_Bio
Are you curious to learn about our Phase 2 trial of AGEN1423, our bifunctional antibody targeting 2 dominant pathways that suppress the immune response to cancer? Check out our #sitc2022 presentation today to hear more from Dr. Bruno Bockorny.
-
Agenus
@Agenus_Bio
Meet Dr. Todd Yancey another featured speaker at our R&D Day! Dr. Yancey has over 40 years of clinical, commercial, and industry experience and we can’t wait to hear his deep insights at #theroadtaken
Register here: agenusbio.zoom.us/webinar/register/WN_jBD6qVO2R62ia6FKUHm4Pw -
Agenus
@Agenus_Bio
We are looking forward to hearing from our Chief Medical Officer, @ODayMD at #theroadtaken. Dr. O’Day has been a leader in the immune-oncology field for three decades. He will be discussing his life lessons and the Journey to Curative benefit in melanoma and beyond.
-
Agenus
@Agenus_Bio
Another Agenus #sitc2022 presentation will feature novel insights into botensilimab, further elucidating its mechanisms and data showing anti-tumor immunity in cold and IO refractory tumors. Data will be presented by Daniel Levey tomorrow. Come join us!
-
Agenus
@Agenus_Bio
Today at #biofuture22! Our CMO @ODayMD & other leaders in I-O including @MiNK_iNKT CEO @jbuell01 discussed the future of next generation cancer therapeutics. Thank you for having us @demycolton!
More info at:
biofuture.com -
Agenus
@Agenus_Bio
Dr. Alexander Eggermont is a global leader in oncology and immunology! We are excited to have him speaking at our R&D Day this year. Join us on November 12th to hear his unique perspective on botensilimab and its role in the future of IO.
-
Agenus
@Agenus_Bio
At #sitc2022 the Agenus team will present data showing the differentiated ability of botensilimab to modulate both innate & adaptive immunity, consistent with its clinical activity in poorly immunogenic tumors. Join our presentation by Agenus scientists on Nov 10th to learn more.
-
Agenus
@Agenus_Bio
See our full Q3 earnings report & corporate update!
Here: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Don’t miss Agenus at #sitc2022! We are excited for you to hear from our talented group of presenters and to tell you more about our growing clinical experience with botensilimab.
www.sitcancer.org/2022/home -
Agenus
@Agenus_Bio
Dr. Larry Norton is a world-renowned leader in oncology treatment and research from the Memorial Sloan-Kettering Cancer Center. Tune in for this unique opportunity to hear from Dr. Norton and others. #theroadtaken
Register at: agenusbio.zoom.us/webinar/register/WN_jBD6qVO2R62ia6FKUHm4Pw -
Agenus
@Agenus_Bio
Dr. Breelyn Wilky will present data on botensilimab, a novel innate/adaptive immune activator, +/-botensilimab in cold and IO refractory solid tumors at #theroadtaken. Make sure to register for the webcast! In person attendance is at capacity. Sign-up at: agenusbio.zoom.us/webinar/register/WN_jBD6qVO2R62ia6FKUHm4Pw
-
Agenus
@Agenus_Bio
Meet our R&D Day Keynote Presenter, Dr. Michael Atkins! Dr. Atkins is a seasoned leader in I-O and the recipient of the SITC 2022 Lifetime Achievement Award. To hear about his experiences in the field and the potential of botensilimab. Register here: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus is counting down for our R&D Day “The Road Taken”! Please join us on November 12th, 2022, to hear from a lineup of incredible featured speakers, including Michael Atkins, MD, recipient of the SITC 2022 Lifetime Achievement Award.
-
Agenus
@Agenus_Bio
Congratulations @GSK! Today the EMA accepted the marketing authorization application for their RSV older adult vaccine candidate. GSK's AS01 adjuvant system contains Agenus’ QS-21 STIMULON™. This is an important step forward in fighting RSV. Learn more: www.gsk.com/en-gb/media/press-releases/gsk-marketing-auth…
-
Agenus
@Agenus_Bio
Did you know Agenus’ QS-21 STIMULON™ is a key component of @GSK’s Shingrix vaccine? New data shows Shingrix can provide at least 10 yrs of protection against shingles in adults aged 50 years & over. Learn more at: www.gsk.com/en-gb/media/press-releases/new-data-show-shin…
-
Agenus
@Agenus_Bio
Agenus' CMO @ODayMD will join scientific leaders, innovators, and influencers at #biofuture22, where he will speak on the next generation of cancer therapeutics. Find out more at biofuture.com
-
Agenus
@Agenus_Bio
Agenus' Senior Director, Head of Drug Discovery, @dhanschand speaks today on the topic of Enhanced CTLA-4 Blockade alongside fellow industry leaders, and SITC series co-chairs James P. Allison and Alan J. Korman. Congratulations, Dhan! www.sitcancer.org/education/webinars-online/cancer-io-dee…
-
Agenus
@Agenus_Bio
Agenus to Host “The Road Taken” R&D Event on November 12, 2022. Featured speakers include @ODayMD, @breelynwilkyMD, Dr. Michael Atkins, and more!
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Don't miss tomorrow's installment of SITC's highly focused webinar series Targets for Cancer IO, featuring Agenus' Senior Director, Head of Drug Discovery, @dhanschand on the topic of Enhanced CTLA-4 Blockade. www.sitcancer.org/education/webinars-online/cancer-io-dee…
-
Agenus
@Agenus_Bio
Agenus leaders are continuing the critical conversations begun last month in Paris at #esmo 2022. We're grateful for opportunities to gather around the urgent topic of #cancertherapy @ODayMD @jbuell01
-
Agenus
@Agenus_Bio
Meet the people powering the next wave of IO innovation. Aashna Gupta joined Agenus in 2022.
agenusbio.com/join-us/ -
Agenus
@Agenus_Bio
Checkpoint inhibitor (CPI) refractory advanced melanoma remains an area of significant unmet need and is an area of focus for both Agenus and Targovax.
www.targovax.com/en/targovax-receives-approval-to-proceed… -
Agenus
@Agenus_Bio
Congratulations to Agenus' Jeff Tan on being selected as a panelist at Fierce Pharma's New Product Planning Summit.
www.newproductplanning.com -
Agenus
@Agenus_Bio
Today Agenus announced the initiation of the botensilimab ACTIVATE Phase 2 trials, which will initially evaluate botensilimab in microsatellite stable colorectal cancer (MSS CRC) and advanced refractory melanoma.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus is pleased to announce the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; and Todd Yancey, MD, as Senior Global Clinical Development, Medical Affairs and Commercial Advisor.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
This week we're showcasing the newly redesigned Agenus website. Visit our Join Us page to explore global career opportunities and hear from Agenus employees in their own words why they continue to choose Agenus!
agenusbio.com/join-us/ -
Agenus
@Agenus_Bio
This week we're showcasing the newly redesigned Agenus website. Explore our Capabilities section to learn about our VISION platform and how it seeks to use advanced analytics to optimize drug design.
agenusbio.com/capabilities/vision/ -
Agenus
@Agenus_Bio
This week we're showcasing the newly redesigned Agenus website. On our homepage you'll find a Spotlight on botensilimab--Agenus' novel adaptive and innate immune activator.
agenusbio.com -
Agenus
@Agenus_Bio
This week we're showcasing the newly redesigned Agenus website. Visit to explore our pipeline and discover what makes Agenus a leader in I-O innovation.
agenusbio.com/pipeline/ -
Agenus
@Agenus_Bio
Agenus is pleased to announce the launch of our newly redesigned website. Follow us this week as we showcase some of its features!
-
Agenus
@Agenus_Bio
Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
We are “Living Diversity” to drive creativity & inventive power, intentionally #lifescienceleader. “We sought out a biopharma enterprise where diversity has always been an operating principle...” CEO @jbuell01 spoke with @WayneKoberstein & @LifeSciLeader1 www.lifescienceleader.com/doc/living-diversity-inside-min…
-
Agenus
@Agenus_Bio
Blocking ILT2 is believed to be important to the anti-cancer response & combating resistance to immune checkpoint inhibitors. AGEN1571 is uniquely designed to enhance activation of both innate & adaptive immunity.
Learn more: agenusbio.com/publications/
Agenus
@Agenus_Bio
AGEN1571 is a novel clinical asset that has been designed to combine tolerability and efficacy with other agents in the Agenus clinical portfolio, including botensilimab. Hear more from @dhanschand:
-
Agenus
@Agenus_Bio
Agenus to Participate at BTIG Biotechnology Conference
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report on August 9th: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
July is #sarcomaawareness Month, and Agenus is proud to be supporting @curesarcoma's work to raise awareness and advocate for patients. Agenus is also proud to contribute to the #io research we believe has the potential to change patient outcomes and reshape disease treatment.
-
Agenus
@Agenus_Bio
Read more about our journey to ESMO GI, and the impact we hope our botensilimab data has on MSS CRC research, over at @wbz: www.cbsnews.com/boston/news/sponsored-esmo-gi-agenus-resu…
-
Agenus
@Agenus_Bio
Agenus to Participate in @WilliamBlair's Biotech Focus Conference: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Thank you to our team in Barcelona and beyond, who made our time at @ESMOWORLDGI so outstanding. We look forward to seeing where #innovation in the field of #io research takes us!
-
Agenus
@Agenus_Bio
Join us at 10am EST, for our post-#esmogi webcast, featuring presentations by @ODayMD, @DrElkhoueiry, @DrMhidalgo, and Dr. Heinz-Josef Lenz, M.D, followed by a Q&A session! #cancerresearch
-
Agenus
@Agenus_Bio
Don’t forget to join us, including @DrElkhoueiry and @ODayMD, for our post-presentation webcast, today at 10am EST. #esmogi investor.agenusbio.com/events/event-details/agenus-esmo-g…
-
Agenus
@Agenus_Bio
Thank you to Dr. Anthony El-Khoueiry, @ESMOWORLDGI, and all our Agenus scientists and team members! You make it possible for us to continue addressing unmet need and advocating for patients. #esmogi
-
Agenus
@Agenus_Bio
90-95% of metastatic CRC is microsatellite stable (MSS). Our global Phase 2 trial in MSS CRC is planned to begin later this year. #cancerresearch #esmogi
-
Agenus
@Agenus_Bio
Botensilimab was well tolerated, with no grade 4 or 5 treatment-related adverse events. No hypophysitis and pneumonitis is rare. #esmogi
-
Agenus
@Agenus_Bio
Bot/bal delivered a 24% ORR (10/41 patients), 73% disease control rate (partial response + stable disease), and median DOR was not reached. 80% of objective responses were ongoing at data cut-off, and 30% of objective responses exceeded 1 year. #esmogi
-
Agenus
@Agenus_Bio
Our Phase 1 trial of bot/bal was in heavily pre-treated patients, with a median of 4 prior lines of therapy. 34% of patients had previously received #immunotherapy and failed to respond. #esmogi
-
Agenus
@Agenus_Bio
Bot is an Fc enhanced CTLA-4 inhibitor, designed to extend the benefits of I-O to cold tumors which are traditionally unresponsive to immunotherapies & reduce complement mediated toxicity. #esmogi
-
Agenus
@Agenus_Bio
We’re in Barcelona, Spain, and our team is thrilled to be sharing our presentation, “Botensilimab, a Novel Innate/Adaptive Immune Activator, Plus balstilimab (anti-PD-1) for Metastatic Heavily Pretreated Microsatellite Stable Colorectal Cancer,” with #esmogi
-
Agenus
@Agenus_Bio
Our team is just minutes away from presenting the opening session at @ESMOWorldGI! Stay tuned for live updates!
-
Agenus
@Agenus_Bio
Only two days until our team presents at the @ESMOWorldGI Congress! Don’t forget to register for our post-presentation webcast at 10am EST, June 29th: investor.agenusbio.com/events/event-details/agenus-esmo-g…
-
Agenus
@Agenus_Bio
We are featuring a #spotlightonbotensilimab leading up to our upcoming oral presentation at @ESMOWorldGI. Botensilimab is an innate & adaptive immune activator. Clinical responses have been observed in 9 cold & treatment-resistant cancer types, including colorectal & pancreatic.
Agenus
@Agenus_Bio
Botensilimab is an immunotherapy with the potential to transform the #io treatment landscape. Multiple monotherapy responses have been observed in patients who express a biomarker associated with poor outcomes to CTLA-4 therapy. #spotlightonbotensilimab
Agenus
@Agenus_Bio
#spotlightonbotensilimab: Optimizing safety is critical to improving #cancercare. Botensilimab was designed to reduce difficult side effects that can offset potential medical gain and decrease quality of life.
-
Agenus reposted
Agenus
@Agenus_Bio
We are featuring a #spotlightonbotensilimab leading up to our upcoming oral presentation at @ESMOWorldGI. Botensilimab is an innate & adaptive immune activator. Clinical responses have been observed in 9 cold & treatment-resistant cancer types, including colorectal & pancreatic.
-
Agenus
@Agenus_Bio
Congrats to Agenus' partner @targovax on the FDA approval of an IND application to initiate US clinical trials of TG01 containing Agenus' proprietary adjuvant QS21-STIMULON™. Read the press release here: www.targovax.com/en/targovax-announces-that-the-fda-has-g…
#immunotherapy #clinicaltrials -
Agenus
@Agenus_Bio
We are less than 1 week away from @ESMOWorldGI in Barcelona! On June 29th @DrElkhoueiry will share clinical data on botensilimab & balstilimab in MSS CRC in a late-breaking oral session #wcgic2022. More info at: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
June 29th @ 10AM EST $AGEN to host a webcast to review late-breaking Botensilimab & Balstilimab data presented at @ESMOGI #wcgic2022. Hear from @ODayMD @DrElkhoueiry @DrMhidalgo & Dr. Heinz-Josef Lenz. More info at: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Save the date: On June 29th at 10 AM ET we will host a webcast following our presentation of clinical data on botensilimab in MSS #colorectalcancer at @ESMOWorldGI. Stay tuned for registration info! #wcgic2022
-
Agenus
@Agenus_Bio
Agenus’ CEO @garo_armen and CMO @ODayMD participated in a fireside chat at last week’s Jefferies Healthcare Conference in New York City. Listen in here: investor.agenusbio.com/events/event-details/jefferies-hea…
-
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
In celebrating #pridemonth we are excited to announce our CEO, @jbuell01, was named #15 on @FastCompany & @lesbiantech’s 3rd Annual #fcqueer50 list!
"Jennifer has always encouraged her employees to be their most authentic selves at work." Check out more: www.fastcompany.com/queer-50/list/rank/15 -
Agenus
@Agenus_Bio
Tune in today at 3:30 PM for our virtual Annual Shareholders Meeting: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Our three newest collaborations, with @targovax @oxfordbio, and Immunogenesis, will help advance our portfolio and are exciting next steps to broaden the #io combinations and indications under evaluation for #cancerpatients
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Advances Portfolio with 6 Clinical Collaborations
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
We are excited for our collaboration with @oxfordbio, providing scientific support as they advance their antibody-drug conjugate, OBT076, in combination with balstilimab to improve immune response in, and bring benefit to, patients with solid tumors.
-
Agenus
@Agenus_Bio
$AGEN Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
Oral presentation @ESMOWorldGI will be on June 29 at 1:05 PM. Data to be presented in heavily pretreated MSS-CRC.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
We are thrilled to be collaborating with @targovax, advancing I-O agents in pursuit of improving safety and outcomes for patients in need
Circio Holding ASA
@circio_asa
We’re thrilled to announce a clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial!
For more information, see www.circio.com/en/targovax-announces-clinical-collaborati…
#cancer #immunotherapy #cancerresearch #immunooncology #clinicaltrials -
Agenus
@Agenus_Bio
$AGEN Corporate Update and First Quarter 2022 Financial Report
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
The latest $AGEN Newsletter is now available!
Here we highlight AGEN1571, our novel antibody targeting ILT2, which we presented data on at #aacr2022. Our IND has been cleared & we expect clinical trials to begin this year. Learn more:
agenusbio.com/newsletters/agenusnews-vol-5-iss-2-april-20… -
Agenus
@Agenus_Bio
Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers
investor.minktherapeutics.com/news-releases/news-release-… -
Agenus
@Agenus_Bio
$AGEN featured in the 2022 “Scrip Asks” series where industry executives discuss therapeutic area advances - read @ODayMD discuss how our next-generation CTLA-4 antibody could enhance the possibilities of immunotherapy. @ScripEleanor
scrip.pharmaintelligence.informa.com/SC145964/Scrip-AsksW… -
Agenus
@Agenus_Bio
UroGen submits IND application supporting planned Phase 1 clinical study of UGN-301 (zalifrelimab) intravesical solution in recurrent non-muscle invasive bladder cancer
investors.urogen.com/news-releases/news-release-details/u… -
Agenus
@Agenus_Bio
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Read $AGEN featured in @statnews, where @dhanschand discusses the importance and potential of TGF-beta in I-O, and our anti-TGF-beta program AGEN1423.
www.statnews.com/2022/02/17/tgf-beta-cancer-immunotherapy/ -
Agenus
@Agenus_Bio
The latest Agenus newsletter is now available.
Agenus is positioned to launch into a year of dynamic advancement in 2022 - with new clinical data, portfolio expansion, and international impact. Read more about our focus on key value drivers in 2022:
agenusbio.com/newsletters/agenusnews-vol-5-iss-01-februar… -
Agenus
@Agenus_Bio
Hear Dr. Steven O’Day join a panel discussion hosted by @Endpts to review the potential of emerging #checkpoint targets at 2pm EST on 1/27! @ODayMD #immunooncology #cancer #lifesciences
webinars.endpts.com/the-checkpoint-debate-is-about-to-get… -
Agenus
@Agenus_Bio
Read @garo_armen and other industry leaders express their thoughts on what the future might hold for #immunotherapies in #cancer in this story by @jasonmmast and @endpts. #oncology
Jason Mast
@Jasonmmast
For the first time since PD-1s were approved, a new kind of checkpoint inhibitor is on its way. That’s big, experts say, but it’s not clear yet what it means for the future of a field thats waited a decade for new breakthroughs
endpts.com/a-new-cancer-immunotherapy-brings-cautious-hop… -
Agenus
@Agenus_Bio
This year, we look forward to accelerating development of our pipeline to broaden the reach of immunotherapies to more patients & tumor types. @omalleygynonc highlights the durable responses induced by our CTLA-4 antibody candidates in many GYN cancers: www.targetedonc.com/view/sitc-2021-updates-for-cervical-c…
-
Agenus
@Agenus_Bio
Bal/Zal Phase 2 cervical cancer trial results published in Journal of Clinical Oncology; 26% ORR (33% ORR in PD-L1+ patients), mDoR not reached after 21 months of follow-up.
Click here to read more: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
$AGEN has been named to the Boston Business Journal’s list of 2021 Middle Market Leaders, their 50 highest growth middle-market companies in MA. We are thrilled to be nominated and look forward to further growth and progress next year. @BosBizJournal
www.bizjournals.com/boston/news/2021/01/14/bbj-reveals-20… -
Agenus
@Agenus_Bio
Rottapharm Biotech Clinical Collaboration: An important step for treatment-resistant colorectal cancer
The 1st patient has been dosed in their Ph 1/2 study of CR6086 combined with balstilimab in advanced CRC.
Read the latest $AGEN newsletter here: agenusbio.com/newsletters/agenusnews-vol-4-iss-21-decembe… -
Agenus
@Agenus_Bio
Tune in today at 1:50PM ET for our fireside chat by @garo_armen and @ODayMD at the annual Evercore ISI HealthCONX Conference: wsw.com/webcast/evercore21/agen/2323050
-
Agenus
@Agenus_Bio
The latest Agenus Newsletter is now available!
AGEN1181 Achieves Responses Across 9 Cancers: Seventeen Objective Responses as Single Agent or in Combination with Balstilimab
agenusbio.com/newsletters/agenusnews-vol-4-iss-20-novembe… -
Agenus
@Agenus_Bio
Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #agen1181 clinical data from #sitc21
investor.agenusbio.com/events/event-details/fireside-chat… -
Agenus
@Agenus_Bio
#agen1181 demonstrates clinical responses across nine treatment-resistant cancers at #sitc21
#oncology #immunotherapy
investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797
investor.minktherapeutics.com/news-releases/news-release-…
#sitc21 -
Agenus
@Agenus_Bio
Hear @ODayMD and @DrMhidalgo discuss the latest #agen1181 Phase 1 data from #sitc21 in a webcast hosted by William Blair.
investor.agenusbio.com/events/event-details/william-blair… -
Agenus
@Agenus_Bio
Our #sitc21 abstract summarizing #agen1181 data from >100 patients treated is live!
#agen1181 +/- balstilimab shows durable responses in 9 cancer types, including patients who have failed PD-1 therapy; Ph2/3 to commence in colorectal and GYN cancers.
jitc.bmj.com/content/9/Suppl_2/A509 -
Agenus
@Agenus_Bio
See $AGEN full Q3 2021 earnings report and corporate update here:
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Provides Update on Balstilimab Development
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Today, we took another step in advancing our immuno-oncology therapies to cancer patients. We announced that the first patient has been dosed with AGEN1777, our first-in-class #tigit bispecific licensed to @bmsnews, triggering a $20M milestone payment.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
WHO recommends broader use of the world’s first malaria vaccine, containing Agenus’ QS-21 Stimulon. Read today’s story from @BosBizJournal. @garo_armen
www.bizjournals.com/boston/news/2021/10/07/five-things-yo… -
Agenus reposted
Kimberly Ha
@pharmaprodigy
Yesterday, @WHO rec. widespread use of the 1st malaria vaccine to young children in sub-Saharan Africa —what made the news more interesting was the fact that it was a 27-yr old biotech in Lexington that made the vaccine possible.
@garo_armen @Agenus_Bio
www.bizjournals.com/boston/news/2021/10/07/five-things-yo… -
Agenus
@Agenus_Bio
Tune in today, at 1:30pm EST, to hear @jbuell01 speak at the BioFuture 2021 panel, “Next Gen Oncology Therapeutics: Changing the Cancer Landscape.”
biofuture.com/biofuture-registration/
Agenus
@Agenus_Bio
Live from #biofuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology
-
Agenus
@Agenus_Bio
Targeting ILT-4 with $AGEN discovered antibody, MK-4830, may increase the anti-tumor activity of pembrolizumab even in tumors with low levels of T-cell inflammation. Publication in Clinical Cancer Research discusses potential of ILT-4 blockade to abrogate PD-1/PD-L1 resistance
Clinical Cancer Research
@CCR_AACR
Antibody MK-4830 alone or in combination with #pembrolizumab shows antitumor activity and presents the potential for a new mechanism to treat anti–PD-1/PD-L1 resistance. aacrjournals.org/clincancerres/article/28/1/57/675028/Fir….
@lillian_siu -
Agenus
@Agenus_Bio
Oh the talent density @Agenus_Bio and @MiNK_iNKT!
Jennifer Buell
@jbuell01
Saturday I-O University w practice-changing giant @ODayMD; sharing lessons from curing melanomas to #conquer other cancers. The best part is… he’s on our team @Agenus_Bio! #cancer #immunology
-
Agenus
@Agenus_Bio
Agenus to Present AGEN1181 Clinical Data at SITC
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
September is #gynecologiccancerawarenessmonth and we at $AGEN are committed to fighting gynecologic cancers by advancing important therapeutic options for patients, spreading awareness, and encouraging education.
-
Agenus
@Agenus_Bio
Bal/Zal Doubles Responses Compared to Currently Available Therapies at #esmo21
Data demonstrate the power of our combo approach to improve patient outcomes and address difficult tumors, while remaining well-tolerated for patients.
Today's Newsletter: agenusbio.com/newsletters/agenusnews-vol-4-iss-18-septemb… -
Agenus
@Agenus_Bio
$AGEN featured in @endpts #esmo21 highlights. Read here:
endpts.com/the-best-of-the-rest-highlights-from-the-below… -
Agenus reposted
Jennifer Buell
@jbuell01
Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer www.onclive.com/view/balstilimab-plus-zalifrelimab-displa… via @onclive
-
Agenus reposted
OncLive.com
@OncLive
Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer @myESMO #esmo21 @OSUCCC_James #gyncsm www.onclive.com/view/balstilimab-plus-zalifrelimab-displa…
-
Agenus reposted
Contemporary OB/GYN®
@ContempOBGYN
Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer. www.contemporaryobgyn.net/view/balstilimab-for-patients-w…
-
Agenus
@Agenus_Bio
"Agenus congratulates @Ginkgo on their trading debut on @NYSE. We are excited to continue our collaboration with Ginkgo to revolutionize vaccines through our subsidiary @saponiQx" -@garo_armen
Ginkgo Bioworks
@Ginkgo
The future won’t be mined, extracted, wired or launched.
It will be grown. -
Agenus
@Agenus_Bio
Bal/Zal combination data presented at #esmo21 shows improved responses across histology subgroups, and anti-PD-1 alone. Further data to be presented on Sept. 19th.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
$AGEN combination of balstilimab plus zalifrelimab doubles responses in 2L cervical cancer in data to be presented at ESMO
investor.agenusbio.com/index.php/news-releases/news-relea… -
Agenus
@Agenus_Bio
ICYMI: Follow the link to join, @jbuell01, this afternoon, at 4:20 EDT, for our presentation at the Baird 2021 Global Healthcare Conference.
investor.agenusbio.com/events/event-details/baird-global-… -
Agenus reposted
SaponiQx
@saponiQx
SaponiQx is proud to partner with @Ginkgo Bioworks to develop the next generation of saponin adjuvants. Pairing SaponiQx’s unique expertise in saponins and Gingko Bioworks’ Foundry technology will provide a platform for innovation! #biotechnology #agenus
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
New $AGEN Subsidiary, SaponiQx, builds innovative adjuvant platform and forms collaboration with Ginkgo Bioworks
Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
$AGEN continues to make critical advancements with balstilimab - recently publishing data validating balstilimab's potential to provide significant benefit for patients with cervical cancer, which we highlight in today's newsletter.
Click to read more: agenusbio.com/newsletters/agenusnews-vol-4-iss-17-septemb… -
Agenus
@Agenus_Bio
Agenus to participate in Sept investor conferences
Agenus' President & COO Jen Buell, PhD @jbuell01 will participate in the Baird 2021 Global HC Conf on Sept 15, and the HCW 23rd Annual Global Investment Conference available on-demand starting Sept 13
investor.agenusbio.com/index.php/news-releases/news-relea… -
Agenus
@Agenus_Bio
VISION: Leading to Optimal Therapeutics and Clinical Designs
This newsletter describes VISION and highlights key capabilities that make it a critical component of Agenus' innovation engine.
Click to read more: agenusbio.com/newsletters/agenusnews-vol-4-iss-16-august-… -
Agenus
@Agenus_Bio
Results from a Ph2 trial of #antipd1 balstilimab monotherapy in advanced #cervicalcancer published in Gynecologic Oncology
Data suggest that bal may be a differentiated PD-1; benefit seen in hard to treat tumors including #adenocarinoma & PD-L1-
doi.org/10.1016/j.ygyno.2021.08.018 -
Agenus
@Agenus_Bio
Balstilimab Monotherapy Data Published in Gynecologic Oncology
Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumors
Responses seen across all histology subgroups
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
In case you missed it, read the latest Agenus Newsletter here: agenusbio.com/newsletters/agenusnews-vol-4-iss-15-august-…
Featuring an overview of our manufacturing capabilities and plans, highlighting this essential component of $AGEN business strategy.
Stay tuned for another issue coming next week. -
Agenus reposted
Kimberly Ha
@pharmaprodigy
We brought 17 new discoveries in the last 6 years. Delivered our first BLA filing and our first potential FDA decision later this year. We have fully integrated commercial infrastructure. @jbuell01 $AGEN @Agenus_Bio
-
Agenus
@Agenus_Bio
See $AGEN full earnings report and corporate update here: investor.agenusbio.com/news-releases/news-release-details…
#agenearnings -
Agenus
@Agenus_Bio
$AGEN CEO @garo_armen: "This quarter was one of our most productive in company history. Agenus is executing across each of its major pillars – significant value creators, cash generators, supportive programs, & key operational activities."
#agenearnings
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Balstilimab BLA accepted for Priority Review by the U.S. FDA with a PDUFA date of December 16, 2021
Commercial preparation underway for a highly efficient, targeted launch to lay the foundation for future Agenus products.
#agenearnings $AGEN
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
VISION platform knowledge base expanding to support AGEN1181 response prediction and combination discovery
#agenearnings $AGEN
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Significant Value Creators: Allogeneic iNKT cell therapy
MiNK Therapeutics filed an S-1 to support planned IPO
#agenearnings $AGEN
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Significant Value Creators: AGEN1181 (Fc-enhanced anti-CTLA-4)
Data readout expected at upcoming conference
Registrational trials to commence by YE2021
#agenearnings
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Cash Generators: $200M Upfront Collaboration on Anti-TIGIT Bispecific Antibody, AGEN1777, Closed with BMS
FDA Accepts IND; Ph1 dosing in solid tumors planned for this quarter
#agenearnings
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus will report earnings and provide a corporate update TODAY at 8:30am ET.
Tune in by calling (833) 614-1394 (US) or (914) 987-7115 (International). Conf ID: 3686849
Or listen to the webcast at edge.media-server.com/mmc/p/gsbikqz2
#agenearnings
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Corporate Update and Second Quarter 2021 Financial Report
The 1H 2021 saw multiple milestones for Agenus, including a collaboration with BMS and advancing AGEN1181 to an important data inflection point.
Conference Call TODAY at 8:30am ET
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus Manufacturing: Key to Delivering on Our Promise to Patients
This newsletter features an overview of our manufacturing capabilities and plans, highlighting why these are essential components of the Agenus business strategy.
Click to read more: agenusbio.com/newsletters/agenusnews-vol-4-iss-15-august-… -
Agenus
@Agenus_Bio
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021
Dr. Jennifer Buell @jbuell01 will participate in a fireside chat on August 9, 2021 from 3:00 - 3:25 p.m. ET.
To listen to the live event, please contact your BTIG representative.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
July is #sarcomaawarenessmonth!
@breelynwilkyMD partners w Agenus on multiple sarcoma trials w balstilimab, zalifrelimab, & AGEN1181. Listen to her speak about the importance of #sarcoma awareness & the benefit #immunotherapy has had for patients w this disease
@CureSarcomaThis media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
Introducing MiNK Therapeutics!
Visit @MiNK_iNKT and www.minktherapeutics.com to explore
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
PD-1 resistance is a big challenge for I-O therapy, which the predictive potential of Agenus' VISION platform could help overcome.
Listen to @ODayMD discuss this & other aspects of PD-1 resistance at the William Blair Biotech Focus Conference: investor.agenusbio.com/events/event-details/william-blair… -
Agenus
@Agenus_Bio
TUNE IN today to hear Dr. Steven O'Day @ODayMD speak on the William Blair Biotech Focus Conference 2021 panel “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at 4:20pm ET.
Click to listen: wsw.com/webcast/blair59/register.aspx?conf=blair59&page=p… -
Agenus
@Agenus_Bio
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
Agenus' CMO Steven O'Day, MD @ODayMD will participate in a panel on July 14 from 4:20 - 5:20 p.m. ET
Click for more information & to register:
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Is Fc enhancement required for optimal performance of anti-TIGIT molecules?
Dr. @dhanschand spoke at the @sitcancer seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" to address this question & discuss this emerging IO target #tigit www.sitcancer.org/events/event-description?CalendarEventK… -
Agenus
@Agenus_Bio
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021.
@bmsnews
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus' latest newsletter now available:
A Strategy for Innovation: Significant Strides in the Field of I-O
Since its founding Agenus has used its deep knowledge of the immune system's biology to create therapies to optimally target cancer. Read more: agenusbio.com/newsletters/agenusnews-vol-4-iss-13-june-29… -
Agenus
@Agenus_Bio
June is Cancer Immunotherapy Month! At the World Vaccine Congress last month, Agenus' CMO @ODayMD spoke about how #immunotherapy has changed the landscape of cancer treatment and continues to evolve to provide benefit to even more #cancerpatients. #cim21 investor.agenusbio.com/events/event-details/title-would-b…
-
Agenus
@Agenus_Bio
Hear Agenus' Head of Drug Discovery Dr. Dhan Chand speak at the SITC seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" TODAY from 2-4pm ET! Click here to register and watch: www.sitcancer.org/events/event-description?CalendarEventK…
@dhanschand @sitcancer #immunotherapy #tigit -
Agenus
@Agenus_Bio
Agenus' Head of Drug Discovery Dhan Chand, PhD @dhanschand will speak at a @sitcancer seminar on #tigit on June 29 at 2 - 4pm EST. Mark your calendars to join the discussion on this exciting #immunotherapy target!
Register here: www.sitcancer.org/education/deepdive
Society for Immunotherapy of Cancer
@sitcancer
Join expert faculty on June 29 for SITC's TIGIT Pathway: A Deep Dive in #cancer #immunotherapy Targets, which will discuss the emerging immunotherapy target, #tigit, including the pathway biology and therapeutic interventions using this pathway. REGISTER: www.sitcancer.org/education/deepdive
-
Agenus
@Agenus_Bio
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
The FDA has set a target action date of December 16, 2021.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
$AGEN listed as one of biggest #asco21 risers in @evaluatevantage stock round-up. Agenus presented on differentiated activity of anti-PD-1 antibody balstilimab & new clinical data on AGEN2373, a CD137 agonist antibody www.evaluate.com/vantage/articles/events/conferences/asco…
-
Agenus
@Agenus_Bio
Agenus at #asco21
Agenus’ CMO @ODayMD offers his thoughts on Agenus' #ai VISION platform and AGEN2373 data presented @ASCO. Click to read more: investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus’ Presentations at #asco21 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
Bal demonstrates superior tumor killing potential in a VISION study. AGEN2373 shows no liver toxicity; combo trials are planned
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset.
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus newsletter now available: Setting the Stage for Innovation with Our Own PD-1
Having a PD-1 is critical to our I-O strategy. It provides commercial flexibility & opportunities to advance this agent for strategic combinations
Click to read: agenusbio.com/agenusnews-vol-4-iss-11-june-2-2021-setting… -
Agenus
@Agenus_Bio
Agenus to Participate in Fireside Chat at the @Jefferies 2021 Virtual Healthcare Conference
Agenus' President and COO @jbuell01 will participate in a fireside chat on Friday, June 4, 2021 from 10:30am - 10:55am ET
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
May is #nationalcancerresearchmonth, and we’re highlighting the incredible work our scientists do advancing #immunotherapy
#ncrm21 #researchsaveslives -
Agenus
@Agenus_Bio
Listen to the latest @BioCentury podcast episode to hear about Agenus’ collaboration with @bmsnews and AGEN1777’s bispecific and Fc-enhanced design
#tigit #oncology #immunotherapy
www.biocentury.com/article/636637/lag3-before-you-leap-pl… -
Agenus reposted
Chris Garabedian
@cngarabedian
REMINDER 🧬 @BiotechCH “Biotech Clubhouse: Sunday Hangout” - reviewing news of the week w/ me, @bradloncar, & @daphnezohar Join us tomorrow Sun May 23 at 4:00pm EDT w/ special guest @Agenus_Bio President/COO @jbuell01 to discuss their @bmsnews TIGIT deal! www.joinclubhouse.com/event/PAAjr28O
-
Agenus
@Agenus_Bio
Like the rest of Agenus' differentiated pipeline, AGEN1777 is optimally designed to address an unmet need.
rb.gy/dpntx4
Agenus
@Agenus_Bio
We are proud to collaborate with industry leader @bmsnews to develop this Fc enhanced anti-TIGIT bispecific while continuing to advance our other innovations like our Fc enhanced anti-CTLA-4 AGEN1181 to serve patients with cancer and disrupt the IO space
#immunotherapy #tigit -
Agenus reposted
BioSpace
@biospace
@bmsnews makes potential $1.56 billion commitment to Agenus' antibody program
#biotechnology #antibodies #pharmaceutical
www.biospace.com/bristol-myers-squibb-licenses-agenus-ant… -
Agenus reposted
BioPharma Dive
@BioPharmaDive
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target www.biopharmadive.com/news/bristol-myers-agenus-tigit-can… by @NedPagliarulo $BMY $AGEN
-
Agenus reposted
Boston Business Journal
@BosBizJournal
A Lexington biotech firm has signed its largest licensing deal ever for a tumor-fighting antibody that is still in preclinical development. www.bizjournals.com/boston/news/2021/05/18/bristol-meyers…
-
Agenus reposted
PharmaTimes
@PharmaTimes
BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme feedproxy.google.com/~r/PharmatimesNewsRssFeed/~3/Pc9kzRO… #pharmanews #lifesciences
-
Agenus reposted
Immuno-Oncology Insights
@ImmunoInsights
Bristol Myers Squibb buys rights to Agenus's anti-TIGIT candidate in $1.56 billion deal @bmsnews @Agenus_Bio #immunotherapy
www.insights.bio/Errors/MissingEntity -
Agenus
@Agenus_Bio
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
Balstilimab shows a differentiated profile both clinically and preclinically. AGEN2373 has been well tolerated in a dose escalation trial with no liver toxicity observed
investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
MedCity News
@medcitynews
.@bmsnews is paying $200M for global rights to an @Agenus_Bio bispecific antibody that preclinical research shows has potential to best rest of the class. If it reaches the market, $AGEN could earn up to $1.36B in milestones, via @frankvinluan medcitynews.com/2021/05/bristol-myers-writes-200m-check-f… $BMY #cancer
-
Agenus reposted
BioWorld
@BioWorld
TIGIT fidgets lessen as Agenus’ mystery preclinical bispecific bags BMS pact worth up to $1.3B-plus… www.bioworld.com/articles/507202-tigit-fidgets-lessen-as-…
-
Agenus reposted
Scrip, Citeline Commercial
@PharmaScrip
Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT
insights.citeline.com/SC144379/Bristol-Pays-Out-200m-For-… #pharmascrip -
Agenus
@Agenus_Bio
Agenus & @bmsnews entered into a collaboration on AGEN1777, a product of our innovation engine.
Julie DeSander, VP Business Development, discusses how this collaboration will help advance the study of our innovations w the goal of helping cancer patients investor.agenusbio.com/news-releases/news-release-details… -
Agenus reposted
Bloomberg
@business
Bristol Myers Squibb will pay as much as $1.56 billion for the rights to a new experimental drug that uses the body’s immune system to combat cancer www.bloomberg.com/news/articles/2021-05-18/bristol-myers-…
-
Agenus
@Agenus_Bio
Agenus is excited to collaborate with Bristol Myers Squibb with the goal of transforming the I-O landscape and serving more patients with unmet needs @bmsnews #tigit #immunotherapy #oncology investor.agenusbio.com/news-releases/news-release-details…
-
Agenus reposted
BioCentury
@BioCentury
BMS is paying Agenus $200M up front for global rights to a bispecific antibody targeting TIGIT $AGEN www.biocentury.com/article/636475/bms-sees-potential-firs…
-
Agenus reposted
Endpoints News
@endpts
Bristol Myers Squibb is enlisting a preclinical program from Agenus to its pipeline, plunking down $200 million upfront for a bispecific antibody that targets both TIGIT and another undisclosed target.
endpts.com/bristol-myers-bets-big-on-anti-tigit-bispecifi… -
Agenus
@Agenus_Bio
Read @BostonGlobe coverage of Agenus' collaboration with @bmsnews, "the biggest such deal for Agenus since the company was founded in 1994."
#tigit #immunotherapy #oncology
www.bostonglobe.com/2021/05/18/business/lexington-biotech…
The Boston Globe
@BostonGlobe
Lexington biotech licenses experimental cancer drug to Bristol Myers Squibb for $200m bos.gl/VqZhrWW
-
Agenus
@Agenus_Bio
"Bristol Myers Strikes $1.6 Billion Pact for New Cancer Fighter"
Click to read @business coverage of Agenus' collaboration with @bmsnews for the development of AGEN1777 and what it could mean for the future of cancer immunotherapy: www.bloomberg.com/news/articles/2021-05-18/bristol-myers-…
#tigit #cancerre ... -
Agenus
@Agenus_Bio
BMS nabs rights to Agenus' anti-TIGIT bispecific antibody programme beta.firstwordpharma.com/story/5302123 via @fwpharma
-
Agenus
@Agenus_Bio
Agenus to Host Conference Call to Discuss Global Licensing Agreement with @bmsnews for Agenus’ Anti-TIGIT Bispecific Antibody Program
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus and @bmsnews enter into a collaboration with an aggregate value of up to $1.6B for development of Agenus’ differentiated anti-TIGIT bispecific AGEN1777. Click to learn more: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus' President and COO Jennifer S. Buell, PhD, will share her thought on Precision Medicine in IO at the 7th Annual #sachs_ioif Forum on May 19 at 10:10am
@jbuell01 #immunooncology #immunotherapy #cancerresearch #innovationinhealthcare #biotechnology
Sachs Associates
@SachsAssociates
Looking forward to hosting the Precision Medicine in IO Panel during our 7th Annual #sachs_ioif Forum on 18th-20th May 2021. Reserve your ticket now.
More info @ www.sachsforum.com/7ioif-about.html -
Agenus
@Agenus_Bio
TUNE IN to hear AgenTus management speak at upcoming conferences on #celltherapy @Agentus_CellTX @AllogeneicCell #covid19 #inkt #immunotherapy
MiNK Therapeutics
@MiNK_iNKT
2 AgenTus presentations @ 3rd Allogeneic CT Summit on May 17-19 & CT for Infectious Diseases . Marc Exley presenting on “Increase Safety by Managing GvHD” @ 13:40 EST May 19 & Marc Van Dijk presenting “Allogeneic Invariant NKT cells as Treatment for COVID-19” @ 13:00 EST July 21
-
Agenus
@Agenus_Bio
Agenus Corporate Update and First Quarter 2021 Financial Report
•Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer
•Balstilimab and AGEN2373 data to be presented at ASCO
•iNKT cell therapy Phase 1 initiated in cancer
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus' CMO Dr. Steven O’Day spoke today at the World Vaccine Congress about ‘Future Perspectives for Combination Immunotherapies’
Today's newsletter The Agenus Difference discusses the importance of combinations & our continued innovation w this approach
agenusbio.com/newsletters/agenusnews-vol-4-iss-9-may-04-2… -
Agenus
@Agenus_Bio
TUNE IN! Panel on Future Perspectives for Combination Immunotherapies starts at 1pm ET! Hear Dr. Steven O'Day at the World Vaccine Congress 2021: www.terrapinn.com/conference/world-vaccine-congress-washi… @ODayMD @vaccinenation #wvcusa #immunotherapy #cancerresearch
-
Agenus
@Agenus_Bio
Hear $AGEN CMO Dr. Steven O'Day's thoughts on the promises and challenges of combination immunotherapies at the World Vaccine Congress 2021 TODAY at 1pm! Click to register and watch: www.terrapinn.com/conference/world-vaccine-congress-washi… @ODayMD @vaccinenation #wvcusa
-
Agenus
@Agenus_Bio
Agenus to Present at the 2021 ASCO Annual Meeting
Agenus will present on two of its programs, balstilimab (anti-PD-1) and AGEN2373 (CD137 agonist antibody)
@ASCO #asco21 #oncology #immunotherapy
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
Agenus' CMO Dr. Steven O'Day will be at the World Vaccine Congress Washington 2021! Mark your calendars for the panel on Future Perspectives for Combination Immunotherapies on May 4. Click for more information & to register: www.terrapinn.com/conference/world-vaccine-congress-washi… @ODayMD @vaccinenation #wvcusa
-
Agenus
@Agenus_Bio
"FDA Approval Sought for Balstilimab for Recurrent or Metastatic Cervical Cancer"
Click to read @OncLive coverage of $AGEN submission of balstilimab (anti-PD-1) BLA for recurrent or metastatic #cervicalcancer. #immunotherapy #oncology www.onclive.com/view/fda-approval-sought-for-balstilimab-… -
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: Agenus’ Own Unique Anti-CTLA-4 and Anti-PD-1 Antibodies
Two presentations on AGEN1181 at #aacr21 showed that it appears to be working even in tumors that are not expected to respond to #immunotherapy. Read more: agenusbio.com/newsletters/v4-i08_2021-agenus-own-unique-a… -
Agenus
@Agenus_Bio
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus subsidiary @Agentus_CellTX dosed the first cancer patient with its iNKT #celltherapy! Watch Dr. @JoeGrossman7 discuss this immunotherapy and its potential to treat both #cancer and #covid19.
Agenus
@Agenus_Bio
Agenus expects this therapy to be effective in both liquid and solid tumors based on preclinical models and to be potentially more affordable and more accessible than currently approved cell therapies.
Click to learn more: boston.cbslocal.com/2021/04/14/agentus-immune-cell-therap… -
Agenus
@Agenus_Bio
Agenus Doses First Cancer Patient with iNKT Cell Therapy
investor.agenusbio.com/news-releases/news-release-details…
The Phase 1 trial has been initiated in hematologic cancers @DanaFarber with expansion into solid tumors expected to begin shortly. Initial data readouts anticipated in 4Q2021 @Agentus_CellTX -
Agenus
@Agenus_Bio
Agenus' next-generation anti-CTLA-4 AGEN1181 is optimally designed with differentiated activity seen in the clinic. Watch $AGEN's CMO @ODayMD discuss the power of this cancer immunotherapy & the exciting responses presented at #aacr21! Click to learn more: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
New Clinical Responses for AGEN1181 Presented at #aacr21 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Dr. @jbuell01, President & COO of $AGEN, will participate in the Precision Medicine in IO Panel at the 7th Annual Digital Immuno-Oncology Innovation Forum #sachs_ioif #immunooncology #immunotherapy #precisionmedicine
Sachs Associates
@SachsAssociates
Dr. Buell(@jbuell01) brings over 20 years of biopharmaceutical industry experience. Her efforts in the rapid advancement of discovery candidates through development has resulted in @Agenus_Bio' record of advancing numerous I-O candidates to the clinic in the past four years.
-
Agenus
@Agenus_Bio
$AGEN senior management take bonus in equity over cash: investor.agenusbio.com/node/17711/html investor.agenusbio.com/node/17721/html
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: Optimally Targeting TIGIT
TIGIT has emerged as the next validated I-O target w the potential to be a game-changing therapy for cancer patients. Click to read about the science of TIGIT & our bispecific AGEN1777: agenusbio.com/newsletters/v4-i07_2021-optimally-targeting… -
Agenus reposted
Jennifer Buell
@jbuell01
Please to participate in #longwoodhealthcareleaders conference to discuss @Agenusbio #ai efforts & describe our #vision Immune Platform to predict patient response
Longwood Fund
@LongwoodFund
Today's #longwoodhealthcareleaders meeting is focused on accelerating the translation of discoveries into medicines to help patients. We look forward to hosting leaders in biomedicine www.longwoodhealthcareleaders.com/april2021
-
Agenus
@Agenus_Bio
Agenus @ #sgomtg! @omalleygynonc presents on our RaPiDS trial, a collaboration w @GOG expected to further validate the use of bal+/-zal in 2L #cervicalcancer. Watch Dr. O'Malley discuss the trial & the potential to provide treatment to even more #patients
agenusbio.com/newsletters/v4-i02_2021-cervical-cancer-awa… -
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: The Central Role of iNKT Cells: An Agenus Perspective
This newsletter highlights the central role of iNKT cells in the immune system & their diverse functionality. Click to read more: agenusbio.com/newsletters/v4-i06_2021-the-central-role-of… -
Agenus
@Agenus_Bio
$AGEN Corporate Update and Fourth Quarter & Full Year 2020 Financial Report investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN will present @AACR #aacr21 on next-gen #ctla4 AGEN1181 which shows increased efficacy & improved safety profile over first-generation anti-CTLA-4. Stay tuned for Exploring AGEN1181, a series of posts discussing its optimized design & promising data! investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: Novel Immune Tools Tutorial: TIGIT, iNKTs, CTLA-4
In this newsletter, we give deeper insights into the science behind some of our exciting emerging medicines: CTLA-4, TIGIT, & iNKT cells. Click to read more: agenusbio.com/v4-i05_2021-novel-immune-tools-tutorialtigi… -
Agenus
@Agenus_Bio
$AGEN & @Agentus_CellTX CTO Dr. Marc van Dijk spoke @CAR_TCell #carteu about the potential of iNKT #celltherapy, clinical plans in #cancer & #covid_19, & combination potential w Agenus' checkpoint antibodies. Watch the replay for more insights: investor.agenusbio.com/events/event-details/car-tcr-europ…
-
Agenus
@Agenus_Bio
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: Overcoming the Limitations of Current PD-1s
Our PD-1 bal shows activity regardless of patients' #pdl1 status in R/M #cervicalcancer. Read about this potential differentiator & our work to identify better biomarkers: agenusbio.com/v4-i04_2021-overcoming-the-limitations-of-c… -
Agenus
@Agenus_Bio
S1E1 of Agenus Insights discussed #tigit the next validated #io target in the immune revolution. @jbuell01 probed @ODayMD & @dhanschand on the key attributes of $AGEN TIGIT bispecific & what it adds to the current TIGIT landscape. See the replay for more: investor.agenusbio.com/events/event-details/agenus-insigh…
-
Agenus
@Agenus_Bio
$AGEN CTO Dr. Marc van Dijk to speak at #cartcr Summit Europe on Wed Feb 17 @ 11am GMT on "Providing Mechanistic Rationale for Combination Therapies Through Functional Characterisation." Click to learn more & to register: cartcr-europe.com @CAR_TCell @Agentus_CellTX
-
Agenus
@Agenus_Bio
The key to #biopharma development in 2021 will be advances in disease-fighting #technology. @jbuell01, President and COO of $AGEN, and other industry experts talk to @PharmaScrip about the progress they expect to see. Read about their vision here: scrip.pharmaintelligence.informa.com/SC143776
-
Agenus
@Agenus_Bio
TUNE IN today @ 1pm ET to "Optimally Targeting TIGIT" to hear @ODayMD & @dhanschand discuss the potential of #tigit as the next validated #io target & the importance of Fc-enhancement for optimal performance. Learn more and register here: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN is continuing to see responses that demonstrate the exciting potential of AGEN1181, our Fc-enhanced anti-CTLA-4. 2 new confirmed responses announced this week. See further updates in our corporate deck: investor.agenusbio.com/static-files/e9101e50-36c6-420c-ba…
-
Agenus
@Agenus_Bio
$AGEN is excited to welcome Andy Hurley as Chief Commercial Officer! Andy brings 3 decades of experience as a strategic commercial leader in #biopharma. He comes to Agenus from @SyneosHealth where he served as Senior Vice President. Read more: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: A Powerful Team to Accomplish the Agenus Plan
Agenus' #io breakthroughs are driven by our innovative team. Read more about our new members’ vision for advancing & developing our strong pipeline of therapies: agenusbio.com/newsletters/v4-i03_2021-a-powerful-team-to-… -
Agenus
@Agenus_Bio
Andy Hurley Named $AGEN Chief Commercial Officer investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN announces Agenus Insights, a R&D miniseries that will offer key insights into the most impactful areas of research in #immunooncology today. Join us for the inaugural episode "Optimally Targeting TIGIT" on Feb 11 at 1pm ET. Learn more & register: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN Announces Agenus Insights - Virtual R&D Miniseries investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN announced 2 new responses today with its next-gen #ctla4 AGEN1181 in #ovariancancer and MSS #colorectalcancer, indications that usually respond poorly to #immunotherapy, as @ODayMD points out. Read more: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN Announces New Responses for AGEN1181 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN announced promising preliminary results of its iNKT #celltherapy trial in patients w moderate to severe symptoms of #covid19. 75% (3/4) patients extubated & released after treatment; 50% (2/4) extubated within 24 hours of treatment: investor.agenusbio.com/news-releases/news-release-details… @Agentus_CellTX
-
Agenus
@Agenus_Bio
Could Cell Therapy Be The Answer To COVID-19? Click to learn more about @Agentus_CellTX iNKT cell therapy trial & the potential of these cells to fight #covid19: cbsloc.al/2NXKoja
-
Agenus
@Agenus_Bio
$AGEN Announces Positive Preliminary Results of iNKT Cell Therapy Trial in #covid19 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
A recent @oncogenejournal article reports that $AGEN's PD-1 balstilimab has activity in recurrent/metastatic #cervicalcancer regardless of #pdl1 status & compares favorably to currently-approved therapies. Read more: go.nature.com/3auw1KH
-
Agenus
@Agenus_Bio
For #cervicalcancerawarenessmonth, Agenus speaks w experts in the field of #gynecology about this deadly disease. Watch our latest newsletter to hear about the challenges faced by #cervicalcancer patients & the transformative potential of #immunotherapy www.agenusbio.com/newsletters/v4-i02_2021-cervical-cancer…
This media couldn't be displayed. See it on the original post. -
Agenus
@Agenus_Bio
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
How will #biopharma tackle #covid19 in 2021? @jbuell01, President and COO of $AGEN, and other leading industry experts answer @PharmaScrip's thought-provoking question. Read their responses here: insights.citeline.com/SC143620/Scrip-AsksWhat-Does-2021-H…
-
Agenus
@Agenus_Bio
Agenus to Participate in B. Riley Securities' Oncology Investor Conference investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
#ai-driven #biomarker detection is critical for optimization of #io cancer treatments. #vision is designed to accurately predict treatment responses, important for identifying optimal therapies & combinations. Learn more from Dr. Cailin Joyce: bioprocessintl.com/analytical/diagnostics/ebook-predictiv…
-
Agenus
@Agenus_Bio
2021- Agenus Focusing on Our Highest Potential Opportunities – READ MORE on our focus on our highest potential I-O product candidates, as well as significant partnership opportunities: agenusbio.com/newsletters/v4-i01_2021-focusing-on-our-hig…
-
Agenus
@Agenus_Bio
The #biotech industry and the way we do business have been transformed by #covid19. Listen to @jbuell01 speak with @DatasiteGlobal about $AGEN's innovative strategies for relationship building and #dealmaking in a digital setting #jpm2021
Datasite
@DatasiteGlobal
Getting ready for dealmaking at #jpmweek? Watch our interview with @jbuell01, President and Chief Operating Officer at @Agenus_Bio: www.datasite.com/us/en/insights/multimedia/videos/taking-… #jpm2021 #wheredealsaremade #healthcare
-
Agenus reposted
Jennifer Buell
@jbuell01
It is great to be with this exemplary crew conquering #sarcoma @breelynwilkyMD @Agenus_Bio #cancer
Breelyn Wilky, MD, FASCO 🎗
@breelynwilkyMD
some familiar faces here with my other #sarcoma tweeples!
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: A Pivotal Year: 2020 in Review
2020 has been a year of innovation & progress for Agenus. The conclusion of our 2020 newsletter series discusses Agenus' achievements this year:
agenusbio.com/newsletters/v3-i25_a-pivotal-year-2020-in-r…
Agenus
@Agenus_Bio
Stay tuned for the first issue of our 2021 series on January 12, which will outline our plans for the new year!
-
Agenus
@Agenus_Bio
Save the date! @Agentus_CellTX
MiNK Therapeutics
@MiNK_iNKT
AgenTus’ CTO Marc Van Dijk, to present at the CAR-TCR Europe on “Providing Mechanistic Rationale for Combination Therapies Through Functional Characterisation” @11AM GMT/12 PM CET on Wednesday February 17th @Agenus_Bio @CAR_TCell #cartcr #immunotherapy
-
Agenus
@Agenus_Bio
$AGEN President & COO @jbuell01 spoke w Umer Raffat at the Evercore ISI 3rd Annual #healthconx Conference last wk about Agenus' strong pipeline based on #immunology.
Key points covered: AGEN1181 responses in MSS disease, PD-L1(-) tumors, & a genetic polymorphism. (1/2)
Agenus
@Agenus_Bio
Bali #bla filing: 2 late responses w bali mono require 6 mo follow-up. Bali mono and bali/zali combo on track to be filed.
Listen to full discussion here: investor.agenusbio.com/events/event-details/evercore-isi-… rb.gy/cci6ua (2/2) -
Agenus
@Agenus_Bio
$AGEN is excited to welcome Dr. @JoeGrossman7 as VP Head of Exploratory Medicine! Dr. Grossman is a GI cancer expert who joins Agenus from @harvardmed and @BIDMChealth. Read more about Dr. Grossman and his thoughts on AGEN1181 Ph2 trial expansion: investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
AGEN1181, Fc-enhanced anti-CTLA-4, reports new responses in CRC; expanded Phase 2 trial underway. Responses in tumors unlikely to respond to CPIs (PD-L1(-), MSS endometrial, CRC, ovarian). investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Completion of Balstilimab BLA Filing Extended To 1H2021 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
AgenT-797 @Agentus_CellTX iNKT #celltherapy promotes direct tumor killing & tumor microenvironment conditioning & can be manufactured efficiently at a low cost. #covid19 trial is underway @WeillCornell and cancer trials are expected to begin soon #sitc2020 agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
$AGEN latest newsletter now available: Leveraging the Immune System to Defeat COVID-19
#celltherapy shows promise as treatment for #covid19. iNKT cell therapy has entered the clinic to treat patients w moderate to severe cases of COVID-19 @Agentus_CellTX agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2… -
Agenus
@Agenus_Bio
AGEN1181, our Fc-enhanced next-gen #ctla4, was presented at #sitc2020 by Dr. @ODayMD who will join $AGEN as CMO. AGEN1181 shows durable clinical benefit & no neuroendocrine toxicities; first known CTLA-4 to show selective depletion of intratumoral Tregs agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
$AGEN Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN to Participate in Evercore ISI 3rd Annual #healthconx Conference investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN's #ctla4 zali is active in #pd1 failures as shown in a study in #raretumors presented at #sitc2020. Out of 28 evaluable patients: DCR of 51.9%; 1 CR, 2 PRs. We have launched a Ph2 trial of bali + zali w SOC in #softtissuesarcoma w @breelynwilkyMD agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle? Thanks to #io360 you can hear from $AGEN President & COO @jbuell01, Dr. Chuck Drake and others describe what's needed - like our AGEN1181 a next gen CTLA-4 molecule. theconferenceforum.org/immuno-oncology-360/what-do-next-g…
-
Agenus
@Agenus_Bio
$AGEN VISION platform studies cancer cell interactions in simulated tumor microenvironment to predict how immunotherapies will perform in patients & discover optimal combos. VISION outperforms standard IHC testing in predicting response to #pd1 therapy agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
AGEN2373, $AGEN's #cd137, demonstrated stable disease in 4 patients with advanced solid tumors and no liver toxicity up to 1mg/kg at #sitc2020. It also promotes intratumoral #treg depletion
Agenus
@Agenus_Bio
Read more about our 7 presentations at #sitc2020 in our most recent newsletter: agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
$AGEN's #tigit molecules are Fc-enhanced. Our #sitc2020 presentation shows this is important for superior tumor control and optimized performance compared to clinical-stage TIGITs and could broaden benefit to an additional 40% of #patients agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
-
Agenus
@Agenus_Bio
$AGEN's goal is to bring treatments to cancer patients with #innovation and speed. We are excited to announce that Agenus is being recognized with a spot on @DeloitteTMT's 2020 Technology #fast500 list, which celebrates innovative industry disruptors www2.deloitte.com/us/en/pages/technology-media-and-teleco…
-
Agenus
@Agenus_Bio
$AGEN latest newsletter is now available.
Perspectives on Seven Agenus Programs Presented at SITC:
agenusbio.com/wp-content/uploads/2020/11/NL-201020-SITC-2…
Read about the programs and data Agenus presented on at #sitc2020 and their context within Agenus' broader pipeline and strategy #oncology -
Agenus
@Agenus_Bio
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data investor.agenusbio.com/events/event-details/agenus-and-dr…
-
Agenus
@Agenus_Bio
$AGEN presents on 7 novel programs at #sitc2020 including our Fc-enhanced #tigit and our #ai R&D VISION platform. See highlights below! Click to view full posters: www.agenusbio.com/sitc-2020
-
Agenus
@Agenus_Bio
Meet our #sitc2020 presenters! Dr. Cesar Perez is a principal investigator for the Ph1/2 trial of zalifrelimab at the @SylvesterCancer where he is also the Head and Neck Oncology Lead #immunotherapy #oncology #antictla4
-
Agenus
@Agenus_Bio
Meet our #sitc2020 presenters! As a senior scientist at $AGEN, Dr. Simarjot Pabla @PablaSimarjot is working on Agenus’ VISION platform. He is focused on using #artificialintelligence and machine learning to identify optimal treatment combinations for patients #immunotherapy
-
Agenus
@Agenus_Bio
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Meet our #sitc2020 presenters! Dr. Claire Galand @ClaireGaland is the senior scientist for the #pharmacology team at $AGEN. She currently leads the preclinical research for AGEN2373, our anti-CD137 #immunotherapy #oncology
-
Agenus
@Agenus_Bio
$AGEN President & COO Dr. @jbuell01 reports that iNKTs are a unique cell type that combines both arms of immunity, adaptive and innate, making them invaluable in combatting diseases like #cancer & #covid19. Trial is underway @WeillCornell #celltherapy
Jennifer Buell
@jbuell01
Learn How iNKT cells can treat #cancer and #covid19 in #biopharma-reporter.com First patient dosed with @Agentus_CellTX iNKTs www.biopharma-reporter.com/Article/2020/11/09/First-patie…
-
Agenus
@Agenus_Bio
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Welcome Dr. @joegrossman7, our clinical expert advancing innovative early clinical trials for optimal combinations for patients with #cancer! #biology #immunotherapy
Jennifer Buell
@jbuell01
$AGEN expands our excellent: team Welcome Dr. @JoeGrossman7, an expert in GI cancers & leader in novel approaches harnessing Organoids for Personalized Therapy (or HOPE) study #pancreaticcancer #biology #digitalhealth www.statnews.com/2019/10/04/pancreatic-cancer-tumors-in-a…
-
Agenus
@Agenus_Bio
Could #celltherapy be the answer to #covid19? @DrMhidalgo, the Chief of Hematology and Oncology at @WeillCornell, speaks about iNKT cell therapy for COVID-19 and cancer. Read more here: boston.cbslocal.com/2020/11/02/covid-19-agentus-immune-ce… #fightcovid19 #immunesystem @Agentus_CellTX investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
•Has potential to decrease viral shedding and prevent lung injury from #inflammation
•Has potential to suppress #cytokinestorm by regulating #immunesystem
investor.agenusbio.com/news-releases/news-release-details… @Agentus_CellTX #fightcovid19 (2/2) -
Agenus
@Agenus_Bio
$AGEN iNKT #celltherapy is a unique #covid19 treatment because it:
•Utilizes the body’s own #immunesystem
•Increases iNKT cells in body which COVID-19 depletes
•Is allogeneic; does not require genetic modification
before dosing (1/2) -
Agenus
@Agenus_Bio
Meet our #sitc2020 presenters! As an AgenTus scientist, Dr. Burcu Yigit works on AgenT-797, @Agentus_CellTX iNKT #celltherapy candidate. The first #covid19 patient was recently dosed with AgenT-797, and trials in #cancer are expected to begin shortly investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
We are so excited to welcome @ODayMD to $AGEN as our CMO! Dr. O’Day and Agenus share a strong passion for improving the lives of #cancerpatients. His deep understanding of I-O will be invaluable in our mission to bring treatment access to patients investor.agenusbio.com/index.php/news-releases/news-relea…
-
Agenus reposted
Jennifer Buell
@jbuell01
A courageous leader. A true pioneer. A dedicated & tireless doctor. A brilliant scientist. A compassionate man. Together, we will extend the benefit of his hands & mind from the few to the many #cancer patients. We are thrilled to welcome Dr. @ODayMD to $AGEN. #immunotherapy
-
Agenus reposted
John Castle
@joccastle
@ODayMD is an I-O pioneer who cares deeply about patients. Great step forward for $AGEN.
-
Agenus
@Agenus_Bio
Dr. Steven O’Day Named $AGEN Chief Medical Officer @ODayMD investor.agenusbio.com/index.php/news-releases/news-relea…
-
Agenus
@Agenus_Bio
Agenus #therapies bring hope to #cancerpatients
Our latest newsletter tells the story of Lurdes, a cervical cancer patient who participates in $AGEN's bali + zali trial and has a >90% tumor reduction to date. Watch full video and read her story here: www.agenusbio.com/agenus-therapies-bring-hope-to-cancer-p… -
Agenus
@Agenus_Bio
$AGEN dosed the first patient with iNKT #celltherapy! This immune cell therapy is designed to eliminate the COVID-19 virus, dampen harmful inflammation, and protect from reinfection @Agentus_CellTX #fightcovid19 #immunotherapy investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN Doses First COVID-19 Patient with iNKT Cell Therapy investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Meet our #sitc2020 presenters! As an $AGEN scientist, Rebecca Ward has worked on multiple antibody programs in preclinical development, including balsilimab, from target discovery to IND. She is currently working on AGEN1777, our #tigit bispecific
-
Agenus
@Agenus_Bio
Agenus R&D Update & Third Quarter Financial Report investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN's #tigit antibodies are engineered with enhanced Fc engagement, which is designed to optimize their tumor killing ability as monotherapy or with PD-1. Listen to Dhan speak about TIGIT and Fc engagement at the TIGIT Therapies Digital Summit: investor.agenusbio.com/events/event-details/tigit-therapi… #oncology
-
Agenus
@Agenus_Bio
investor.agenusbio.com/news-releases/news-release-details…
Breaking Data
@DataisBreaking
Phase 2 #clinicaltrials led by @OSUCCC_James & @Agenus_Bio found that #balstilimab given alone or in combo with #zalifrelimab demonstrated promise for the treatment of advanced #cervicalcancer: cancer.osu.edu/news/preliminary-results-of-two-large-immu…
-
Agenus
@Agenus_Bio
Hear @dhanschand $AGEN head of drug discovery discuss #tigit at the TIGIT summit today! Dhan speaks about the importance of Fc enhancement for TIGIT engagement and how we can use current knowledge about TIGIT MOA for optimal design tigit-therapies.com/speaker/dhan-chand/ www.agenusbio.com/wp-content/uploads/2020/10/NL-201020-TI…
-
Agenus reposted
Dhan Chand
@dhanschand
Please join me and others at the #tigit Therapies Digital Summit today as we discuss new discoveries in the TIGIT field and how @Agenus_Bio is translating them into more effective TIGIT targeted therapies. Link: www.tigit-therapies.com
-
Agenus reposted
Jennifer Buell
@jbuell01
See $AGEN discovery leader @dhanschand with seminal publication in @Cancer_Cell on importance of Fc enhancement, takes center stage at the #tigit summit tigit-therapies.com and describes how to optimize TIGIT targeting! #immunotherapy #cancer #digitaltransformation
-
Agenus
@Agenus_Bio
Meet Our #sitc2020 Presenters! Dr. David O'Malley is the lead investigator for the Ph2 trials of balstilimab +/- zalifrelimab. He is also the Director of the Division of Gynecologic Oncology at the @OSUCCC_James #immunotherapy #oncology #cervicalcancer
-
Agenus
@Agenus_Bio
Meet Our #sitc2020 Presenters! Dr. Steven O'Day @ODayMD is a principal investigator for AGEN1181 P1 trial at the John Wayne Cancer Institute @JohnWayneCI, where he is the Executive Director & Director of Immune-oncology investor.agenusbio.com/news-releases/news-release-details… #immunotherapy #oncology
-
Agenus
@Agenus_Bio
TIGIT: The 3rd Validated I-O Target: Agenus Fc-enhanced TIGITs to Maximize Benefit. Read more: agenusbio.com/wp-content/uploads/2020/10/NL-201020-TIGIT-… #oncology #immunotherapy #tigit
-
Agenus
@Agenus_Bio
Agenus to Report Third Quarter Earnings investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Introducing our series Meet Our Presenters: SITC Edition! $AGEN announced yesterday that 7 abstracts were accepted for presentation at #sitc2020. As we count down to SITC, watch out for posts introducing our presenters and the exciting data and programs they will be showcasing
-
Agenus
@Agenus_Bio
Agenus to Present on Seven Novel Programs at SITC 2020 investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
We’re watching @barbara_ryan12 speak about investing in #biotech in the world today! Tune in to Making Money with Charles Payne @cvpayne
-
Agenus
@Agenus_Bio
Susan Hirsch Joins Agenus’ Board of Directors investor.agenusbio.com/news-releases/news-release-details…
-
Agenus reposted
John Nosta
@JohnNosta
Watch list! “...the largest trials of immuno-oncology therapies in relapsed cervical cancer to date and show that balstilimab and zalifrelimab may present meaningful new therapies for patients with cervical cancer."
cancer.osu.edu/news/preliminary-results-of-two-large-immu… #oncology #cancer
@Agenus_Bio $AGEN -
Agenus
@Agenus_Bio
Read @OSUCCC_James coverage of $AGEN data on balstilimab +/- zalifrelimab in cervical cancer at #esmo20:
cancer.osu.edu/news/preliminary-results-of-two-large-immu…
It has been wonderful to work with Dr. O'Malley of @OSUCCC_James in presenting our exciting data!
investor.agenusbio.com/news-releases/news-release-details… -
Agenus
@Agenus_Bio
$AGEN newsletter is now available: "Did You Know? Facts About Agenus": agenusbio.com/wp-content/uploads/2020/10/NL-201006-Facts-…
-
Agenus reposted
Scientific American
@sciam
New immune-therapies are only as good as the access patients have to them. In a recent live Q&A with our followers, Dr Jennifer Buell answered your questions about developing new therapies with access in mind [Sponsored by @Agenus_Bio]
-
Agenus
@Agenus_Bio
$AGEN is committed to fighting #cervicalcancer and providing accessible treatment options. $AGEN has treated women in the largest trials of IO therapies in R/M cervical cancer to date and has initiated a rolling BLA for bali in R/M cervical cancer #gynecologiccancerawarenessmonth
-
Agenus reposted
John Nosta
@JohnNosta
Could @Agenus_Bio have the BETTER PD-1, alone or in COMBINATION with a CTLA-4. $AGEN #biotech #cancer #oncology @jbuell01 #keytruda
-
Agenus reposted
Kimberly Ha
@pharmaprodigy
Thanks @CancerNetwrk for covering @Agenus_Bio #cervicalcancer results #esmo2020 www.cancernetwork.com/view/balstilimab-monotherapy-combin…
@jbuell01 @barbara_ryan12 -
Agenus reposted
Jennifer Buell
@jbuell01
Excellent coverage of our #esmo20 data - thank you @CancerNetwrk! #cervical #cancer
Kimberly Ha
@pharmaprodigy
Thanks @CancerNetwrk for covering @Agenus_Bio #cervicalcancer results #esmo2020 www.cancernetwork.com/view/balstilimab-monotherapy-combin…
@jbuell01 @barbara_ryan12 -
Agenus
@Agenus_Bio
A rewarding initiative born from visionary Mary Stutts! Thank you to our interns & our leaders @Agenus_Bio Berkeley for building the next generation of innovators & disruptors. Great coverage @abc7newsbayarea!
Jennifer Buell
@jbuell01
$AGEN is proud to partner with visionary Mary Stutts & TCEL, empowering youth through virtual internships driven by our CMO Al Dadson. Great success! abc7news.com/education/how-mother-daughter-duo-is-helping… via @abc7newsbayarea @Agenus_Bio
-
Agenus
@Agenus_Bio
$AGEN newsletter is now available: Balstilimab Monotherapy and Balstilimab plus Zalifrelimab Trials Presented at ESMO: agenusbio.com/wp-content/uploads/2020/09/NL-200922-ESMO-2…
#esmo20 #oncology #immunotherapy #cervicalcancer -
Agenus
@Agenus_Bio
Replay of discussion of $AGEN #esmo20 data presentation hosted by @Phipps_MC @WilliamBlair with Dr. O'Malley @OSUCCC_James is now available and can be accessed here: williamblair.zoom.us/rec/play/B24AGQRo_TrZJb9OPQG5_54R2kB… #oncology #immunotherapy #cervicalcancer
Agenus
@Agenus_Bio
Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #esmo20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: investor.agenusbio.com/news-releases/news-release-details… #oncology
-
Agenus
@Agenus_Bio
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab #fightcancer #esmo20
@Agenus_Bio
Morgan Buell Gallion
@morgan_buell
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab #fightcancer #esmo20 @Agenus_Bio finance.yahoo.com/news/agenus-agen-initiates-rolling-bla-…
-
Agenus
@Agenus_Bio
WATCH NOW: the inaugural episode of "18 Minutes with..." @MediaJerNYC @sciam and $AGEN President & COO, Dr. Jennifer Buell (@jbuell01). Learn about disruptive approaches to #cancer, #covid19, & #immunotherapy
-
Agenus
@Agenus_Bio
Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #esmo20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: investor.agenusbio.com/news-releases/news-release-details… #oncology
-
Agenus reposted
Jennifer Buell
@jbuell01
Excellent presentation by @lillian_siu on MK-4830, a first-in-class, ILT4 targeting antibody discovered @Agenus_Bio and partnered with @Merck. Siu described how MK-4830 reprograms tumour-associated macrophages, relieving myelosuppression & enhancing T cell activity.
ESMO - Eur. Oncology
@myESMO
#esmo20: 2 promising immuno. targets in solid tumours: preliminary efficacy reported w/ MK-4830, first-in-class human ILT4-targeting monoclonal antibody; PRS-343, a HER2/4-1BB bispecific molecule appears 2 offer HER2 inhibition w/ immune response regulatn www.esmo.org/meetings/esmo-virtual-congress-2020/daily-re…
-
Agenus reposted
Kimberly Ha
@pharmaprodigy
Excited for patients with cervical cancer! Potential new therapy: www.onclive.com/view/balstilimab-monotherapy-or-plus-zali… @OncLive @Agenus_Bio @garo_armen @jbuell01 @barbara_ryan12 #balstilimab #pd1 #cervicalcancer #esmo2020
-
Agenus
@Agenus_Bio
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status. #esmo20
Targeted Onc
@TargetedOnc
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status.
www.targetedonc.com/view/activity-observed-with-balstilim… #gyncsm #esmo20 -
Agenus
@Agenus_Bio
Highlights of data featured in $AGEN #esmo20 presentation. View full video on $AGEN website: agenusbio.com/balstilimab-balstilimab-zalifrelimab/ #oncology #immunotherapy
-
Agenus
@Agenus_Bio
Cervical cancer claims the lives of more then 4500 young women each year; @Agenus_Bio is committed to change this current reality. #cervicalcancer #immunotherapy #esmo20
John Nosta
@JohnNosta
BREAKING! In metastatic cervical #cancer, Agenus advances efficacy with their complementary CTL4 and PD1 combo—27% response vs monotherapy 14% with #keytruda. @agenus_bio @jbuell01 #oncology #esmo2020
-
Agenus reposted
John Nosta
@JohnNosta
BREAKING! In metastatic cervical #cancer, Agenus advances efficacy with their complementary CTL4 and PD1 combo—27% response vs monotherapy 14% with #keytruda. @agenus_bio @jbuell01 #oncology #esmo2020
-
Agenus
@Agenus_Bio
$AGEN bal +/- zal at #esmo show ORR of 19 & 27% in PD-L1 (+); PD-L1 (-) responders & favorable safety with treatment-related d/c 3.7 & 6.5% investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
$AGEN's presentation is one of the many affected by this delay
ESMO - Eur. Oncology
@myESMO
#esmo20: We are currently experiencing a technical delay in the uploading of presentations for some Mini Oral sessions. We are working hard to fix this issue as quickly as possible so please bear with us. Many apologies for the inconvenience. www.esmo.org/meetings/esmo-virtual-congress-2020?hit=some
-
Agenus
@Agenus_Bio
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Watch @jbuell01's full interview with @sciam here: www.scientificamerican.com/custom-media/cancer-covid-19-a… #immunotherapy #covid__19 #18minuteswith
-
Agenus
@Agenus_Bio
$AGEN's late-breaking ESMO abstract has been released and can be viewed here under Gynaecological cancers 2: cslide.ctimeetingtech.com/esmo2020/attendee/confcal_1/ses…. The countdown to $AGEN's ESMO presentation begins! #esmo2020 #oncology #immunotherapy
-
Agenus
@Agenus_Bio
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline investor.agenusbio.com/news-releases/news-release-details…
-
Agenus
@Agenus_Bio
TUNE IN to Scientific American's #18minuteswith Dr. Jennifer Buell on @sciam Facebook live at 4pm where
@jbuell01 will discuss the future of cancer treatments.
Scientific American
@sciam
Join our #18minuteswith live Q&A session with Dr. Jennifer Buell on 9/16 at 4 pm EDT and pose your questions as we discuss immunotherapy in the era of COVID19 [Sponsored by @Agenus_Bio] x.com/i/broadcasts/1YpKkNVdaPMxj
-
Agenus
@Agenus_Bio
$AGEN's late-breaking ESMO abstract will be published on the ESMO site at 6:05 pm EDT on Thursday, September 17th. The oral presentation will be pre-released in the ESMO Mini Oral Session - Gynaecological cancers 2 at 3:00 am EDT on Friday, September 18th. www.esmo.org/meetings/esmo-virtual-congress-2020/programme
-
Agenus
@Agenus_Bio
Paul Clark Joins Agenus Board of Directors investor.agenusbio.com/2020-08-31-Paul-Clark-Joins-Agenus…
-
Agenus
@Agenus_Bio
Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer investor.agenusbio.com/2020-08-26-Agenus-Announces-ESMO-O…
-
Agenus
@Agenus_Bio
A Vaccine is just a Formula without a Few Medical Essentials....
Including $AGEN QS-21 adjuvant
www.bloomberg.com/features/2020-covid-vaccine-manufacturi… -
Agenus
@Agenus_Bio
Agenus Provides R&D Update & Second Quarter Financial Report investor.agenusbio.com/2020-08-06-Agenus-Provides-R-D-Upd…
-
Agenus
@Agenus_Bio
Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference investor.agenusbio.com/2020-08-04-Agenus-to-Present-on-Ta…
-
Agenus
@Agenus_Bio
$AGEN R&D update & 2Q Earnings:
- Registration plans for bal +/- zali
- $AGEN/Betta partnership
- AGEN1181 +/- bal (anti-PD-1)
- iNKT cells for COVID-19 & cancer
- AGEN1223 & AGEN2373 update
- Myeloid cell targets (TIGIT(s)/novel) investor.agenusbio.com/2020-07-29-Agenus-R-D-update-Secon… -
Agenus
@Agenus_Bio
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals investor.agenusbio.com/press-releases?item=246
-
Agenus
@Agenus_Bio
AGENUS NEWSLETTER: The immune system is complex. $AGEN's portfolio is designed to empower the body’s immune system to do its job – to cure disease.
READ MORE: agenusbio.com/wp-content/uploads/2020/07/NL-200728-Immuno… -
Agenus
@Agenus_Bio
$AGEN files new shelf registration statement as current shelf nears expiry. www.sec.gov/Archives/edgar/data/1098972/00011931252019697…
-
Agenus
@Agenus_Bio
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit investor.agenusbio.com/2020-07-21-Agenus-To-Participate-i…
-
Agenus reposted
Jennifer Buell
@jbuell01
$AGEN optimal combos with allogeneic cell therapy (iNKT), checkpoint antibodies for cures in preclinical models resistant to anti-PD-1. @Agenus_Bio is well-positioned to deliver these combos from our proprietary pipeline. #aacr2020 #cancer agenusbio.com/publications/
Agenus
@Agenus_Bio
$AGEN Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020 investor.agenusbio.com/2020-06-22-Agenus-Cell-Therapy-and…
-
Agenus
@Agenus_Bio
At #aacr2020, $AGEN demonstrated potential for curative combinations with #celltherapy & #checkpoint antibodies in models refractory to anti-PD-1. @Agenus_Bio proprietary pipeline is positioned to deliver these combos! #immunotherapy #cancer
-
Agenus reposted
Dhan Chand
@dhanschand
At #aacr2020 we @Agenus_Bio demonstrate the curative combination potential of our pipeline in models that are refractory to first generation IO therapies.
$AGEN is best positioned to advance more effective combinations for cancer patients today.
Agenus
@Agenus_Bio
$AGEN Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020 investor.agenusbio.com/2020-06-22-Agenus-Cell-Therapy-and…
-
Agenus
@Agenus_Bio
$AGEN Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020 investor.agenusbio.com/2020-06-22-Agenus-Cell-Therapy-and…
-
Agenus
@Agenus_Bio
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China investor.agenusbio.com/2020-06-22-Agenus-and-Betta-Pharma…
-
Agenus reposted
MiNK Therapeutics
@MiNK_iNKT
@Agentus_CellTX CEO Walter Flamenbaum & CTO Marc Van Dijk reveal proprietary allogeneic iNKTs have potential to treat solid tumors with antibody combos (with $AGEN CPIs) affordably. iNKTs are advancing in #covid19 & #cancer @RaymondJames #healthcare conference
-
Agenus
@Agenus_Bio
Experts Drs. Marc Van Dijk & Walter Flamenbaum join cell therapy expert panel @RaymondJames Conference: #celltherapy: Promise of the Next Generation.
-
Agenus reposted
Agenus
@Agenus_Bio
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
NEWSLETTER: #asco20 highlights and $AGEN pipeline of Fc engineered TIGIT & CTLA-4 with our plans to unlock value for patients with #cancer agenusbio.com/wp-content/uploads/2020/06/NL-200602-ASCO-H…
-
Agenus
@Agenus_Bio
$AGEN stands for #equality.
-
Agenus
@Agenus_Bio
TUNE IN: Shoptalk Virtual Conference with @garo_armen Chairman and CEO at @Agenus_Bio, to discuss the future of retail based on progress in COVID-19 therapeutics and vaccines on June 11 1-1:45pm ET.
Shoptalk
@shoptalk
Register now at virtual.shoptalk.com/shoptalkvirtual/Introducing-Scenario…
Don't miss our next Shoptalk Virtual Conference on Thu, June 11 from 1-1:45 pm ET. Our interview with @garo_armen, Chairman and CEO at @Agenus_Bio, will explore the future of retail based on progress in COVID-19 therapeutics and vaccines. -
Agenus reposted
HemOnc Today
@HemOncToday
FDA clears IND application for natural killer T-cell therapy @Agenus_Bio @Agentus_CellTX to treat #covid19 - phase 1 trial to come bit.ly/2Ax2Rwscome api.whatsapp.com/send?phone=5565999038583&text=Ooi☺️
-
Agenus
@Agenus_Bio
FBR has informed callers to use 973-413-6102
Agenus
@Agenus_Bio
EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration
-
Agenus
@Agenus_Bio
EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration
-
Agenus
@Agenus_Bio
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT… #covid19 #immunology
-
Agenus reposted
Steven O'Day, MD
@ODayMD
Proud to be leading the charge with @Agenus_Bio and my oncology colleagues with a next generation CTLA-4 antibody.
Jennifer Buell
@jbuell01
ASCO Presentation of Agenus' AGEN1181 by Dr. Steven @ODayMD AGEN1881 is an Fc enhanced, multi-functional T cell engager which also binds CTLA-4. investor.agenusbio.com/2020-05-29-ASCO-Presentation-of-Ag… #asco2020
-
Agenus
@Agenus_Bio
ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day investor.agenusbio.com/2020-05-29-ASCO-Presentation-of-Ag… #asco2020
-
Agenus
@Agenus_Bio
$AGEN sends special thanks to our AGEN1181 PIs & staff for your excellent care & continued accrual during this difficult #covid19 pandemic: Dr. @ODayMD @JohnWayneCI; Dr El-Khouiery @USC; Dr. Gordon @HonorHealth; Dr. Bullock @BIDMChealth; Dr. Ramamurthy @UTHealthcareSA #asco2020
-
Agenus
@Agenus_Bio
Agenus NEWSLETTER: Paulo Moriera leads path-breakers: advancing 14 new discoveries to clinic with FIM 2.5x faster than industry & readiness for 2 planned BLA filings in 2020. READ MORE: agenusbio.com/wp-content/uploads/2020/05/NL-200519-Clinic…
-
Agenus
@Agenus_Bio
Join @Agenus_Bio at #rbchealthcare2020 at 1:20PM when our President & COO Dr. Jennifer Buell (@jbuell01) will meet with Biotech Analyst Dr. Gregory Renza on Beyond 2020: The Changing Face of Healthcare.
-
Agenus
@Agenus_Bio
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy - May 13, 2020 investor.agenusbio.com/2020-05-13-FDA-Clears-AgenTus-IND-…
-
Agenus
@Agenus_Bio
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
Agenus First Quarter Update: AGEN1181+/- bali (PD-1) benefits 70% in P1; Bali/Zali combo shows 26% ORR (n=55); Two INDs filed for allogeneic iNKTs in cancer & COVID-19; Two TIGITs advancing to IND; structured to reduce burn ~$50 investor.agenusbio.com/2020-05-07-Agenus-First-Quarter-Re…
-
Agenus reposted
Jennifer Buell
@jbuell01
$AGEN Fc enhanced #tigit outperforms tested competitors (#aacr2019) & novel TIGIT bispecific shows potent tumor killing in difficult to treat CRC model. Both headed to clinic 1H21. #immunotherapy agenusbio.com/wp-content/uploads/2020/05/NL-200504-TIGIT-…
-
Agenus
@Agenus_Bio
NEWSLETTER: Two $AGEN TIGIT antibodies on track to enter clinic in 1H 2021. READ MORE: agenusbio.com/wp-content/uploads/2020/05/NL-200504-TIGIT-…
-
Agenus
@Agenus_Bio
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
.@armish, together we are a formidable force.
B. Arman Aksoy
@armish
BTW, did I mention that I took a new job @Agenus_Bio?
With regards,
-- Recovering academic -
Agenus
@Agenus_Bio
$AGEN NEXT NEWSLETTER (May 5) highlights @Agenusbio TIGIT(s). Why the excitement? What are optimal combos? Learn more about our novel TIGIT programs with superior pre-clinical tumor killing as monotherapy in PD-1 combo. #tigit #immunotherapy
agenusbio.com/wp-content/uploads/2019/04/Agenus_AACR_TIGI… -
Agenus
@Agenus_Bio
$AGEN IN ACTION: Scientists protect front-line healthcare workers #edith Nourse Rogers Memorial Veterans Hospital. 3D printed masks can be sanitized - learn more! agenusbio.com/covid-masks/ @MassDVS @DeptVetAffairs www0.bostonglobe.com/news/nation/2020/04/23/medical-facil…
-
Agenus
@Agenus_Bio
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
-
Agenus reposted
Jennifer Buell
@jbuell01
.@KanandaBarrons - $AGEN embraced #covid19 call to help with efforts designed to:
1. Protect #healthcareworkers w mucosal immunity (QS-21)
2. Damper dangerous COVID-19 inflammation with allogeneic iNKTs
agenusbio.com/wp-content/uploads/2020/04/NL-200407-COVID1… -
Agenus
@Agenus_Bio
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors to address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors to address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors to address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors to address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors. We will address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
NEWSLETTER: Today's @Agenus_Bio News highlights our innovation and dives into how we design new candidates at the molecular level. agenusbio.com/wp-content/uploads/2020/03/NL-200324-Discov…
-
Agenus
@Agenus_Bio
@Agenus_Bio management is hosting daily calls with investors to address your questions in a 1-on-1 format. To register, please call 781-674-4408.
-
Agenus
@Agenus_Bio
@Agenus_Bio management will host a Q&A with investors today at 4PM. We will address your questions in a 1-on-1 format to clarify our ATM, balstilimab/zalifrelimab BLAs, Fast Track Designation, and R&D progress. To schedule please call 781-674-4408.
-
Agenus
@Agenus_Bio
$AGEN CEO @garo_armen will host daily calls to answer any of your questions and provide clarification on our ATM. To schedule please call 781-674-4408.
-
Agenus
@Agenus_Bio
$AGEN triggered $15M milestone through sales of @GSK #shingrix plus ~$65M under our ATM to strengthen our balance sheet. While ATM remains in place, we have no plans to transact at current levels.
-
Agenus
@Agenus_Bio
Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Mar 12, 2020 investor.agenusbio.com/2020-03-12-Agenus-Reports-Fourth-Q…
-
Agenus
@Agenus_Bio
$AGEN Dr. Simarjot Pabla leverages big data & machine learning in @Agenus_Bio VISION platform to understand T cell dysfunction and predict cancer patient response to #immunotherapy. Poster presentation today at MIT's AI Powered Drug Discovery & Manufacturing @MIT_AIDMConf
-
Agenus
@Agenus_Bio
Join @Agenus_Bio at #io360 today at 10:20AM when Dr. Jennifer Buell @jbuell01 will be among thought leaders in the space discussing “What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?" Info: theconferenceforum.org/conferences/immuno-oncology-360/ov… #io360nyc #immunotherapy
-
Agenus
@Agenus_Bio
In today's Newsletter: $AGEN next-gen #ctla4 #agen1181 achieves CR in an aggressive tumor after #pd1 failure. #discovery: patient had genetic factor normally associated with poor/no response to CTLA-4. Early signal to broaden potential population of responders to 1st-gen CTLA-4.
-
Agenus
@Agenus_Bio
Dr. John Castle @joccastle of $AGEN will be a panelist at today's 2nd Emerging Frontiers in Oncology Summit, benefiting @climbtofight cancer at @massbio. @Agenus_Bio is excited to be at the forefront of innovation in I-O! #oncology
-
Agenus
@Agenus_Bio
NEWSLETTER: $AGEN Investor Day recap: balstilimab +zalifrelimab combo interim data shows near doubling of response rates in 2L cervical cancer vs standard of care with acceptable safety. Link: agenusbio.com/wp-content/uploads/2020/02/NL-200225-Invest… #immunooncology #drugdiscovery #biotech
-
Agenus reposted
John Nosta
@JohnNosta
30 years of lack luster therapy in #cervicalcancer may be changing. (Interesting data on stable disease and CR.) @Agenus_Bio #oncology #biotech #cancer #immunotherapy @jbuell01 #digitalhealth
-
Agenus
@Agenus_Bio
$AGEN Investor Day starts today at 9AM ET. @Agenus_Bio will present data from 3 clinical programs including balstilimab (PD-1) and zalifrelimab (CTLA-4) interim analyses and AGEN1181, our next-gen CTLA-4. Webcast info: investor.agenusbio.com/presentation-webcasts?item=66
-
Agenus
@Agenus_Bio
@Agenus_Bio Investor Day is next Thursday 2/20 from 9-11AM ET. $AGEN will present clinical data for balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), & AGEN1181 (next-gen anti-CTLA-4). Webcast details will be posted at investor.agenusbio.com/presentation-webcasts
-
Agenus
@Agenus_Bio
NEWSLETTER: $AGEN features @kateeweiss’s battle against #cervicalcancer. @Agenus_Bio is committed to delivering new ways to fight cancer & empower patients. $AGEN joined @GlamFoods to educate, nourish, & inspire cancer-fighting heroes. #worldcancerday2020 agenusbio.com/newsletters/
-
Agenus
@Agenus_Bio
This week @MassGovernor Baker proclaimed January “Cervical Cancer Awareness Month.” We at $AGEN are recognizing Kate Weissman who is championing this cause. @Agenus_Bio is advancing NextGen I-O antibodies (AGEN1181) to fight cervical cancer. #cervicalcancerawarenessmonth
-
Agenus
@Agenus_Bio
LATEST NEWSLETTER: #cervicalcancerawarenessmonth @Agenus_Bio is committed to conquering advanced #cervicalcancer with new I-O therapies and combinations. agenusbio.com/wp-content/uploads/2020/01/NL-200121-Iss2-C…
-
Agenus
@Agenus_Bio
@Agenus_Bio is at #jpm20. We’re pleased to announce Dr. Regina Grebla has joined from Evercore and is heading IR and Communications. Please connect with us to learn more about $AGEN’s exciting efforts in 2020 at: investorrelations@agenusbio.com
#jpm2020 #bioweeksf -
Agenus
@Agenus_Bio
.@GileadSciences discloses new oncology targets with first-in-class bispecific discovered by and exclusively licensed from @Agenus_Bio. More than 14 discoveries from $AGEN are in the clinic #innovation #cancer
agenusbio.com/wp-content/uploads/2019/10/NEW-PIPELINE-SLI… -
Agenus
@Agenus_Bio
$AGEN appoints Dr. Jennifer Buell to President & COO of Agenus. "Jen’s tenure @Agenus_Bio, exceptional leadership & cultural attributes, and deep understanding of our science & operations makes her the top candidate for this new position" said @garo_armen investor.agenusbio.com/2020-01-09-Agenus-Announces-the-Ap…
-
Agenus
@Agenus_Bio
$AGEN at #jpm20. On track to file 2 BLAs during 2020 and novel IO combinations in the clinic. agenusbio.com/wp-content/uploads/2020/01/NL-200107-2019-y… for more, contact us at: investorrelations@agenusbio.com
See you in San Francisco!
#jpm2020 #bioweeksf -
Agenus
@Agenus_Bio
$AGEN Commences Phase 1 trial with AGEN1223 - a novel bispecific designed to deplete Tregs from the tumor microenvironment. First patient dosed DEC19, study ongoing with combinations planned. investor.agenusbio.com/2020-01-08-Agenus-Commences-Phase-… #immunology #innovation
-
Agenus
@Agenus_Bio
NEWSLETTER 2020: Reports an exciting 2019 and reveals a look into what's to come in 2020:
(2) planned BLA filings in 2L CC
(2) Novel discoveries to IND
(6) clinical programs with data, including AGEN1181 + balstilimab agenusbio.com/wp-content/uploads/2020/01/NL-200107-2019-y… #immunoncology #innovation -
Agenus reposted
Jennifer Buell
@jbuell01
Tremendously proud of our stellar and accomplished team. I look forward to extraordinary outcomes in 2020!
-
Agenus
@Agenus_Bio
$AGEN achieved all we set out to deliver in 2019 - looking forward to another breakthrough year in 2020! Happy New Year!
Agenus
@Agenus_Bio
$AGEN #2019 PROGRESS
*Received $184M in partnership transactions & grants;
*13 $AGEN discoveries in clinic;
*7 $AGEN owned discoveries in clinic alone or in combos (ie AGEN1181+ balstilimab);
- Hit accrual targets for BOTH BLA path trials
- GSK SHINGRIX w QS-21 >$1Bn sales -
Agenus
@Agenus_Bio
$AGEN delivered >$500M in partnership transactions & milestones in <4 yrs; no public (market) offering in that timeframe and no plans for one.
-
Agenus
@Agenus_Bio
$AGEN #2019 PROGRESS
*Received $184M in partnership transactions & grants;
*13 $AGEN discoveries in clinic;
*7 $AGEN owned discoveries in clinic alone or in combos (ie AGEN1181+ balstilimab);
- Hit accrual targets for BOTH BLA path trials
- GSK SHINGRIX w QS-21 >$1Bn sales -
Agenus
@Agenus_Bio
#2019 Progress: $AGEN hits target accrual for BOTH BLA path trials (balstilimab +/- zalfrelimab) for patients with 2L cervical cancer. On track for planned filings in 2020. #immunotherapy #2019goals achieved.
-
Agenus
@Agenus_Bio
$AGEN NEWS: 1st patient dosed with Agenus next-gen anti-#ctla4 (AGEN1181) +#pd1 (balstilimab) combo. AGEN1181 is a novel ‘Fc engineered’ #antibody designed for enhanced #tumor killing ability. investor.agenusbio.com/2019-12-19-Agenus-Commences-Combin… #cancer #immunotherapy investor.agenusbio.com/2019-12-19-Agenus-Commences-Combin…
-
Agenus
@Agenus_Bio
LATEST NEWSLETTER: $AGEN Head of Regulatory & PV Sunil Gupta discusses innovation in oncology and the FDA’s accelerated approval mechanisms as we progress towards our planned BLA filings in 2020. agenusbio.com/wp-content/uploads/2019/12/AGENUS_News_Vol2…
-
Agenus
@Agenus_Bio
DISCOVERIES! Exciting work in our collaboration @Mark_Cobbold MGHCancerCenter @UVA enabling ways to understand adaptive immunity through immunopeptidomics doi.org/10.1038/s41598… www.nature.com/articles/s41598-019-54700-2
-
Agenus
@Agenus_Bio
Dr. @joccastle speaks about $AGEN Novel Agenus Platform Designed to Find Tumor-Recognizing, Tumor-Specific T Cell Receptors #genomicslive #digitaltransformation #neoantigens
John Castle
@joccastle
Honored to give keynote at inaugural #genomicslive @biodataworld Congress, focusing on machine learning and #bigdata applied to @Agenus_Bio #immunotherapy and #neoantigens. #defeatcancer
-
Agenus
@Agenus_Bio
NEWSLETTER: $AGEN R&D Day with experts: Drs. O’Day, Monk, Hidalgo. Highlights of 1. Why blocking CTLA-4 & PD-1 is critically important for durable responses; 2. $AGEN advantage in cervical cancer; 3. Importance of combos for optimal clinical benefit agenusbio.com/wp-content/uploads/2019/12/NL-191203-KOL-pr…
-
Agenus
@Agenus_Bio
Dr. @dhanschand reports on AGEN1181, our next generation CTLA-4 with enhanced features shows preclinical superiority to first generation CTLA-4 as mono and in combination with PD-1. WATCH: vimeo.com/user56415055/review/374268068/597162c48b
-
Agenus
@Agenus_Bio
$AGEN RD DAY: Dr. Steven O’Day reveals the revolution in IO. The outstanding potential of CTLA-4 & PD-1 - combo delivers cures in 52% of patients w metastatic melanoma, once fatal. “All tumors are immune sensitive” - imagine the possibilities #agenus vimeo.com/user56415055/review/374268228/e8a9acf5a1
-
Agenus
@Agenus_Bio
ASK THE EXPERT: @joccastle at the #neoagsummit tells you how to find the best Neoantigens and the best way to educate the immune system to attack #tcrs #cars #vaccines
-
Agenus
@Agenus_Bio
.@JohnNosta yes! Combinations with these therapies for optimal clinical benefit are also important. @Agenus_Bio developed a pipeline to do so efficiently! Learn more at agenusbio.com
John Nosta
@JohnNosta
It’s clear that a big move in #oncology is the shift from autologous to allogenic therapies. It’s driving the “democratization” of critical #immunotherapy. #cancer @Agenus_Bio @jbuell01 #digitalhealth
-
Agenus
@Agenus_Bio
LIVE NOW: Agenus RD DAY NY with World Experts Drs. O’Day and Hidalgo. #immunotherapy #innovators
stream.rampard.com/20191115/reg.jsp -
Agenus
@Agenus_Bio
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers investor.agenusbio.com/2019-11-11-Agenus-receives-10M-fro…
-
Agenus
@Agenus_Bio
.@Agenus_Bio is proud to partner with @MassBioEd to open the world of opportunity of #biotech to our next generation of talent. Congratulations $AGEN #volunteer team for a fantastic event!
-
Agenus
@Agenus_Bio
Agenus Provides Corporate Update with Third Quarter 2019 Financial Results - Nov 4, 2019 investor.agenusbio.com/2019-11-04-Agenus-Provides-Corpora…
-
Agenus
@Agenus_Bio
$AGEN COO Dr. Jennifer Buell is featured in @PharmExec. Read insights into how @agenusbio pipeline, including nextgen CTLA-4 and bispecifics is designed to bring high impact products to patients @jbuell01 www.pharmexec.com/next-generation-focus-immuno-oncology #biotech #cancer
-
Agenus
@Agenus_Bio
$AGEN Innovation: GSK's Shingrix vaccine containing @Agenus_Bio #qs-21 crosses $1Bn in sales. www.reuters.com/article/us-gsk-results/gsk-raises-profit-… #vaccinessavelives
-
Agenus
@Agenus_Bio
$AGEN satisfies contractual obligation & files registration statement to register shares previously sold to GILD (JAN2019). No new shares sold.
-
Agenus
@Agenus_Bio
$AGEN Dr. Paisley Myers is featured in @touchONCOLOGY with insights into our proprietary PTT neoantigen platform & approach to novel cancer therapies with antibodies, vaccines, cell therapies #featured #oncology touchoncology.com/wp-content/uploads/sites/2/2019/10/Myer…
-
Agenus
@Agenus_Bio
LATEST NEWSLETTER: #esmo19 CTLA-4 & PD-1 inhibitors demonstrate remarkable efficacy and durability; $AGEN CTLA-4 & PD-1 advance for planned BLA filing 2020 #immunotherapy agenusbio.com/wp-content/uploads/2019/10/AGENUS_News_Vol2…
-
Agenus
@Agenus_Bio
LATEST NEWSLETTER: $AGEN UK is our centre of excellence for drug discovery. New drug candidates, like AGEN1181, are designed for superior therapeutic benefit under accelerated timelines not typically seen in our industry #mondaymotivation #innovation agenusbio.com/wp-content/uploads/2019/09/AGENUS_News_Vol2…
-
Agenus reposted
Jennifer Buell
@jbuell01
More data to shows patient benefit with CTLA-4 + PD-1 combination. >50% surviving advanced melanoma with this combo. $AGEN combo advancing for patients w cervical. www.bbc.com/news/health-49853878 #esmo19
-
Agenus
@Agenus_Bio
Did you know our QS-21 Stimulon is a key component in @GSK’s shingles #vaccine, Shingrix? In a recent interview with @BioPharmIntl, @jbuell01 shares insight to our QS-21 Stimulon and the role it plays in vaccine development www.biopharminternational.com/view/turning-plant-cell-cul…
-
Agenus
@Agenus_Bio
We’re featured in the SEP issue of @bpdealmakers! As @jbuell01 said, “We are integrating advanced technologies, including AI platforms, to fuel a new wave of innovative therapies that address resistance pathways that can significantly improve treatment of patients with cancer.”
Biopharma Dealmakers
@bpdealmakers
Our #september issue is here! featuring companies and editorials covering #antibodies, #biopharma deal term sheet negotiation and #oncology #immunotherapy
It also introduces our first BioPharma Thought Leader piece.
go.nature.com/2kdLJnI -
Agenus reposted
Kananda Barrons
@KanandaBarrons
$AGEN "Curing cancers with innovation and speed". agenusbio.com/wp-content/uploads/2019/09/Nature-Feature-C…
@Agenus_Bio is designed to reach tailored cancer cure quickly at affordable prices: Without any doubt, that's the key to maintain the perfect balance between #innovation & rules governing the health sector. -
Agenus
@Agenus_Bio
$AGEN highlighted in Nature Biopharma Dealmakers edition. Curing cancers with innovation & speed - developing next-generation immunotherapeutics
designed to expand benefit for patients with cancer. agenusbio.com/wp-content/uploads/2019/09/Nature-Feature-C… -
Agenus
@Agenus_Bio
Announcement: $AGEN to Manufacture Clinical Supply of GS-1423 for Gilead #immunotherapy #manufacturing investor.agenusbio.com/2019-08-21-Agenus-to-Manufacture-C…
-
Agenus reposted
John Nosta
@JohnNosta
KEY STEPS FORWARD! Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update investor.agenusbio.com/2019-08-08-Agenus-Reports-Second-Q… @Agenus_Bio @jbuell01 #biotech #cancer #oncology #digitalhealth
-
Agenus
@Agenus_Bio
$AGEN advances another discovery, now clear to clinic; CD137 agonist, AGEN2373, which has been specifically designed to overcome
the shortcomings of earlier generation CD137 agonists. agenusbio.com/wp-content/uploads/2019/08/AGENUS_News_Vol2…
#cd137 #immunotherapy #cancer -
Agenus
@Agenus_Bio
Agenus Reports Second Quarter 2019 Financial Results & Corporate Update investor.agenusbio.com/2019-08-08-Agenus-Reports-Second-Q…
- CTLA-4 & PD-1 trials on track; data expected 2H2019; Next gen CTLA-4 advances; $15M in cash milestones triggered cmpds advance; GSK's Shingrix sales projected $1.3Bn 2019 -
Agenus
@Agenus_Bio
LATEST NEWSLETTER highlights Don Vidic, our Head of Commercial & expert in distribution strategy. With BLA filings on track for 2020, Don will defy encumbered norms to drive access to patients the $AGEN way - with innovation, focus, & speed. Read more agenusbio.com/wp-content/uploads/2019/07/AGENUS_News_Vol2…
-
Agenus
@Agenus_Bio
Welcome Don Vidic as Head of Commercial. Don is an innovator & expert in market access & distribution. He joins to actualize our commitment to disruptive commercial models designed to provide access to all patients who need our products. investor.agenusbio.com/2019-07-18-Agenus-Appoints-Don-Vid…
-
Agenus reposted
Agenus
@Agenus_Bio
The PM of Armenia is setting a new standard for leadership and integrity. COAF is working to empower the village children.
Children of Armenia Fund
@coafkids
This month’s #smartconnects with @NikolPashinyan was yet another #win in the books. Check out some of the best #shots taken during the #event.
-
Agenus
@Agenus_Bio
The PM of Armenia is setting a new standard for leadership and integrity. COAF is working to empower the village children.
Children of Armenia Fund
@coafkids
This month’s #smartconnects with @NikolPashinyan was yet another #win in the books. Check out some of the best #shots taken during the #event.
-
Agenus
@Agenus_Bio
Our newsletter sums our differentiation $AGEN. At an inflection '...to me this defines Agenus, not a molecule [or] platform, but convergence allowing us to look at & treat cancer in a new & extraordinary way’ @johnnosta. #immunotherapy #cancerresearch agenusbio.com/wp-content/uploads/2019/07/AGENUS_News_Vol2…
-
Agenus
@Agenus_Bio
$AGEN next newsletter issues on Monday (08JUL) with highlights from our annual shareholder meeting & a special feature from visionary @JohnNosta #happyfourthofjuly agenusbio.com/newsletters/
-
Agenus reposted
John Nosta
@JohnNosta
-
Agenus
@Agenus_Bio
We are gearing up for our Annual General Meeting, in a few hours from now. Thrilled to welcome @JohnNosta to facilitate today's meeting!
Time: 5:00 p.m. ET
Domestic Dial-in: 1-844-492-3727; International Dial-in: 1-412-317-5118; Webcast: www.webcaster4.com/Webcast/Page/1556/30853
@Agentus_CellTX
Agenus
@Agenus_Bio
We are thrilled to welcome top health technology theorist & industry leader @JohnNosta to facilitate our Annual General Meeting tomorrow. We will provide exciting updates on our progress! See press release for meeting details: investor.agenusbio.com/2019-06-13-Agenus-to-Host-Annual-M…
#oncology #cancer #innovation -
Agenus
@Agenus_Bio
We are thrilled to welcome top health technology theorist & industry leader @JohnNosta to facilitate our Annual General Meeting tomorrow. We will provide exciting updates on our progress! See press release for meeting details: investor.agenusbio.com/2019-06-13-Agenus-to-Host-Annual-M…
#oncology #cancer #innovation -
Agenus
@Agenus_Bio
LATEST NEWSLETTER focuses on our "off-the-shelf" PSV-AML #vaccine candidate, which is moving towards the clinic! PSV-AML is based on our Proprietary Phosphopeptide #tumor Targets (PTTs). Learn about PTTs and this novel vaccine candidate: www.agenusbio.com/wp-content/uploads/2019/06/PSV-AML_Fina…
#cancer #oncology -
Agenus
@Agenus_Bio
Today we #wearwhite with @CancerResearch to show our commitment to fight #cancer with #immunotherapy, powered by a remarkable combination of science+people. Some of our @Agenus_Bio Team Members!
#oncology #curecancer -
Agenus
@Agenus_Bio
June is #cancer #immunotherapy Month. On June 14th, with CRI @CancerResearch, we will #wearwhite for a Future #immune2cancer. Come join the cause! www.cancerresearch.org/join-the-cause/cancer-immunotherap…
-
Agenus
@Agenus_Bio
$AGEN featured in @biospace highlights from #bio2019 @BIOConvention ! @jbuell01
BioSpace
@biospace
Here’s a look at just a few of the highlights from BIO2019. www.biospace.com/bio-roundup-agenus-fda-merck-s-frazier-a…
-
Agenus
@Agenus_Bio
Our COO @jbuell01 shares extensive insights on next level immuno-oncology and company progress in today's @biospace #bio2019 roundup article: www.biospace.com/article/bio-roundup-agenus-fda-merck-s-f…
-
Agenus
@Agenus_Bio
At #bio2019 our COO @jbuell01 participated in the “Immuno-Oncology: Taking Immunotherapies to the Next Level” panel
#innovation #oncology -
Agenus
@Agenus_Bio
We are at #bio2019! COO @jbuell01 speaking at the “Immuno-Oncology: Taking Immunotherapies to the Next Level” panel #innovation #oncology
Biotechnology Innovation Organization
@IAmBiotech
Over the past 3 years we've had novel target discovery to clinic in under 15 months, 11 programs moving forward, says @jbuell01 COO of @Agenus_Bio #bio2019
-
Agenus
@Agenus_Bio
As Genomics take a center stage @ #asco2019 and #cancer research – our latest Newsletter focuses on our unique 'Computational I-O' platform, that leverage our #functionalgenomics capabilities, to gain new insights into #cancerbiology. READ: www.agenusbio.com/wp-content/uploads/2019/06/Is9_Final.pdf
#innovation -
Agenus
@Agenus_Bio
$AGEN kicks off #asco19 with an outstanding KOL event & notably a coveted #trentselfie w CEO @garo_armen & COO @jbuell01; @Agenus_Bio is proud to work with practice changing clinician scientists @JTrentMDPhD @breelynwilky
-
Agenus
@Agenus_Bio
$AGEN pivotal trial in #cervicalcancer: majority of patients accrued; Data updates will follow. #asco2019 #oncology #immunotherapy
-
Agenus
@Agenus_Bio
Agenus hosting KOL meetings at #asco2019 to feature its best-in-class #clinical pipeline. #immunotherapy #oncology #ascodailynews
-
Agenus reposted
Agenus
@Agenus_Bio
$AGEN interim analysis from one of its pivotal trials expected by August in race to #cervicalcancer BLA filing
#asco2019 #oncology #immunotherapy -
Agenus
@Agenus_Bio
$AGEN interim analysis from one of its pivotal trials expected by August in race to #cervicalcancer BLA filing
#asco2019 #oncology #immunotherapy -
Agenus
@Agenus_Bio
Congratulations @GSK for the approval of Shingrix #vaccine in China. Our proprietary QS-21 Stimulon® is a key component in #shingrix, which GSK projected to surpass £1 B in sales for 2019, its 2nd full year on the market.
www.gsk.com/en-gb/media/press-releases/gsk-announces-appr…
#adjuvants -
Agenus
@Agenus_Bio
$AGEN scientists presenting at #cimt2019 on our proprietary phosphorylated antigen targets (off the shelf) for use in generating unique #tcrs (novel #act approaches)
John Castle
@joccastle
#cimt2019 kicks off tomorrow. @Agenus_Bio @Agentus_CellTX phosphopeptide TCR platform selected for talk Thursday. @eleni_chantzoura @xavier_michelet @jh_bergmann #cancerimmunotherapy
-
Agenus
@Agenus_Bio
What are our key highlights from Q1 2019? Learn More from our Q1 Earnings Call Transcript here: investor.agenusbio.com/presentation-webcasts?item=60
-Strong balance sheet
-New #clinicaltrial
-Progressing enrollment in lead trials; on track for BLA in 2020
-New INDs (CD137 & PhosphoSynVax #vaccine) on track
Agenus
@Agenus_Bio
Key highlights from Q1 2019:
-Strong balance sheet following $GILD transaction
-New #clinicaltrial w/ AGEN1181 started and accruing
-Enrollment in lead trials progressing; on track for BLA in 2020
-New INDs (CD137 & PhosphoSynVax #vaccine) on track
investor.agenusbio.com/2019-05-09-Agenus-Reports-First-Qu… -
Agenus
@Agenus_Bio
LATEST NEWSLETTER: Learn what makes our proprietary QS-21 Stimulon a potent #adjuvant and about our efforts to #innovate QS-21 production, supported by a grant of ~1M, recently awarded to $AGEN by the Bill & Melinda Gates Foundation @gatesfoundation. Read www.agenusbio.com/wp-content/uploads/2019/05/QS-21-Newsle…
-
Agenus
@Agenus_Bio
Key highlights from Q1 2019:
-Strong balance sheet following $GILD transaction
-New #clinicaltrial w/ AGEN1181 started and accruing
-Enrollment in lead trials progressing; on track for BLA in 2020
-New INDs (CD137 & PhosphoSynVax #vaccine) on track
investor.agenusbio.com/2019-05-09-Agenus-Reports-First-Qu… -
Agenus
@Agenus_Bio
2019 started with some exciting #news for us. See our press release to learn about our Q1 2019 Financial Results and other recent updates. investor.agenusbio.com/2019-05-09-Agenus-Reports-First-Qu…
#oncology #immunotherapy #innovation -
Agenus
@Agenus_Bio
Our Head of Global #biologics Manufacturing, Al Dadson, joins other industry leaders to discuss bioprocess productivity. Learn how our integrated capabilities from cell-line development to GMP manufacturing are enabling us to deliver #innovation with speed www.pharmtech.com/view/search-bioprocess-productivity-imp…
-
Agenus
@Agenus_Bio
Our proprietary QS-21 Stimulon® is a key component in @GSK’s Shingrix vaccine, which GSK projected to surpass £1 B in sales for 2019, its 2nd full year on the market. GSK has pledged an additional $100M towards future production. #vaccines #innovation
seekingalpha.com/article/4258612-glaxosmithkline-plc-gsk-… -
Agenus reposted
John Nosta
@JohnNosta
Mapping immune cells point to new opportunities in immunotherapy hms.harvard.edu/news/alternative-landscape @jbuell01 @Agenus_Bio #cancer #digitalhealth
-
Agenus reposted
Agenus
@Agenus_Bio
We filed definitive proxy statement to increase shares, consistent with historical practice.
@Agenus_Bio has NO CURRENT PLANS for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533… -
Agenus reposted
Jennifer Buell
@jbuell01
$AGEN immune-boosting QS-21 is in worlds’s most effective shingles vaccine (Shingrix >90%), worlds first malaria vaccine (Mosquirix), recipient of @gatesfoundation grant, & advancing in neoantigen #cancer vaccines. #vaccinessavelives #healthforall
Agenus
@Agenus_Bio
Our QS-21 Stimulon is changing the #vaccine landscape. Shingrix performed so well in its launch year that @GSK has pledged an additional $100m in production @FiercePharma @EricSFierce
www.fiercepharma.com/vaccines/gsk-commits-100m-for-expand… -
Agenus
@Agenus_Bio
Our QS-21 Stimulon is changing the #vaccine landscape. Shingrix performed so well in its launch year that @GSK has pledged an additional $100m in production @FiercePharma @EricSFierce
www.fiercepharma.com/vaccines/gsk-commits-100m-for-expand… -
Agenus
@Agenus_Bio
We filed definitive proxy statement to increase shares, consistent with historical practice.
@Agenus_Bio has NO CURRENT PLANS for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533… -
Agenus
@Agenus_Bio
Today is #worldmalariaday. We are proud to contribute to this massive @WHO effort against #malaria in Africa. The World's FIRST #malaria #vaccine contains our QS-21 adjuvant!
www.vox.com/future-perfect/2019/4/24/18514577/malaria-vac… -
Agenus
@Agenus_Bio
Our scientist @dhanschand presented on our #antibody engineering capabilities, and how we are employing an $AGEN discovered, novel Fc-dependent mechanism intended to enhance #cancer fighting ability of anti-#ctla4 - @NeoSynthEvents 4th Annual Precision: #breastcancer World Summit
Agenus
@Agenus_Bio
Our scientist @dhanschand presents on our #antibody engineering capabilities and how we employed an $AGEN discovered, novel Fc-dependent mechanism to enhance #cancer fighting ability of anti-#ctla4 - @NeoSynthEvents 4th Annual Precision: #breastcancer World Summit!
#immunotherapy -
Agenus
@Agenus_Bio
Our scientist @dhanschand presents on our #antibody engineering capabilities and how we employed an $AGEN discovered, novel Fc-dependent mechanism to enhance #cancer fighting ability of anti-#ctla4 - @NeoSynthEvents 4th Annual Precision: #breastcancer World Summit!
#immunotherapy -
Agenus
@Agenus_Bio
We present @ The European Neo-Ag Summit, on how how we discovered novel neoantigens called PTTs & are developing the first fully-human PTT-specific T-cell receptor, targeting MLL. @Agentus_CellTX
For details see: neoantigen-europe.com.
#dyk What PTTs are? -
Agenus
@Agenus_Bio
NEWS!! @BBCWorld
The World's FIRST #malaria #vaccine with our QS-21 is now being tested in children in a large #clinicaltrial. We are thrilled by this news and are proud to contribute to this effort to fight a global health issue.
www.bbc.com/news/world-africa-48012266 -
Agenus
@Agenus_Bio
Our Latest Newsletter focuses on potential first-in-class multispecific #antibodies! Check out the full issue for more: agenusbio.com/wp-content/uploads/2019/04/BiSFInal.pdf
#cancer #immunotherapy #innovation @GileadSciences -
Agenus
@Agenus_Bio
Agenus scientists Drs. John Castle @joccastle and Thomas Horn are featured in @BioCentury to discuss the ALPS program and the importance of #ai in cancer immunotherapy. #ai #bigdata #biotechnews #io #immunotherapy #oncologyresearch
www.biocentury.com/article/301868/how-agenus-machine-lear… -
Agenus
@Agenus_Bio
Our partner @GSK R&D Chief Hal Barron explains how #functionalgenomics, may revolutionize drug development and define the right patient population for #treatment. We are using this approach to gain insights into #cancers, help predict responses & more! amp.timeinc.net/fortune/2019/04/09/functional-genomics-fa…
-
Agenus reposted
Agenus
@Agenus_Bio
$AGEN filed preliminary proxy statement to increase shares, consistent with historical practice.
@Agenus_Bio has no current plans for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533…
Agenus
@Agenus_Bio
$AGEN file preliminary proxy statement for annual shareholders meeting. @Agenus_Bio has no current plans for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533… -
Agenus
@Agenus_Bio
Our fight against #cancers is relentless! @LifeSciLeader1 defined $AGEN as the "One-Stop Shop" in #immunooncology with "candidates in almost every class of #immunotherapy". Read this incredible story on our CEO & our "audacious" approach in #oncology: www.lifescienceleader.com/doc/garo-armen-and-audacity-at-…
Agenus
@Agenus_Bio
In the LAST 30 Days:
-FDA accepted AGEN1423 IND; $7.5M cash milestone triggered from @GileadSciences
-1st patient dosed w/ our next-gen anti-#ctla4
-2 industry leaders joined our team
-Presented @ #aacr2019 #pegs19
Our fight against #cancers is relentless and 'audacious'! Read:
Agenus
@Agenus_Bio
The incredible story of CEO @garo_armen & our "audacious" approach in #oncology featured in @LifeSciLeader1! @WayneKoberstein defines $AGEN as "One-Stop Shop" in #immunooncology with "candidates in almost every class of #cancer #immunotherapy"
www.lifescienceleader.com/doc/garo-armen-and-audacity-at-…
#aacr2019 -
Agenus
@Agenus_Bio
$AGEN filed preliminary proxy statement to increase shares, consistent with historical practice.
@Agenus_Bio has no current plans for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533…
Agenus
@Agenus_Bio
$AGEN file preliminary proxy statement for annual shareholders meeting. @Agenus_Bio has no current plans for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533… -
Agenus
@Agenus_Bio
$AGEN file preliminary proxy statement for annual shareholders meeting. @Agenus_Bio has no current plans for marketed offering.
app.quotemedia.com/data/downloadFiling?webmasterId=101533… -
Agenus
@Agenus_Bio
AGEN1181 now in phase 1 #clinicaltrial, is a novel ‘Fc engineered’ #antibody, designed for enhanced #tumor killing ability. Learn more: www.agenusbio.com/wp-content/uploads/2019/03/News_V2i42.pdf
Our #antibody engineering capabilities help us design such 'next-gen' molecules. Learn more: www.agenusbio.com/wp-content/uploads/2019/04/Issue6-FINAL… -
Agenus
@Agenus_Bio
In the LAST 30 Days:
-FDA accepted AGEN1423 IND; $7.5M cash milestone triggered from @GileadSciences
-1st patient dosed w/ our next-gen anti-#ctla4
-2 industry leaders joined our team
-Presented @ #aacr2019 #pegs19
Our fight against #cancers is relentless and 'audacious'! Read:
Agenus
@Agenus_Bio
The incredible story of CEO @garo_armen & our "audacious" approach in #oncology featured in @LifeSciLeader1! @WayneKoberstein defines $AGEN as "One-Stop Shop" in #immunooncology with "candidates in almost every class of #cancer #immunotherapy"
www.lifescienceleader.com/doc/garo-armen-and-audacity-at-…
#aacr2019 -
Agenus
@Agenus_Bio
We are excited to present @PEGSboston today, on our #antibody engineering capabilities, and how we employed an $AGEN discovered, novel Fc-dependent mechanism to enhance #cancer fighting ability of anti-#ctla4. Learn more: www.pegsummit.com/immunotherapy/
@dhanschand -
Agenus
@Agenus_Bio
The incredible story of CEO @garo_armen & our "audacious" approach in #oncology featured in @LifeSciLeader1! @WayneKoberstein defines $AGEN as "One-Stop Shop" in #immunooncology with "candidates in almost every class of #cancer #immunotherapy"
www.lifescienceleader.com/doc/garo-armen-and-audacity-at-…
#aacr2019












































































































































































































































































































































































































































